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Abstract: Zusammenfassung Die medikamentöse Regulation des Immunsystems hat der Therapie von
bösartigen Tumoren erhebliche Fortschritte gebracht. Eine der vielversprechenden Substanzen, ist der
Immun-Botenstoff Interleukin-12 (IL-12), der das Wachstum verschiedener Tumore hemmt. Diese Tu-
morsuppression wurde mit der Wirkung von IL-12 auf diverse Zellen des Immunsystems in Verbindung
gebracht, wobei unterschiedliche Studien widersprüchliche Resultate präsentierten. Unsere Forschungs-
gruppe konnte zuvor eine zentrale Rolle von ILCs (innate lymphoid cells), deren Entwicklung vom Tran-
skriptionsfaktor ROR￿t abhängt, in der IL-12-induzierte Hemmung des Tumorwachstums beschreiben.
Der Ko-Transfer von nur 10’000 ROR￿t abhängigen ILCs, zusammen mit IL-12 produzierenden Tu-
morzellen, vermochte die Zunahme der Tumormasse zu verhindern. In dieser Arbeit habe ich den thera-
peutischen Effekt von IL-12 auf etablierte Tumore mit dem einer präventiven Verabreichung verglichen.
Während die Immunantwort nach therapeutischer IL-12 Injektion Interferon-￿ (IFN￿) benötigte beruhte
der Erfolg der präventiven Verabreichung nicht auf diesem Botenstoff. Die Injektion von etablierten
Tumoren mit IL-12 stimulierte die Sekretion von IFN￿ durch NK (natural killer) und T Zellen und in
der Abwesenheit von Lymphozyten versagte die IL-12 Therapie. Die spezifische Depletion von ROR￿t
abhängigen ILCs, NK und T Zellen hatte jedoch keine Auswirkungen auf den therapeutischen Effekt
von IL-12, weshalb wir die Notwendigkeit einer Stimulation dieser Zellen durch IFN￿ ausschlossen. IFN￿
führte zur Akkumulation und Aktivierung von Monozyten und deren Nachkommen im Tumorgewebe.
Die IL-12-induzierte Anti- Tumorantwort wurde durch die Depletion von Monozyten nicht beeinflusst,
weshalb auch die Rolle dieses Zelltyps vernachlässigbar war. Zusätzlich hemmte IFN￿ das Wachstum
von Endothelzellen und steigerte die Expression von Adhäsionsmolekülen auf Blutgefässen. Diese Effekte
konnten durch die spezifische Entfernung des IFN￿ Rezeptors auf Endothelzellen neutralisiert werden,
was jedoch keinen Einfluss auf die Tumorsuppression durch IL-12 hatte. Somit konnten wir die Beteili-
gung von Zelltypen, deren Funktion während der Anti-Tumoraktivität von IL-12 in der Literatur häufig
besprochen wurde, ausschliessen. Im Weiteren widmeten wir uns in der folgenden Arbeit der Charakter-
isierung von tumor- hemmenden ILCs nach präventiver Verabreichung von IL-12. Dabei wurden Funktion
und Phänotyp von ROR￿t abhängigen ILCs aus Milz und Darm verglichen. Während der Transfer von
ILCs aus der Milz das Tumorwachstum verhinderte, konnte die Injektion von Darm ILCs diesen Effekt
nicht reproduzieren. Milz ILCs hatten die Expression von ROR￿t eingestellt und exprimierten anstelle
dessen den Transkriptionsfaktor T-bet und NK Zell charakteristische Oberflächenmoleküle. Im Gegensatz
zu Darm ILCs, welche die Expression von ROR￿t beibehielten, konnten wir in Milz ILCs eine erhöhte
Transkription des IL-12 Rezeptors feststellen. Die ungleiche Reaktionsfähigkeit auf IL-12, könnte die
Unterschiede von Milz und Darm ILCs bezüglich Anti-Tumor-Antwort, erklären. Summary Treatment
with immune modulating components is about to revolutionise cancer therapy. One promising candidate,
demonstrating potent anti-tumour responses is the immune mediator interleukin-12 (IL-12). Various im-
mune cell types have been implied in the IL-12- induced tumour rejection, but different studies have
presented conflicting results. Our group previously described the essential role of innate lymphoid cells
(ILCs), depending on the transcription factor ROR￿t, during the IL-12-mediated anti-tumour response.
The co-transfer of only 10￿000 ROR￿t dependent ILCs with IL-12 secreting tumour cells prevented tumour
growth, while other immune cells were unable to elicit this effect. In this thesis I investigated whether
therapeutic delivery of IL-12 to established tumours, provoked a similar ILC-dependent anti-tumour re-
sponse. We discovered that the late therapeutic treatment failed in the absence of interferon-￿ (IFN￿),
while early preventive administration was independent of this cytokine. Upon late IL-12 administration
IFN￿ was predominantly secreted by natural killer (NK) cells and T lymphocytes and the absence of the
lymphoid compartment caused IL-12 treatment to fail. Notably, specific depletion of ROR￿t dependent
ILCs, NK or T cells did, however, not influence IL-12-mediated tumour immunity. Thus, we excluded the
requirement of those cells to respond to IFN￿ in this context. IFN￿ signalling led to the accumulation and
activation of monocytes and their progeny within treated tumours. Nonetheless, these cells were shown
to be dispensable for the anti-tumour response, as IL-12-treated tumours were suppressed in the absence
of monocytes. Moreover, direct IFN￿ signalling inhibited endothelial cell growth and induced the expres-
sion of adhesion molecules on tumour vessels. Endothelium specific ablation of IFN￿ signalling, however,
had no impact on the tumour suppression upon late treatment with IL-12. Thus, we have excluded the
involvement of specific cell types that have previously been suggested to contribute to the IL-12 mediated
anti-tumour immunity. Furthermore, we aimed to characterise the phenotype and function of tumour
suppressive ILCs upon early preventive treatment with IL-12. Whereas the transfer of spleen-derived
ROR￿t-dependent ILCs potently rejected solid tumours, gut-derived ILCs failed to do so. A comparison
of ROR￿t-dependent ILCs in spleen and gut showed differences in their phenotype and transcriptional
profile. In fact, splenic ILCs had down-regulated ROR￿t expression, upregulated the transcription factor
T-bet and phenotypically resembled NK cells. Moreover, they were shown to be responsive to IL-12
and secreted IFN￿ upon stimulation. In contrast, gut-derived ILCs expressed lower levels of the IL-12
receptor and retained ROR￿t expression. These differences in IL-12 responsiveness of ILCs, may explain
the distinct functions of splenic and gut ILCs, regarding the IL-12-mediated tumour suppression. 1
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  1 
I Summary  
Treatment with immune modulating components is about to revolutionise cancer therapy. 
One promising candidate, demonstrating potent anti-tumour responses is the immune 
mediator interleukin-12 (IL-12). Various immune cell types have been implied in the IL-12-
induced tumour rejection, but different studies have presented conflicting results. Our group 
previously described the essential role of innate lymphoid cells (ILCs), depending on the 
transcription factor RORγt, during the IL-12-mediated anti-tumour response. The co-transfer 
of only 10ʼ000 RORγt dependent ILCs with IL-12 secreting tumour cells prevented tumour 
growth, while other immune cells were unable to elicit this effect.  
In this thesis I investigated whether therapeutic delivery of IL-12 to established tumours, 
provoked a similar ILC-dependent anti-tumour response. We discovered that the late 
therapeutic treatment failed in the absence of interferon-γ (IFNγ), while early preventive 
administration was independent of this cytokine. Upon late IL-12 administration IFNγ was 
predominantly secreted by natural killer (NK) cells and T lymphocytes and the absence of the 
lymphoid compartment caused IL-12 treatment to fail. Notably, specific depletion of RORγt 
dependent ILCs, NK or T cells did, however, not influence IL-12-mediated tumour immunity. 
Thus, we excluded the requirement of those cells to respond to IFNγ in this context. IFNγ 
signalling led to the accumulation and activation of monocytes and their progeny within 
treated tumours. Nonetheless, these cells were shown to be dispensable for the anti-tumour 
response, as IL-12-treated tumours were suppressed in the absence of monocytes. 
Moreover, direct IFNγ signalling inhibited endothelial cell growth and induced the expression 
of adhesion molecules on tumour vessels. Endothelium specific ablation of IFNγ signalling, 
however, had no impact on the tumour suppression upon late treatment with IL-12. Thus, we 
have excluded the involvement of specific cell types that have previously been suggested to 
contribute to the IL-12 mediated anti-tumour immunity. 
Furthermore, we aimed to characterise the phenotype and function of tumour suppressive 
ILCs upon early preventive treatment with IL-12. Whereas the transfer of spleen-derived 
RORγt-dependent ILCs potently rejected solid tumours, gut-derived ILCs failed to do so. A 
comparison of RORγt-dependent ILCs in spleen and gut showed differences in their 
phenotype and transcriptional profile. In fact, splenic ILCs had down-regulated RORγt 
expression, upregulated the transcription factor T-bet and phenotypically resembled NK cells. 
Moreover, they were shown to be responsive to IL-12 and secreted IFNγ upon stimulation. In 
contrast, gut-derived ILCs expressed lower levels of the IL-12 receptor and retained RORγt 
expression. These differences in IL-12 responsiveness of ILCs, may explain the distinct 
functions of splenic and gut ILCs, regarding the IL-12-mediated tumour suppression. 
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II Zusammenfassung 
Die medikamentöse Regulation des Immunsystems hat der Therapie von bösartigen 
Tumoren erhebliche Fortschritte gebracht. Eine der vielversprechenden Substanzen, ist der 
Immun-Botenstoff Interleukin-12 (IL-12), der das Wachstum verschiedener Tumore hemmt. 
Diese Tumorsuppression wurde mit der Wirkung von IL-12 auf diverse Zellen des 
Immunsystems in Verbindung gebracht, wobei unterschiedliche Studien widersprüchliche 
Resultate präsentierten. Unsere Forschungsgruppe konnte zuvor eine zentrale Rolle von 
ILCs (innate lymphoid cells), deren Entwicklung vom Transkriptionsfaktor RORγt abhängt, in 
der IL-12-induzierte Hemmung des Tumorwachstums beschreiben. Der Ko-Transfer von nur 
10'000 RORγt abhängigen ILCs, zusammen mit IL-12 produzierenden Tumorzellen, 
vermochte die Zunahme der Tumormasse zu verhindern. 
In dieser Arbeit habe ich den therapeutischen Effekt von IL-12 auf etablierte Tumore mit dem 
einer präventiven Verabreichung verglichen. Während die Immunantwort nach 
therapeutischer IL-12 Injektion Interferon-γ (IFNγ) benötigte beruhte der Erfolg der 
präventiven Verabreichung nicht auf diesem Botenstoff. Die Injektion von etablierten 
Tumoren mit IL-12 stimulierte die Sekretion von IFNγ durch NK (natural killer) und T Zellen 
und in der Abwesenheit von Lymphozyten versagte die IL-12 Therapie. Die spezifische 
Depletion von RORγt abhängigen ILCs, NK und T Zellen hatte jedoch keine Auswirkungen 
auf den therapeutischen Effekt von IL-12, weshalb wir die Notwendigkeit einer Stimulation 
dieser Zellen durch IFNγ ausschlossen. IFNγ führte zur Akkumulation und Aktivierung von 
Monozyten und deren Nachkommen im Tumorgewebe. Die IL-12-induzierte Anti-
Tumorantwort wurde durch die Depletion von Monozyten nicht beeinflusst, weshalb auch die 
Rolle dieses Zelltyps vernachlässigbar war. Zusätzlich hemmte IFNγ das Wachstum von 
Endothelzellen und steigerte die Expression von Adhäsionsmolekülen auf Blutgefässen. 
Diese Effekte konnten durch die spezifische Entfernung des IFNγ Rezeptors auf 
Endothelzellen neutralisiert werden, was jedoch keinen Einfluss auf die Tumorsuppression 
durch IL-12 hatte. Somit konnten wir die Beteiligung von Zelltypen, deren Funktion während 
der Anti-Tumoraktivität von IL-12 in der Literatur häufig besprochen wurde, ausschliessen. 
Im Weiteren widmeten wir uns in der folgenden Arbeit der Charakterisierung von tumor-
hemmenden ILCs nach präventiver Verabreichung von IL-12. Dabei wurden Funktion und 
Phänotyp von RORγt abhängigen ILCs aus Milz und Darm verglichen. Während der Transfer 
von ILCs aus der Milz das Tumorwachstum verhinderte, konnte die Injektion von Darm ILCs 
diesen Effekt nicht reproduzieren. Milz ILCs hatten die Expression von RORγt eingestellt und 
exprimierten anstelle dessen den Transkriptionsfaktor T-bet und NK Zell charakteristische 
Oberflächenmoleküle. Im Gegensatz zu Darm ILCs, welche die Expression von RORγt 
beibehielten, konnten wir in Milz ILCs eine erhöhte Transkription des IL-12 Rezeptors 
feststellen. Die ungleiche Reaktionsfähigkeit auf IL-12, könnte die Unterschiede von Milz und 
Darm ILCs bezüglich Anti-Tumor-Antwort, erklären. 
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III Frequently used abbreviations 
 
APC   antigen presenting cell  
ATP    adenosine 5ʼ-triphosphate 
B16F10-IL-12Fc  B16F10 cells secreting IL-12Fc 
CD   cluster of differentiation 
CCR2   chemokine receptor 2 
Ccr2-/-   mice deficient for the chemokine receptor CCR2 
cDC   conventional DCs 
Cre   loxP site-specific recombinase 
CTLA-4  cytotoxic T lymphocyte antigen-4 
DAPI   4',6-diamidino-2-phenylindole dilactate 
DC   dendritic cell 
DMEM   Dulbecco's Modified Eagle's Medium 
DNA   deoxyribonucleic acid 
dNTP    deoxynucleotide triphosphate 
ECM   extracellular matrix  
eGFP   enhanced green fluorescent protein  
EMT   epithelial-mesenchymal transition  
Eomes   eomesodermin  
eYFP   enhanced yellow fluorescent protein  
FCS   fetal calve serum 
FDA   food and drug administration (US) 
GM-CSF  granulocyte-macrophage colony-stimulating factor  
HBSS   hankʼs balanced salt solution  
Id2    inhibitor of DNA binding 2 
ICAM-1  intercellular adhesion molecule-1  
IFN   interferon 
Ifngr1-/-   IFNγ receptor deficient mice  
Ifngrfl/fl    conditional knock out mice for IFNγ receptor 
IL   Interleukin 
IL12rb2-/-  IL-12 receptor β2-deficient mice  
Il15ra-/-   IL-15 receptor-deficient animals  
ILC   innate lymphoid cells  
iNOS   inducible nitric oxide synthase  
i.t.   intratumoural  
i.v.   intravenous 
Jak   Janus kinase  
loxP   recognition sequence for Cre 
LP gut   lamina propria from the small intestines  
LTi   lymphoid tissue inducer cell 
LysM   Lysozyme 2  
MAPK   mitogen-activated protein kinase  
MCA   3ʼ-methylcholanthrene  
MDSC   myeloid-derived suppressor cells  
MHC   major histocompatibility complex 
MHCII+  MHC class II expressing cell 
MMP   matrix metalloprotease  
mRNA   messenger ribonucleic acid 
MS-1    MILE SVEN 1 endothelial cell line 
NCR   natural cytotoxicity receptor  
 5 
NET   neutrophil extracellular trap 
NK cell  Natural killer cell 
NKG2D  natural killer group 2 member D  
NKT cell   natural killer T cell   
NO   nitric oxide  
pDC   plasmacytoid DCs  
PBS   phosphate buffered saline 
PCR    polymerase chain reaction 
PD-L1   programmed death-ligand 1  
PRR   pattern recognition receptor  
pSTAT   phosphorylated STAT  
R   receptor 
RAG   recombination activating gene   
Rag2-/-Il2rgc-/- mice deficient for the common gamma chain of the IL-2 receptor and 
RAG2 
Rag1/2-/-  RAG1/2-deficient mice  
Rb   retinoblastomaprotein 
Rorc-/-   RORc deficient mice 
Rorcfm+  Rorc-Cre x ROSA26-stopfl/fl-eYFP fate map mice 
Rorcrep+   RORc-eGFP reporter mice  
RORγt   retinoic acid related orphan receptor γt  
RORγtfm+  YFP expressing RORγt dependent cells from Rorcfm+ mice 
RORγtrep+  GFP and RORγt expressing cells from Rorcrep+ mice  
ROS   reactive oxygen species  
s.c.   subcutaneous  
SPLC   splenocytes  
STAT   signal transducer and activator of transcription  
TAM   tumour-associated macrophages  
Taq    polymerase from Thermus aquaticus  
TCR   T cell receptor  
TGF-β   transforming growth factor-β  
TH cell   T helper cell 
TNF   tumour necrosis factor  
Treg    regulatory T cell  
UV   ultraviolet  
VCAM-1  vascular cell adhesion molecule-1  
VEC   VE-Cadherin 
VEGF   vascular endothelial growth factors  
WT   wild type 
6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
7 
IV Introduction 
»1 Cancer 
For a long time, cancer was considered to be a burden of the developed world. This resulted 
from the improved control over infectious diseases, causing increased life expectancy, which 
was accompanied by a higher incidence of malignancies. In 1970, only 15% of cancers were 
diagnosed in developing countries. This frequency, however, rose up to 56% in 2008, 
highlighting the global dimension of the disease. Today, the risk of contracting cancer is 
increasing worldwide, which reflects the growing population, changes in age distribution and 
exposure to risk factors (1). While the incidence is still considerably elevated in high- 
compared to low-income countries, differences in mortality rates are less pronounced (1). 
This clearly illustrates the lack of accessibility to cancer therapeutics in developing countries. 
In high-income countries, therapeutic assessment rarely leads to the cure of cancer, but 
more frequently prolongs survival (2). This implies a high prevalence of cancer and a large 
number of patients that are under constant treatment. It is obvious that the costly therapies 
create a socio-economic problem, which can be expected to grow in concordance with 
cancer incidence.  
Thus, there is a desperate need for novel effective therapeutic strategies that can be afforded 
by low-income countries. Development of such agents in turn requires in depth knowledge of 
the mechanisms, by which cancers develop characteristics of malignancy. For this reason, 
the authors Hanahan and Weinberg defined a set of hallmark capabilities, which cancer cells 
need to acquire, in order to successfully evolve (3). These capabilities are attained by 
mutations in a multistep process, which has similarities to Darwinian evolution. Driving 
mutations lead to the gain of function of oncogenes or loss of function of tumour suppressor 
genes and finally convert a healthy cell to a cancer cell. More recently, the authors revised 
their initial concept, by adding further hallmarks to the development of cancer (4). Partially, 
this was motivated by the increased awareness that tumours, rather than merely consisting 
of cancer cells, involved a plethora of adjacent stromal cells, actively contributing to growth 
and invasiveness. Together, these cells form the “tumour microenvironment”, among others 
comprising endothelial cells, immune cells and tumour-associated fibroblasts. The following 
section will briefly summarise the hallmarks of cancer as defined by Hanahan and Weinberg, 
which will be illustrated by examples of frequent mutations in human melanomas. 
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»1.1 The hallmarks of cancer 
»1.1.1 Sustaining proliferative signalling 
In healthy cells, proliferation is tightly regulated to preserve the specific architecture and 
function of tissues. The cell only enters the growth and division cycle upon stimulation with 
growth factors. These growth factors are either components of the surrounding extracellular 
matrix (ECM) or secreted by neighbouring cells in a paracrine manner. Likewise, systemically 
released hormones can induce proliferation by binding to correspondent receptors. Cancer 
cells acquire mutations that allow them to circumvent this growth control by the environment. 
Some tumours adapt by secreting their own growth signals, resulting in autocrine growth 
stimulation. Moreover, changes of the signalling receptor, such as increased expression, 
structural alterations or modification of receptor composition, may lead to hyper 
responsiveness to proliferative signals. This is for instance observed in advanced melanoma, 
which over-express the epidermal growth factor receptor (EGFR) (5,6). Alternatively, 
mutations in the signalling pathway downstream of growth receptors can lead to constitutive 
activation of the growth cycle. For instance, activation of the RAS-RAF-MEK-ERK-mitogen-
activated protein kinase (MAPK) pathway is observed in various types of cancer, including 
melanoma. BRAF and NRAS mutations are frequently detected in melanomas and result in 
the activation of the MAPK in absence of extracellular stimuli (7,8).  
»1.1.2 Evading growth suppressors 
In addition to proliferation promoting molecules, there are signals that inhibit cell division. 
Similar to growth factors, these molecules are secreted as soluble growth inhibitors, 
immobilised in the ECM or expressed on the surface of neighbouring cells. These inhibitory 
signals can interrupt mitosis, leading to temporary cell quiescence or inducing cell 
differentiation and permanent growth suppression. Avoidance of such anti-proliferative 
signals supports the inordinate growth of tumours. Nearly all anti-mitotic signals are 
managed by the tumour suppressors retinoblastoma protein (Rb) and p53 (4). While Rb 
mainly responds to extracellular signals, p53 blocks proliferation upon intra-cellular stress, 
such as DNA damage and lack of nutrients or oxygen. Mutations leading to a loss of function 
of Rb or p53 are frequently observed in cancer. Genetic alterations of these pathways are 
also common in melanomas arising in familial settings (7). A third of hereditary melanomas 
harbour a germline mutation in the cyklin-dependent kinase inhibitor 2A (CDKN2A) locus (9). 
Loss of the functional CDKN2A gene leads to suppressed Rb and p53 activity and thereby 
unleashes the proliferative potential of cancer cells (9).  
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»1.1.3 Resisting cell death 
Besides the regulation of proliferation and growth, cell death is an important process for 
organ development and tissue homeostasis. Under physiological conditions, cell death 
occurs in a highly programmed fashion, termed apoptosis (10). Induction of apoptosis relies 
on the presence of pro-apoptotic extracellular ligands, the loss of anti-apoptotic survival 
signals or intracellular signs of cell damage. Since these signals are abundant in cancer cells 
(4), blocking pathways involved in the induction of apoptosis is beneficial for the tumour. 
Most of these pathways result in the release of mitochondrial cytochrome C and subsequent 
activation of caspases, initiating the cascade of defined steps characteristic for apoptosis 
(10). The p53 tumour suppressor can, for instance, induce apoptosis by stimulating 
cytochrome C release. Moreover, the expression of pro- and anti-apoptotic members of the B 
cell lymphoma 2 (Bcl-2) family, which control cytochrome C release, have been found to be 
deregulated in melanomas (11). 
Cell death by necrosis is less organised and results in the loss of cell membrane integrity and 
discharge of intracellular components into the extracellular space. Thus, necrosis usually 
triggers an inflammatory response and infiltration of immune cells. Such immune cells can be 
exploited by tumour cells to further promote cell proliferation by providing growth signals (12). 
Thus, tumours may to a certain extent profit from cell death.  
»1.1.4 Enabling replicative immortality 
In addition to the deregulation of proliferation and cell death, cancer cells need to ensure 
limitless replication. Cell intrinsic pathways control the maximal number of division cycles that 
each cell is capable to undergo. After reaching this limit, cells enter the state of senescence, 
in which they fail to further propagate. If senescence can be circumvented, cells proceed to 
the phase of crisis, which in most cases will inevitably lead to chromosomal damage and cell 
death (13). Repetitive nucleotide sequences at the end of chromosomes called telomeres 
constrain replication. With each cell division, these telomeres will lose a number of base 
pairs and thereby erode. The DNA polymerase telomerase can actively insert nucleotides to 
the telomeres and thereby postpones senescence and crisis. Most cancer cells are 
immortalised by over-expressing telomerase (13). In melanomas telomerase activity has 
been correlated with a particularly poor prognosis and is indicative of tumour progression 
(14).  
»1.1.5 Inducing angiogenesis   
In developed healthy tissues, blood vessels are largely quiescent, apart from transient 
activation observed during wound healing and tissue remodelling. In contrast, growing 
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cancers require the sprouting of vasculature (angiogenesis) to maintain the supply of 
nutrients and oxygen, and the disposal of metabolic waste. Thus, tumours promote the 
release of pro-angiogenic factors and inhibit anti-angiogenic molecules, a phenomenon 
termed “angiogenic switch” (15). Pro-angiogenic factors can be secreted as soluble 
mediators, as in the case of vascular endothelial growth factors (VEGFs). In tumours, the 
expression of VEGFs is upregulated by both hypoxia and oncogene signalling (16). VEGFs 
can also be captured within the ECM and are liberated by proteases, such as the matrix 
metalloprotease-9 (MMP-9) (17). Immune cells attracted to the tumour tissue can further 
support angiogenesis by various mechanisms (18).  
»1.1.6 Activating invasion and metastasis     
Many cancers develop the ability to invade tissues and form metastases, which is the 
emergence of tumour cells distant from the primary tumour. Cancer cells can thereby 
populate new niches, which offer more nutrients and space. For the host, this progression is 
less desirable, as metastases are the main cause of death in cancer patients (19). The 
formation of distant metastases involves evasion of the primary tumour to blood or lymph 
vessels, the invasion into a new microenvironment and adaptation to novel conditions (20). 
Initially, the cancer cell detaches from its surrounding by altering cell-to-cell and cell-to-matrix 
adhesion. Melanoma cells and a variety of invasive carcinoma cells, show an impaired 
attachment through the adhesion molecule E-cadherin (21,22). The expression of integrins 
that mediate cell-to-matrix contact has been shown to shift during the process of invasion 
(23). The release and activation of ECM degrading proteases by cancer cells or adjacent 
tissue, further promotes invasive capabilities (24). Many of these alterations are part of the 
epithelial-mesenchymal transition (EMT), a program that is important during migratory 
processes in embryonic development (25). Activation of the EMT leads to multiple cellular 
alterations that support the development of the cells invasive phenotype. Thus, it has been 
suggested that reactivation of EMT contributes to cancer progression (25). Due to the 
essential role of EMT during the dissemination of neural crest cells – which are the ancestors 
of melanocytes – it is not surprising that many EMT related genes are altered in melanomas 
(11,26).   
»1.1.7 Genome instability and mutation 
The hallmarks described so far depend on alterations on the genomic level, which are 
achieved by mutations or epigenetic influences. As spontaneous mutations usually occur at a 
low frequency, cancer cells acquire the means to increase mutation rates. Healthy cells 
possess an entire DNA-maintenance-machinery that detects genomic damage. While minor 
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DNA damage is rapidly repaired, the cell enters senescence or undergoes apoptosis upon 
more extensive damage. Thus, alterations in this machinery can influence mutation rates. 
Whereas in hereditary cancers, mutations often affect DNA repair genes, these mutations are 
rare in sporadic cancer (27). In contrast, spontaneous tumours are thought to accumulate 
mutations due to oncogene-induced replication stress (27). The dysfunction of telomerases 
can lead to chromosomal damage, which contributes to genomic instability (28).  
»1.1.8 Reprogramming energy metabolism 
Cells generate energy by oxygen-independent glycolysis followed by oxidative 
phosphorylation in mitochondria. Both pathways serve to produce the high-energy molecule 
ATP (adenosine 5ʼ-triphosphate), but oxidative phosphorylation yields around 20 times more 
ATP than anaerobic glycolysis. Nevertheless, cancer cells predominantly gain ATP by 
glycolysis even under normoxic conditions, a phenomenon which is known as Warburg effect 
(29). This is partly achieved by upregulating glucose transporters and is pronounced by the 
lack of oxygen (30). It is not completely understood, why cancer cells undergo this metabolic 
switch independently of tissue oxygenation. Due to abnormal architecture of the tumour 
vasculature, oxygenation may fluctuate, which implies an advantage for cells that rely on 
glycolysis. It has also been suggested that glycolytic intermediates may fuel the generation of 
nucleosides and amino acids, required for the rapid growth of cancer cells (31).  
»1.1.9 Hallmarks involving the immune system 
The last two hallmarks “tumour-promoting inflammation” and “evading immune 
destruction” involve the interplay of cancer cells with the immune system. These titles 
allude to the ambivalent role that immune cells have been attributed in the context of cancer. 
On the one hand, they have been described to recognise altered tumour cells and 
successfully eliminate them during different phases of tumour growth. On the other hand, the 
constant surveillance by the immune system exerts a selective pressure on the cancer, 
which in turn shapes the tumour landscape, a phenomenon that was termed cancer 
immunoediting (32). Furthermore, sustained inflammation can promote the development of 
cancer, and supports growth and establishment of invasive features of established tumours 
(12). These aspects of tumour immunity and the role of distinct cellular players will now be 
introduced in some more detail. 
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Illustration 1: The hallmarks of cancer. Illustration depicting the hallmark capabilities that cancer cells have to 
develop to ensure progressive growth and avoid destruction. These capabilities involve overcoming cell intrinsic 
hurdles such as limited growth signals, growth suppression, cell death upon damage, mechanisms of DNA-repair 
and limited cell proliferation. The ability to promote angiogenesis, to metastasise and to alter their metabolism, 
supplies the tumour with nutrients and oxygen, creates new niches and allows them to generate energy in a 
hypoxic environment, respectively. The immune system plays a dual role in carcinogenesis as it can both 
eliminate cancer cells and promote tumour development. These capabilities are supported by cells in the tumour 
microenvironment; here simplified in the tumour tissue. The Illustration is adapted from Hanahan and Weinberg, 
2011 (4). 
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»2 Cancer and the immune system 
»2.1 Immune cells involved in the detection of cancer 
The interplay of the immune system and cancer implies that the immune cells can detect 
aberrant cancer tissue. While leukocytes recognise pathogens by structural patterns that are 
perceived as non-self, tumours may resemble healthy tissue. As a result, the immune system 
develops mechanisms of tolerance, which allow the cancer to grow unhindered. The theory 
that the leukocytes can respond to so-called “danger signals” may, however, explain the 
development of protective immune responses towards cancer (33). Tissue trauma or stress 
causes cell death, which leads to the release of danger signals, such as heat shock proteins 
(33). Binding to pattern recognition receptors (PRRs), danger signals and microbial patterns 
alert cells of the innate immune system, which form the first line of immune defence. While 
the response of innate immune cells is generic, due to their conserved receptors, cells of the 
adaptive immune system detect threats like pathogens or cancer cells more specifically. 
Their receptors can bind to a large variety of molecules, called antigens. Compared to the 
immediate action of innate cells the adaptive response needs several days to develop, as 
adaptive cells require the presentation of their cognate antigen by innate cells. Upon this 
interaction, adaptive cells are activated, clonally expand and elicit a potent immune 
response. Apart from the distinction of innate and adaptive immunity, developmental and 
morphological features are used to classify immune cells into the lymphoid and myeloid 
compartment. While lymphocytes are found within both the innate and adaptive arm of the 
immune system, myeloid cells comprise most of the innate compartment.  
»2.1.1 The myeloid compartment 
This group of cells comprises granulocytes, monocytes, macrophages and dendritic cells 
(DCs). After birth, these cells derive from myeloid progenitor cells in the bone marrow (34). 
Monocytes, expressing the surface markers CD11b and F4/80, circulate in the blood and 
can further give rise to macrophages and DCs. This differentiation is particularly pronounced 
during inflammatory responses, which lead to the recruitment of Ly6C+ inflammatory 
monocytes through chemokine receptor 2 (CCR2) signalling (35).  
A common feature of myeloid cells is the ability to ingest macromolecules (phagocytosis), 
such as pathogens or cellular debris, upon recognition. Phagocytosis is primarily the function 
of tissue macrophages and neutrophil granulocytes, the latter expressing the marker 
Ly6G. Upon phagocytosis, the ingested macromolecules are destroyed by proteolytic 
enzymes, reactive oxygen species (ROS) or anti-microbial proteins, which can be stored in 
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granules. Apart from this intracellular killing mechanism neutrophil granulocytes can also 
excrete such substances to the extracellular space, achieved by the process of degranulation 
(36). More recently they have been shown to release fibers, forming web-like structures 
called neutrophil extracellular traps (NETs), which are mainly composed of DNA. 
Microorganisms captured within those traps are prevented from spreading and killed by 
antimicrobial substances and proteases attached to the NETs (37). Neutrophil granulocytes 
are also involved in healing processes by removing cell debris, reorganising the ECM and 
promoting revascularisation. The latter two features are, for instance, achieved by the 
secretion of the metalloproteinase MMP-9 (36). 
In contrast to the short-lived neutrophil granulocytes macrophages can reside in tissues for 
a long time. Apart from developing from monocytes and stem cells in the bone marrow, a 
number of macrophages were demonstrated to originate from embryonic yolk sac precursors 
(38). These yolk sac-derived macrophages populate tissues like skin, lung, spleen and 
kidney and are thought to self-renew locally. Such cells can be separated from bone marrow-
derived macrophages by their elevated expression of F4/80 and low levels of CD11b on their 
cells surface (39). Among other myeloid cells, macrophages are potent producers of immune 
signalling molecules called cytokines. Upon activation through PRRs, macrophages, for 
instance, secrete the pro-inflammatory cytokines Interleukin-1β (IL-1β), tumour necrosis 
factor (TNF), and IL-12 (40). Such cytokines can provoke an inflammatory response and 
direct the subsequent adaptive immunity.  
Myeloid subsets can present exogenous antigens on their surface, which they obtain from 
the degradation of ingested macromolecules. Cells with such function are referred to as 
antigen presenting cells (APCs). APCs express major histocompatibility complex (MHC) 
class I and II molecules, by which they present peptide antigens to the adaptive αβ T cells in 
lymphoid tissues. In combination with co-stimulatory factors and cytokine signalling this 
interplay of APCs with lymphocytes will lead to the activation of adaptive immune responses 
(41). While MHC class II binds exogenous peptides, MHC class I molecules mainly present 
intracellular antigens. In fact, all nucleated cells express endogenous peptides bound to MHC 
class I on their surface, which is how cytotoxic T cells can detect foreign antigens on infected 
or aberrant cells. In contrast to other somatic cells, specialised APCs can, however, express 
extracellular peptides on MHC class I. This process is known as cross-presentation and 
implies that the APC itself is not required to be infected or malignantly transformed to present 
antigens on MHC class I molecules (42).  
DCs have been shown to be the most potent antigen presenting cells (43). To date this group 
of cells is sub-divided into plasmacytoid (pDCs) and conventional (cDCs) DCs. The first 
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subset is primarily detected in blood and lymphoid organs and secrete large amounts of the 
type I interferons (IFNs). In contrast, cDCs populate non-lymphoid and lymphoid tissues. In 
non-lymphoid organs a population of CD103+CD11b- cDCs can be distinguished from 
CD11b+ cDCs. A proportion of CD11b+ cDCs develop from circulating monocytes. Non-
lymphoid cDCs are highly migratory and can also be found in lymphoid tissues. Further, 
lymphoid organs harbour CD8+CD11b- and CD8-CD11b+ cDCs. All DC subsets are 
characterised by variable expression of CD11c. This surface marker is, however, not specific 
for DCs, as it is also expressed on other cells, such as macrophages (44).  
»2.1.2 The lymphoid compartment 
Cells within this compartment arise from common lymphoid progenitor cells in the bone 
marrow and share the morphology of a small cell with a round nucleus and scarce 
cytoplasm. The lymphoid compartment comprises natural killer (NK) cells, T cells, NKT cells 
and B cells. 
NK cells do not directly target pathogens, but detect and eliminate infected or aberrant cells. 
In order to recognise a compromised cell, NK cells express a set of activating and inhibitory 
surface receptors. The balance between signalling through those receptors regulates the 
activation status of the NK cells (45). Activation can occur upon binding of surface molecules 
that are induced on target cells by cellular stress. The activating receptor natural killer group 
2 member D (NKG2D), for example, detects various ligands that are induced upon DNA 
damage (46). NK cell function is further sustained by cytokine signalling; in particular IL-15 
and IL-12 are known to be strong stimulators (47). IL-15 is further required for NK cell 
maturation as shown by the paucity of NK cells present in IL-15 signalling-deficient mice (48). 
Inhibitory signals can be provided by receptors that recognise MHC class I molecules on the 
surface of target cells. The loss of MHC class I expression is often observed on cancer cells, 
which renders them susceptible to NK cell killing (46). Upon activation, NK cells exert effector 
functions, such as the release of perforin and granzyme, which induce apoptosis of the target 
cell. Furthermore, stimulated NK cells secrete cytokines, such as IFNγ. Due to their lack of 
antigen specificity and ability to elicit prompt responses, they are thought to belong to the 
innate arm of the immune system. The activating receptor NKp46 was described to be the 
most specific marker for NK cells of different species (49). This natural cytotoxicity receptor 
(NCR) was recently also detected on subsets of innate lymphoid cells (ILCs). NK cells are 
now thought to belong to a family of ILCs (50), which will be described later.  
T cells and B cells recognise pathogens or transformed cells by specific receptors, which are 
generated by random somatic gene recombination (51). While each clone expresses one 
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antigen specific receptor, the diversity of genetically rearranged receptors within the 
population ensures that virtually any antigen is recognised. The receptor may also bind self-
antigen, which is why the adaptive cells are subjected to a selection process, eliminating 
most self-reactive cells. Such cells elicit an effective primary immune response and 
subsequent encounter with antigen can provoke a more potent and more rapid immune 
response, a phenomenon that is ascribed to immunological memory (52). The development 
of T and B cells can be experimentally blocked by using mice deficient for the recombination 
activating genes (RAG) 1 and 2, which are required for the generation of antigen receptors 
(53,54). 
Most T cells rearrange the α and β chain of the T cell receptor (TCR) locus. After their 
maturation and selection in the thymus they migrate to secondary lymphoid organs where 
they may encounter their cognate antigen presented by APCs. Upon binding to the peptide-
MHC complex, TCR signalling initiates the stimulation of the T cell. T cells are characterised 
by the expression of CD3, a co-receptor associated with the TCR that is required for signal 
transduction. Upon T cell activation the expression of CD3 can be down-regulated (55), 
which may impede the detection of T cells in vivo. 
αβ  T cells can be divided into a CD8 and CD4 expressing population. The function of CD8+ 
T cells is central for immune responses against cancer cells. The TCR on CD8+ T cells 
specifically binds to MHC class I presented peptides. Co-stimulatory signals and cytokines in 
addition to TCR engagement lead to the activation of CD8+ T cells. Once they are primed, 
CD8+ T cells can screen nucleated somatic cells for aberrant antigen bound to MHC class I 
molecules. Upon detection of their cognate antigen CD8+ T cells can kill their target cell and 
are therefore called cytotoxic T cells. Similar to NK cells CD8+ T cells can induce cell death 
upon the release of perforin and granzyme. Furthermore, CD8+ T cells express Fas ligand, 
which mediated apoptosis over the death receptor Fas on the target cell. Moreover, cytotoxic 
T cells secrete the cytokines TNF an IFNγ (reviewed in Andersen et al., 2006 (56). 
CD4+ T cells recognise peptides presented on MHC class II molecules. Their main function 
is to secrete a set of cytokines, which influence the subsequent immune response. Moreover, 
they support B cell function and cytotoxic T cell responses, and are thus referred to as T 
helper (TH) cells. Depending on the composition of cytokines contributed by the APC, 
activated TH cells can adopt distinct functions (57). TH1 cells secrete IFNγ and IL-2 upon the 
up-regulation of the transcription factor T-bet. This subtype is known to support cytotoxic 
effector T cell functions. In contrast, TH2 cells express the transcription factor GATA3 and 
secrete IL-4, IL-5, IL-10 and IL-13. A subset of TH17 cells expresses the transcription factor 
retinoic acid related orphan receptor γt (RORγt) and secretes IL-17 (57). Although TH 
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subtypes were thought to be terminally differentiated cells, it is now recognised that these 
cells are functionally plastic (58). Another TH subtype has regulatory function as it establishes 
tolerance towards self and non-self antigens and is therefore termed regulatory T cell (Treg). 
Their development depends on the expression of transcription factor forkhead box protein 3 
(FoxP3) and they secrete the immune suppressive cytokines IL-10 and transforming growth 
factor-β (TGF-β). Tregs can inhibit T cell activation by their expression of the cytotoxic T 
lymphocyte antigen-4 (CTLA-4), which binds to the co-stimulatory molecules CD80/86 on 
APCs (59).  
A small fraction of T cells rearrange the γ and δ chain of the TCR locus. These γδ TCRs have 
a more limited diversity than αβ TCRs and are not restricted to MHC molecules. The scope of 
the antigens that γδ  T cells respond to is not fully understood. After their maturation in the 
thymus, γδ T cells do not migrate to lymphoid organs but rather populate epithelial sites. 
Their response has innate-like kinetics and they can react to cytokines without further antigen 
stimulation. Therefore, γδ T cells are considered to have functional properties that can be 
placed in between innate and adaptive immunity (reviewed by Vantourout and Hayday, 2013 
(60)).  
Also NKT cells act at the interface of adaptive and innate immune responses.  These cells 
express a semi-invariant αβ TCR that recognises lipid antigens presented on CD1d, a MHC 
class I-like molecule. In addition NKT cells express functional NK cell receptors and can 
produce TH1- and TH2-associated cytokines (61). 
The role of B cells is generally neglected in studies of anti-tumour immune responses. 
Similar to T cells, B cells express rearranged B cell receptors (BCR), which is the membrane 
bound form of an antibody. These antibodies are secreted in a soluble form and are not 
limited to peptide recognition as are TCRs, but bind to a variety of chemical structures. 
Although tumour specific antibodies have been described and B cells frequently infiltrate 
tumour tissue, the induced responses have not been observed to be efficient (62). The ability 
of B cells to present antigens to T cells has rather been associated with a tumour-promoting 
role (63).   
 
»2.2 Cancer immunoediting 
The idea that immune responses may influence the growth of cancer was motivated by the 
observation of cancer remissions upon infectious diseases (64). It was hypothesised that the 
immune system can eliminate cancer cells, limiting the number of clinically apparent 
malignancies, a phenomenon that was later termed “cancer immunosurveillance” (65,66). 
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Experimental evidence was contributed by the study of immune-deficient rodents. Mice, 
lacking either cellular components or molecular players of the immune system, were shown 
to be more susceptible to sarcoma formation, upon induction with the carcinogen 3ʼ-
methylcholanthrene (MCA), compared to immunocompetent mice (67-69). The subsequent 
study by Shankaran and colleagues provided a new twist to the understanding of cancer 
immunity (32). MCA-induced tumours derived from immunocompromised mice, lacking 
adaptive immune cells, were spontaneously rejected when transplanted into syngeneic 
immunocompetent mice. In contrast, tumour transplantation from wild type donors to 
immunocompetent hosts, led to progressive growth of the cancer. This suggested that 
cancers, growing in immune-deficient mice, are more susceptible to immune responses and, 
thus, are more immunogenic. Besides surveilling tissues for tumour cells, the immune system 
also seems to shape the tumour quality, a phenomenon that was termed “cancer 
immunoediting” (32). By now cancer immunoediting is described as the interplay between the 
immune system and the cancer tissue, which comprises the three phases of elimination, 
equilibrium and escape (70-72).  
»2.2.1 Elimination 
This phase describes the phenomenon of immune surveillance. Elimination has never been 
visualised in vivo, but has rather been demonstrated to take place in an indirect way. The 
increased susceptibility of immunocompromised mice to develop carcinogen-induced, 
spontaneously arising and mutation driven cancers, indicated that the immune system 
prevented the occurrence of malignancies. Utilising mice deficient for distinct populations of 
the immune system suggested that most immune cell types took part in processes of the 
elimination phase (reviewed in Vesely et al., 2011 (72)). The involvement of different 
leukocyte populations seems to depend on the type of cancer, method of cancer induction, 
anatomic location or tumour growth rates (71,72).  
First, the innate arm of immunity reacts to developing tumours via danger signals and 
damage-associated molecular patterns (DAMPs), released by the tumour itself or the 
damaged adjacent tissue (71). Moreover, stress ligands expressed on the cancer cellsʼ 
surface may bind to activating receptors on NK cells, NKT cells, γδ T cells and CD8+ αβ T 
cells. For instance, NKG2D-deficient mice have been shown to develop more mutation driven 
lymphomas and prostate cancer (73). The cytokine secretion by such cells further supports 
subsequent immunity. Especially IFNγ was attributed a major role in cancer elimination 
(67,74). Among other effects, IFNγ induces cytotoxic effector functions by NK and CD8+ T 
cells, such as the release of perforin, a cytolytic protein that was shown to be essential in 
immune surveillance of cancer (69,75). In spite of this effective initial recognition and attack 
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of the cancer cells by innate immune cells, most systems were demonstrated to rely on the 
action of adaptive immune cells towards the tumour (71). These adaptive responses require 
the presentation of tumour antigens, which are distinguished by their high or low specificity 
(76). The expression of viral peptides, mutated proteins and cancer-germline antigens is 
highly specific for the tumour tissue and result in strong T cell activation. In contrast, low-
specificity tumour antigens derive from the cancers tissue of origin or from over-expressed 
proteins. Such antigens normally induce immunologic tolerance, but have also been shown 
to elicit anti-tumour T cell responses (76).   
»2.2.2 Equilibrium 
During equilibrium, the cancer and the immune system reach a state of dynamic balance. 
Although effector functions of the immune cells restrict tumour growth, they fail to eliminate 
neoplastic cells, which can be explained by the cancer cell heterogeneity. This phase is 
characterised by the cancer cells acquiring immune evasive mutations, while immune cells 
adapt to these alterations and is terminated by elimination or escape of the tumour. The 
phase of equilibrium may explain the long latency from the initial mutations that create the 
aberrant cancer cells, to the clinical appearance of the malignant neoplasia. Moreover, 
certain human cancers, such as melanoma and breast cancer, are renown for their potential 
to form distant metastases long after detection and successful treatment of the primary 
tumour. This cancer dormancy could be attributed to the processes of equilibrium (reviewed 
in Vesely et al., 2011 (72)).  
Equilibrium was experimentally assessed by Koebel and colleagues who induced occult 
sarcomas by exposing mice to low doses of the carcinogen MCA (77). Subsequent depletion 
of CD4+ and CD8+ T cells, IFNγ or IL-12 yielded the outgrowth of such occult tumours, 
underlining the essential role of adaptive immunity for the phase of equilibrium. Notably, 
depletion of NK cells did not accelerate tumour growth (77). In a model of murine leukaemia 
up-regulation of programmed death-ligand 1 (PD-L1) on dormant tumour cells was found to 
inhibit the effector function of CD8+ T cells (78) or even induced T cell apoptosis (79), 
demonstrating the progressive immune evasion of the cancer cells. Moreover, occult 
metastases were found early after formation of mutation-driven melanoma and the depletion 
of CD8+ T cells resulted in progressive growth (80). 
»2.2.3 Escape 
This phase is represented by the failure of the immune system to control tumour growth, 
which leads to the development of a clinically apparent malignant disease. Escape of the 
tumour can occur primarily, if the immune system does not succeed to recognise the cancer 
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cells, or can be the result of the equilibrium phase. The remaining tumour cells have adapted 
to evade targeting by leukocytes, which results in progressive tumour growth (reviewed in 
Vesely et al. (72)). Cancer cells can for instance evade the immune system by inhibiting the 
direct recognition by lymphocytes, as achieved by loss of NKG2D ligands (81) or tumour 
specific antigens. Similarly, the tumour can accumulate defects in its antigen processing and 
presentation machinery (71), which impairs CD8+ T cell killing. This can be observed when 
the cancer cells lose their responsiveness to IFNγ, a cytokine affecting many components of 
the antigen presentation pathways (82). There is also evidence that cancers impair DC 
maturation and thereby hamper antigen presentation to T cells (83). In addition, many tumour 
cells evade cytotoxic immune functions by using their “resisting cell death” hallmark. For 
example, this is achieved by mutations of the death receptors for tumour necrosis factor-
related apoptosis-inducing ligand (TRAIL) (84) and Fas ligand (85).  
Many of the qualities that allow the tumour to evade immune destruction are directed towards 
creating an immunosuppressive tumour microenvironment. Interestingly, this cancer-related 
immune suppression was observed to be local, as splenic T cells respond normally to 
administered antigen (86). This local effect is supported by the presence of 
immunosuppressive cytokines at the tumour site. Cancer cells can secrete TGF-β or 
stimulate its production by cells in the tumour microenvironment (87). The effects of TGF-β 
are versatile and mainly lead to the inhibition of DC, T cell and NK cell function (87). 
Moreover, IL-10 has primarily been attributed to a strong immune suppressive role in cancers 
with multiple targets (88). In patients, both TGF-β and IL-10 are correlated with poor 
prognosis or metastatic disease (88). Interestingly, TGF-β in the tumour tissue was shown to 
convert effector T cells into Tregs (89), which further contributes to the increased IL-10 and 
TGF-β levels and suppression of T cell activity. Tregs have also been suggested to 
accumulate at the tumour site due to local proliferation or enhanced migration (90). The latter 
mechanism is supported by increased chemokine expression (91). In fact, there is an array 
of chemokines derived from tumour cells or the surrounding stroma that support the 
migration of leukocytes to the tumour (92). Some immune cell types may, however, harm the 
cancer, which is why many tumours actively suppress leukocyte trafficking. Partly, this is 
achieved by down-regulating adhesion molecules, such as intercellular adhesion molecule-1 
(ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), on the tumour vasculature (93).    
The interplay of cancer cells with leukocytes of the myeloid lineage has proven to be 
particularly profitable for tumour escape. The cancer is thought to suppress maturation of 
such cells, causing myeloid cells to display diverse immune suppressing functions. Due to 
their regulatory capacity, a group of immature myeloid cells found in tumour tissue has been 
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termed myeloid-derived suppressor cells (MDSCs) (94). The IFNγ-induced up-regulation of 
the inducible nitric oxide synthase (iNOS) in MDSCs is thought to inhibit T cell survival and 
function (94). It is disputed whether those cells should be regarded as a distinct myeloid 
subtype or if their immune suppression merely represents a functional state. Huang and 
colleagues suggested that the chemokine CCL2 and the corresponding receptor CCR2 are 
essential for the recruitment of such suppressive myeloid cells. In the absence of CCR2 
signalling a reduced tumour growth was observed, which was attributed to the loss of 
myeloid suppression (95).  
CCR2 is also involved in the attraction of tumour-associated macrophages (TAM).  Notably, 
recent studies suggest that the majority of TAMs derive from CCR2+ Ly6C+ inflammatory 
monocytes (96-98). Depending on their activation status, macrophages have been suggested 
to adopt pro-inflammatory or immunosuppressive functions (99,100). The majority of TAMs 
were shown to promote tumour growth by multiple mechanisms (101). TAMs have, for 
instance, been demonstrated to secrete IL-10 and TGF-β (102). Moreover, myeloid cells, in 
particular macrophages, potently support tumour angiogenesis by secreting of VEGF or 
MMP-9 (18). There is also evidence that secretion and activation of metalloproteinases by 
TAMs promote tumour invasiveness and metastasis (17).  
»2.2.4 Inflammation-induced cancer 
Apart from inhibiting and promoting tumour growth, immune responses can also induce de 
novo cancer formation. It is well documented that chronic particularly inflammation increases 
the risk of developing cancer. Such correlations have been found in pathogen-mediated 
inflammation, such as hepatitis virus-induced hepatocellular carcinoma, and autoimmune 
diseases, as observed in inflammatory bowel disease patients. The constant tissue damage, 
and regeneration or remodelling during chronic inflammatory responses may contribute to the 
pathogenesis of such cancers. For instance, the tissue is exposed to ROS produced by 
myeloid cells, which are actively mutagenic to surrounding cells. The mechanisms by which 
inflammation can induce tumour development are similar to the immune cell functions during 
immunoediting (reviewed in Grivennikov et al., 2010 (12)).   
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Illustration 2. The three phases of cancer immunoediting. Upon malignant transformation the cancer cells 
may succumb to anti-tumour immune responses (elimination), enter a dynamic balance with the immune system 
(equilibrium) or control and avoid intratumoural immune cells (escape). Highly immunogenic tumours present 
antigens and express immune stimulatory surface molecules, such as NKG2D leading to detection and 
elimination by leukocytes. These molecules are lost in poorly immunogenic cancers, which are dominated by the 
presence of immune inhibitory ligands, such as PD-L1. The selective pressure that the immune system exerts on 
the cancer ultimately supports tumour escape. In this phase cancer cells attract leukocytes with 
immunosuppressive function, fostering tumour invasiveness and angiogenesis. DC: dendritic cell, CD4+: T helper 
cell, CD8+: cytotoxic T cell, MØ: macrophage, γδ T: γδ T cell, NK: NK cell, NKT: NKT cell, MDSC: myeloid-derived 
suppressor cell, Treg: regulatory T cell. This illustration is adapted from Schreiber et al., 2011 (71). 
 
»2.2.5 Evidence for cancer immunoediting in humans 
Although the processes of immunoediting cannot be assessed experimentally in humans 
there is certain evidence that these take place in cancer patients. For instance, immune 
suppressed individuals generally have a greater risk of developing cancer (71). Patients 
suffering from acquired immune deficiency syndrome (AIDS) show an increased frequency of 
malignancies, although most of the cancers have a viral aetiology and are associated with 
herpes- or papilloma virus infection (103). The increase of virus-associated cancers also 
dominate reports, studying malignancies in recipients of organ transplants who are treated 
with immune suppressing drugs to avoid transplant rejection. A dramatic increase of non-
melanoma skin cancer (200-fold) (104) and a more moderate elevation of melanoma cases 
have, however, been described in kidney transplanted patients (104,105). While these 
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findings demonstrate the failure of immunosurveillance, there is also data supporting the fact 
that the immune system may specifically respond to cancer cells and control tumour growth. 
The tumour infiltration with T, NK and NKT cells has been associated with improved 
prognosis in various malignancies (72). This link was first observed in melanomas (106,107) 
and was followed by the discovery of melanoma antigen specific T cells (108). The potent 
immune response elicited by antigen specific recognition is illustrated by the finding that such 
melanoma responsive T cells detect and attack healthy melanocytes upon treatment with 
immune modulating substances, leading to the clinical appearance of vitilligo (109). 
Remarkably, several case studies of spontaneously regressing melanomas were 
accompanied by the expansion of T cells (110-112). 
»2.2.6 Bright prospects for cancer immunotherapy  
The potential of therapeutically promoting protective anti-tumour immunity and interfering 
with tumour escape spread hope for the treatment of cancer with immune modulating 
components, termed immunotherapy. The discovery of tumour antigens and responsive T 
cells that particularly brought vaccine based strategies into focus. The specificity of T cell 
responses to tumour tissue appears as an attractive target, as many conventional anti-
cancer therapies are associated with strong side effects that result from damaging healthy 
tissues (113). Various strategies of vaccination are currently being clinically tested, and show 
promising results. Particularly melanoma patients have profited from this development, as 
some of the therapeutic approaches have shown curative effects (114). In the context of 
melanoma therapy, some of these treatment strategies will be further discussed in the next 
paragraph. 
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»3 Cutaneous melanoma 
Cutaneous melanomas are highly malignant neoplasias arising from melanocytes. In 
humans, these cells predominantly reside within the basal layer of the epidermis and 
produce the pigment melanin. Characterised by their aggressive and invasive growth, 
melanomas can metastasise even at early stages of disease, when the tumour is small. 
Although they develop less frequently than non-melanoma skin cancers, melanomas are the 
main cause of skin cancer related death. While mortality rates have stabilised in Europe, the 
incidence of cutaneous melanomas is rising rapidly (7).  
 
  
Illustration 3: Melanocyte residing in the skin. 
Illustration depicting a melanocyte resident within 
the basal layer of the human epidermis above the 
basal membrane. The keratinocytes (KC) forming 
the epidermis are provided with the pigment 
melanin, secreted by melanocytes.  
 
 
»3.1 Development and Risk 
Melanomas can arise form melanocytic naevi, benign lesions that are composed of 
melanocytes often referred to as moles. Therefore, individuals with large numbers of such 
naevi are at higher risk to develop melanomas (9,115). Naevi can appear to be 
morphologically atypical and are termed dysplastic naevi when fulfilling three of the following 
criteria: they exceed the size of 5 mm in diameter (I), show irregular colouring (II) or border 
(III), have an asymmetric contour (IV) or are accompanied by an erythema (V). These naevi 
in particular are correlated with an increased disease risk and should therefore be observed 
carefully (116). Only 20-40% of all melanomas, however, develop from naevi while 60-80% 
appear on healthy skin (117).  
Ultraviolet (UV) radiation exposure has been causally linked to the incidence of cutaneous 
melanomas (118,119). Ultraviolet B radiation was recently shown to directly cause driving 
mutations, usually caused by C to T or G to A transitions, which supply melanoma cells with 
a fitness advantage (120,121). As pigments protect the skin against the impact of UV 
radiation, pale skin (phototype 1,2) predisposes individuals to developing melanomas. The 
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occurrence of melanomas in organs other than the skin, such as the gut and other mucosal 
sites demonstrates that melanomas can also establish independent of UV radiation.    
Hereditary genetic conditions can increase the risk for developing melanoma. Some of these 
alleles predispose for a high risk, which is why several members of one family are affected 
by the disease, melanomas may occur in multiple locations and they arise early in life (9). 
Although such risk alleles are very rare they are characterised by a high penetrance and the 
resulting tumours account for up to 10% of all melanomas (122). Many of these mutations 
ultimately interfere with the Rb pathway or with the function of the tumour suppressor gene 
p53 (7). Low to intermediate risk alleles rather effect traits that render the individual 
susceptible to sporadic melanoma, such as fair skin (9). 
 
»3.2 Diagnosis and Staging 
Early visual recognition of melanoma is essential as it improves curative rates (7). Once a 
melanoma has been diagnosed, staging of the disease is performed to predict the individual 
prognosis and to define treatment strategies. A staging system has been introduced by the 
American Joint Committee on Cancer (AJCC) and is revised frequently (123,124). In the 
following paragraph this staging system will be briefly introduced. 
Stage 0 melanomas are also called in situ melanomas and refer to the detection of aberrant 
melanocytes in the epidermal layer of the skin. The discovery of the cancer at this initial 
stage correlates with an excellent prognosis. Unfortunately, the minority of melanomas are 
diagnosed this early.  
Stage I and II melanomas are established local tumours and are primarily evaluated by the 
tumour thickness, often termed Breslowʼs index, which predicts the survival rate of the patient 
accurately. The tumours are substaged using the thresholds of 1, 2 and 4 mm in thickness. 
This substaging is further fine tuned by using the ulceration status, as ulcerations usually 
predict an impaired prognosis. Moreover, assessment of primary mitotic rate of the cancer 
cells can complement the staging, as it was shown to be the second best predictor of survival 
rate after the tumour thickness at this stage.  
Stage III melanomas have metastasised into local lymph nodes or into lymphatic vessels 
and are further substaged by the number of affected lymph nodes and the volume of the 
metastasis. Status of the sentinel lymph node involvement has been demonstrated to be the 
strongest overall prognostic factor in melanoma patients (124,125). Identification of lymph 
node metastases is mainly achieved by clinical detection, which can be complemented by 
sentinel lymph node biopsy (7,126). Also for this group tumour thickness and ulceration 
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status have been shown to well predict survival rates.  
Stage IV melanomas are diagnosed when distant metastases have occurred. Metastases 
can arise virtually anywhere in the body but liver, lung, bones and brain are most often 
affected. The subcategories are defined by assessing serum levels for lactate 
dehydrogenase and the localisation of metastases. Regardless of the substaging stage IV 
disease is, however, hard to control and prognosis is poor (124).  
 
»3.3 Treatment strategies 
Melanomas have proven to be resistant to many conventional anticancer treatments, such as 
chemotherapy and radiation therapy. To date surgical excision of the primary tumour is the 
best treatment for this cancer type. Recently, increased understanding of the molecular 
biology of melanomas has led to the introduction of novel targeted therapies and 
immunotherapies. Many of these new compounds have shown to improve survival rates 
significantly and may revolutionise the treatment of melanomas (126). Unfortunately, virtually 
all treatments provoke side effects, few patients respond to therapy and cancers develop 
drug resistance. Thus, the combination of different treatment strategies is particularly 
attractive (7).   
»3.3.1 Local therapy 
Surgical assessment of melanomas is the standard treatment of the localised disease and 
involves wide local excision of the primary tumour. Depending on tumour thickness the 
recommended margin of resection will be adapted. For stage III patients with clinical 
involvement of the regional lymph nodes complete lymphadenectomy of the local lymphatic 
basin is performed. For metastatic patients at stage IV surgical treatment has limited benefits 
and is only implied as palliative treatment, when it has the prospects of increasing life quality 
(126,127). With the novel targeted and immune modulating drugs applied as pre-treatment 
before surgical intervention, resection of residual tumours at stage IV may become more 
attractive (126).  
Radiation therapy is currently not routinely used in melanoma treatment as this form of 
cancer is considered to be relatively radiation resistant. It is usually considered for the 
adjuvant therapy of high-risk postoperative patients with stage III disease or melanomas 
localised on head or neck, for which surgical possibilities are limited (128). Moreover, stage 
IV patients with brain and bone metastases were shown to benefit from local radiation 
therapy (129). Although in this palliative setting, radiation therapy rarely increases the 
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survival of patients, it can improve their life quality by reducing symptoms (129).  
»3.3.2 Systemic therapy 
Systemic treatment is indicated at metastatic stages of melanoma disease. Until recently, 
chemotherapy with dacarbazin and immunotherapy with Interleukin-2 (IL-2) or IFNα were the 
only treatment options approved by the US food and drug administration (FDA) (130). In the 
last decade, however, major treatment advances have been achieved by the approval of 
monoclonal antibodies blocking CTLA-4 and BRAF kinase inhibitors (126). The molecular 
basis and effect of compounds currently used to treat melanoma patients are discussed in 
the following paragraph. Many more components and strategies are under investigation in 
pre-clinical and clinical trials. 
Dacarbazin is an alkylating agent, which acts by attaching an alkyl group to the guanine 
base of DNA and thereby causes DNA damage and cell death. As cancer cells proliferate at 
higher frequencies compared to healthy cells, they are more susceptible to dacarbazin-
induced DNA damage (130). Although, overall survival was never shown to be improved by 
dacarbazin, response rates are estimated at 10-30% (131). Treatment with dacarbazin also 
damages other proliferating tissues, leading to a variety of adverse effects. Damage to the 
gut mucosa causes nausea and vomiting, and impaired hematopoiesis results in leukopenia 
and anemia (130).  
The term “targeted therapy” defines treatments using components that interfere with 
mutationally altered molecular pathways. As such genetic alterations can vary between 
melanomas, characterisation of the mutational landscape previous to treatment is essential. 
In melanoma therapy, targeted agents are directed towards molecules involved in the RAS-
RAF-MEK-ERK-MAPK pathway, which is frequently over-activated (132). BRAF inhibitors 
have shown the most striking effects among many tested substances. The FDA approved the 
use of the specific BRAF inhibitor vemurafenib in 2011, after a phase III clinical trial had 
shown a highly significant increase of survival upon vemurafenib compared to dacarbazine 
treatment (133). Moreover, patients receiving BRAF inhibitors showed a response rate of 
48% and tumour size was reduced drastically. After around 6 month, however, most patients 
suffer from a relapse of the disease caused by drug resistance of the cancer cells (7,134). 
Most likely, this resistance occurs due to melanoma cell heterogeneity, selective pressure 
exerted by BRAF inhibitor treatment and stimulation of alternative pathways of MAPK 
activation (134). Moreover, BRAF inhibitors paradoxically activate the MAPK pathway in 
healthy cells. This off-target effect may explain the frequent appearance of keratoacantomas 
and sqamous cell carcinomas on the skin of treated patients (135). Thus, the combined 
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therapeutical inhibition of BRAF and downstream MEK are currently under investigation 
(132). Furthermore, components targeting other frequent mutations in melanomas, such as 
mutations of KIT, NRAS and PTEN, are in development (132). 
»3.3.3 Systemic Immunotherapy 
IFNα  has been demonstrated to have a multitude of effects on malignancies, as it inhibits 
proliferation, induces apoptosis and modulates immune responses. The latter property is 
characterised by a boost of DC function, enhanced antigen presentation and the promotion of 
Th1 responses (136). IFNα is used as adjuvant therapy of high-risk melanomas with lymph 
node involvement or after resection of tumours with increased thickness. Although in these 
settings high dose IFNα-2b prolonged recurrence-free survival, there is limited data 
demonstrating an overall survival benefit (126).  
IL-2 is an immune regulatory cytokine that has a variety of effects on the immune system, 
including the activation of T and NK cells. The mechanism behind its anti-tumour activity is, 
however, not fully understood. High dose IL-2 treatment has the potential of inducing durable 
responses or complete regression of melanomas (137). Unfortunately, only a small number 
of patients can profit from high dose IL-2, as response rates evaluated in a set of clinical 
trials were low (137-140). Moreover, treatment with high dose IL-2 is limited by its severe 
toxic effects, such as arrhythmias, hypotension and impacts on liver and kidney function, 
yielding a 1-2% mortality rate (126).  
Anti-CTLA-4 treatment has revolutionised melanoma therapy since its approval by the FDA 
in 2011. Blockage of the inhibitory effect of CTLA-4 on T cells was thought to improve 
effector T cell responses towards cancer cells (141). In contrast, a more recent study showed 
that the increased effector T cell activity resulted from anti-CTLA-4-mediated depletion of 
Tregs in the tumour tissue. (142). Treatment with the anti-CTLA-4 antibody ipilimumab was 
demonstrated to substantially elevated overall survival rates in phase III clinical trials 
(143,144). Notably, ipilimumab induced long-term survival in a small fraction of treated 
patients, some of which had ceased treatment (137). Anti-CTLA-4 treatment causes severe 
autoimmune adverse effects, including colitis, dyspnea, anemia, hypopituitarism, 
hypophysitis and rash (143).  
Another “immune check-point” is targeted by antibodies binding programmed cell death 1 
(PD-1), which leads to enhanced T cell responses. Such antibodies are currently being 
tested in phase III clinical trials and show promising results (137).  
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»3.4 Modelling melanoma in mice  
Investigation of molecular aspects of development and progression of melanomas, and 
preclinical testing of therapeutic strategies require animal models. The mouse is one of the 
most frequently used species for this purpose. The modelling of murine melanomas has been 
achieved by using genetically modified animals, xeno-transplatation models and syngeneic 
transplantation models, which are reviewed by Becker and colleagues (145). The discovery 
of common mutations in melanomas allowed the development of genetically modified animal 
models targeting driver genes in melanomas. In these mice, melanomas arise spontaneously 
or can be induced, for example by UV radiation or chemical substances (146). Xeno-
transplantation models utilise immune compromised mice as hosts for human melanomas. 
This approach has been shown to successfully model melanoma properties, such as 
invasiveness and metastasis formation. Due to their immune suppression they are, however, 
not suitable to study cancer immunity. Syngeneic transplantation models on the other hand 
have proven useful to investigate the immune response to melanomas (145). One of the 
most frequently used cell lines is the B16 melanoma, which is also subject of this study. B16 
cells originate from a spontaneous melanoma of C57BL/6 origin and different variants have 
been selected due to their invasive and metastatic properties (147). One variant, termed 
B16F10, was described to have a high survival and growth potential in vivo and formed more 
lung metastases when injected intravenously (i.v.), compared to other variants (147). The 
fact that the B16 line grows in C57BL/6 mice makes it ideal for immunological studies, as 
there are many genetically modified mice, generated to suit that purpose. Due to the paucity 
of MHC class I molecules on B16 cells this model was regarded to be poorly immunogenic. 
The discovery of melanoma-associated antigens and clonally expanded T cells within the 
tumour, however, demonstrate that the immune system does respond to B16 cells (145). The 
most commonly used models for the transplantation of B16 cells are the subcutaneous (s.c.) 
inoculation, which is thought to model a melanoma, and the artificial metastasis lung model, 
in which B16 cells are injected intravenously (148). B16 tumours have been used to 
investigate a variety of therapeutic components, some of which have thereafter been 
successful in clinical trials. One of the most frequently examined therapies is the treatment 
with IL-12.  
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»4 Interleukin-12 
The pro-inflammatory cytokine IL-12 was first described as an NK cell and T cell activatory 
factor (149,150), inducing the production of IFNγ (149). It is secreted by APCs and 
phagocytes, activated by stimulation of PRRs, as observed for Toll-like receptors, which 
recognise a multitude of microbial patterns. (151). Optimal production is achieved when the 
APC is primed by additional signals, such as IFNγ (152), IL-15 (153) or CD40-CD40-ligand 
interaction (154). Conversely, IL-10 and TGF-β have been found to potently inhibit the 
production of IL-12 (155,156), illustrating the tight regulation of IL-12 secretion. IL-12 consists 
of a light (p35) and a heavy chain (p40), which by covalent binding form the active 70kD 
heterodimer (150,157,158). Whereas the p35 subunit was found to be expressed 
ubiquitously, p40 expression is confined to immune cells (158). The p40 subunit is, however, 
not exclusive for IL-12 as it together with the molecule p19 is part of the IL-23 molecule 
(159). The two cytokines also share receptor chains as the IL-12 receptor (IL-12R) consists 
of IL-12Rβ1 and IL-12Rβ2, while the IL-23 receptor comprises IL-12Rβ1 and IL-23R (160-
162). These overlaps may explain why the function of the two cytokines was initially 
described as “similar as well as distinct” (159). Particularly in anti-tumour immune responses, 
these two cytokines play opposing roles (163). The IL-12R is mainly detected on pre-
activated T and NK cells (160) and has more recently also been identified on subsets of ILCs 
(50). Similar to secretion of the cytokine, receptor expression is strictly regulated. Whereas 
low levels of the IL-12R can be detected on the innate, resting NK cells (164), T cells require 
activation through TCR engagement to express the IL-12R (165). Moreover, IL-12Rβ2 
expression was found to correlate with responsiveness to IL-12 and could be induced by 
IL-12 and IFNγ signalling, while IL-4 was a potent inhibitor (165). Receptor engagement 
results in the activation of the Janus kinase (Jak) – signal transducer and activator of 
transcription (STAT) pathway, leading to STAT4 phosphorylation, which mediates the main 
cellular effects of IL-12 (166).  
The effects of IL-12 have predominantly been investigated in lymphocytes, but IL-12 
signalling may also affect other cell populations. For instance, IL-12 has been shown to act 
on APCs, which may imply an autocrine feedback mechanism for the secretion of IL-12 
(167). IL-12R engagement on NK and T cells promotes proliferation and enhances cytotoxic 
effector functions (149,150,168). IL-12-induced cytotoxicity was later shown to be mediated 
mainly by triggering perforin and granzyme expression and by upregulating adhesion 
molecules (reviewed in Trinchieri et al., 2003 (164)). IL-12 is also a powerful driver of T 
helper cell differentiation. Polarisation towards the IFNγ secreting TH1 phenotype was shown 
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to be promoted by IL-12 signalling (169), while TH2 responses were suppressed (170). IL-12 
stimulation is, however, not absolutely required for the TH1 fate and rather potentiates the 
development by providing proliferative signals and inducing IFNγ. Instead, the transcription 
factor T-bet was sufficient for the stimulation of IFNγ and generation of Th1 cells in the 
absence of IL-12 and STAT4 signalling (171). Moreover, T-bet was found to induce the 
expression of the IL-12Rβ2 chain and thereby increases the responsiveness to IL-12 (172).  
 
 
 
 
 
 
 
 
 
 
Illustration 4: IL-12 and IL-23, their 
receptors and signal transmitters. The 
IL-12 and IL-23 cytokines both contain the 
p40 heavy chain, which dimerises with p35 to 
form IL-12 or with p19 to form IL-23. Upon 
binding to the correspondent receptors, which 
entail the IL-12Rβ2 subunit, IL-12 mainly 
signals over STAT4, while IL-23 stimulation 
predominantly leads to STAT3 and STAT4 
phosphorylation. Adaptation from Trinchieri 
et. al. (265) 
 
 
IL-12 stimulates lymphocytes to secrete a variety of cytokines, such as TNF, granulocyte-
macrophage colony-stimulating factor (GM-CSF) and IL-2 (164) and is a particularly potent 
inducer of IFNγ (149,164). IFNγ itself has a plethora of cellular effects, which are reviewed by 
Boehm et al. and Schroeder et al. (173,174). These effects are initiated upon signalling 
through the IFNγ receptor (IFNγR), primarily leading to STAT1 phosphorylation. Apart from 
responses similar to IL-12 as promotion of cytotoxicity and TH1 polarisation, IFNγ activates 
myeloid cells and their anti-microbial functions, such as the release of nitric oxide (NO) and 
ROS. In addition, IFNγ induces antigen presentation by controlling various steps of the MHC 
class I and class II pathways and thereby promotes the activation of CD4+ and CD8+ T cells. 
By stimulating the IL-12 secretion by APCs (152) IFNγ solidifies the generation of TH1 
responses.  
For IFNγ the cellular responses are, however, not restricted to the leukocyte compartment as 
for IL-12, but the IFNγR is expressed on all somatic cells. IFNγ signalling, for instance, 
upregulates adhesion molecules such as ICAM-1 (175) and VCAM-1 (176) and enhances 
Introduction 
32 
secretion of chemokines, leading to facilitated leukocyte trafficking. Notably, IFNγ also 
inhibits proliferation and induces apoptosis, which is why it can limit immune responses, 
inhibit angiogenesis and suppress growth of tumours (173,174).   
 
»4.1 IL-12 in tumour immunity 
There is evidence that IL-12 has a role in the immune surveillance of tumours and interferes 
with cancer development. Initially, mice lacking the p40 subunit were utilised to test the effect 
of IL-12 on early tumourigenesis. In a model of MCA-induced fibrosarcoma, for instance, 
tumours growth was increased in p40-deficient animals compared to controls (177). The 
discovery of IL-23, sharing both p40 subunit and IL-12Rβ1 chain, however, put these results 
into perspective. Using mice deficient for the p35 subunit, Langowski and colleagues 
observed that the lack of IL-12 increased susceptibility to chemically induced papillomas. In 
contrast, p19 knock out mice developed fewer papillomas, demonstrating the tumour 
promoting effect of IL-23 (163). In another study, utilising mice deficient for p35, UVB 
exposure led to increased numbers of skin tumours and transition from benign lesions to 
carcinomas was enhanced (178). In addition, IL-12Rβ2-deficient mice (IL12rb2-/-) have been 
shown to develop plasmacytomas and lung carcinomas, which arose completely 
spontaneous (179). While these data suggest the importance of endogenous IL-12 in 
suppressing tumour establishment, many more studies focused on the therapeutic potential 
of exogenously administered IL-12.  
The first evidence of treatment efficiency was contributed in 1993, when Brunda and 
colleagues demonstrated the anti-tumour effect of systemically delivered IL-12 in a series of 
transplantable tumour models (180). The effect appeared to be dose-dependent and induced 
suppression of tumour growth even when treatment was initiated 14 days after tumour cell 
inoculation (180). Further studies supported these results and not only transplantable 
tumours but also carcinogen (181) and genetically induced malignancies (182) were 
demonstrated to be sensitive to IL-12 treatment (183). Nastala and colleagues were the first 
to establish the important role of IL-12 stimulated IFNγ for subsequent rejection of tumours 
(184). Many more studies confirmed confirming this observation, by both depleting IFNγ 
signalling genetically and by using blocking antibodies  (reviewed by Colombo and Trinchieri, 
2002 (183)).  
The various tissue specific responses to IFNγ have briefly been introduced above. In the 
context of tumour immunity, however, the anti-proliferative effect, particularly that on tumour 
vessels, deserves some more attention. The anti-angiogenic effect of IL-12 was first 
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described by Voest et al. and was attributed to increased IFNγ production (185). Later, 
Kanegane and colleagues associated the IFNγ inducible chemokines CXCL-10 (IP-10) and 
CXCL-9 (Mig) with the IL-12-mediated inhibition of angiogenesis and vascular damage, 
causing tumour necrosis. By neutralising IFNγ or both CXCL-10 and CXCL-9, the tumour 
suppression by IL-12 was abolished. They concluded that inhibition of vessel formation was 
essential for the subsequent anti-tumour response (186). Furthermore, IFNγ-induced 
inhibition of VEGF (187), VEGF receptor 3 (188) and MMP-9 (187,189) production were 
correlated with the inhibition of both angiogenesis and tumour progression, upon IL-12 
administration . Both direct and indirect effects of IFNγ on endothelial cells were suggested to 
inhibit their growth (188). Several studies implied that a lymphocyte-endothelial cell 
interaction is needed to elicit the full anti-angiogenic effect (189,190). The upregulation of 
ICAM-1 and VCAM-1 is thought to further promote this response, by mobilising immune cells 
to the tumour (189). In contrast, another report demonstrated that the tumour cells 
themselves secreted CXCL-10 upon IFNγ signalling, generating the anti-angiogenic activity 
(191).  
IFNγ-independent rejection of tumours upon IL-12 treatment has also been reported. In the 
C26 colon carcinoma model, for instance, the anti-tumour effect of IL-12 partially relied on 
GM-CSF-secreting CD4+ T cells (192). Moreover, IL-12 induced the IFNγ-independent 
release of perforin by NK cells or T cells, suppressing lung B16 melanomas (75) and 
orthotopic GL-261 gliomas (193).   
T cell responses were considered critical for the IL-12-induced anti-tumour immunity in a 
number of reports (180,184,193). Whereas the anti-tumour response towards s.c. renal 
adenocarcinomas (RENCA) was reduced upon depletion of CD8+ T cells (180),  tumour 
suppression required both CD8+ and CD4+ T cells in subcutaneous MCA-207 sarcomas 
(184) and intracranial Gl261 gliomas (193). Other studies, rather focused on metastasis 
models, however, suggested the involvement of NKT cells (194) or observed a RAG2-
independent mechanism, in which NK cells were sufficient for IL-12-induced tumour 
suppression (195). Smyth and colleagues reconciled this controversy by showing that the 
contribution of NKT and NK cells to tumour rejection varied, dependent on the tumour model 
and IL-12 treatment regimen. For i.v. injected B16 lung tumours NK cells, eliminated by anti 
NK1.1 depletion, were required for the anti-tumour immunity upon high doses of IL-12. In 
contrast, the effect of low doses or delayed treatment start was reduced in Jα281 knock out 
mice, lacking NKT cells (177). Park et. al. later demonstrated that IL-12 suppressed growth 
of s.c. tumours and liver metastases in CD1-deficient mice, independently of NKT cells. 
Whereas liver metastases were controlled by NK cells, s.c. tumours were still rejected in anti-
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NK1.1 treated RAG2-deficient mice (Rag2-/-), suggesting that the site of tumour implantation 
determined the mechanism of IL-12-mediated suppression. Moreover, in Rag2-/- mice 
deficient for the common gamma chain of the IL-2 receptor (Rag2-/-Il2rgc-/-; lacking all 
lymphocyte populations) the IL-12-induced anti-tumour response was abolished. Thus, the 
authors concluded that a distinct, non-T non-B non-NK, but gamma chain-dependent cell 
was required for the rejection of s.c. B16 melanomas (196). In a transfer model of engineered 
tumour-antigen specific CD8+ T cells secreting IL-12, Kerkar and colleagues found that 
CD11b+ cells of the myeloid compartment responded IL-12 administration (197). This partly 
IFNγ-dependent stimulation of myeloid cells led to increased antigen cross-presentation, 
which allowed the transferred T cells to accumulate in the tumour tissue and thereby 
potentiated the effect of treatment (197).  
»4.1.1 Innate lymphoid cells in IL-12-induced tumour rejection 
Our group previously investigated the mechanism of IL-12-induced tumour suppression in a 
model of s.c. transplanted B16F10 cells, which were modified to secrete IL-12Fc (B16F10-
IL-12Fc). The fusion of IL-12 with the crystallisable fragment of mouse immunoglogulin G3 
(Fc) was performed to increase the half-life time, the local containment and, hence, the effect 
of IL-12. Similar to the study of Park et al. (196), IL-12Fc-induced suppression of B16F10 
tumours was independent of adaptive immune cells and NK cells (198). Instead, a subtype of 
ILCs, dependent on the transcription factor RORγt, was observed to mediate tumour 
rejection. To identify RORγt-dependent ILCs a transgenic system was utilised, in which 
RORγt expressing cells were irreversibly labelled with the fluorophore enhanced yellow 
fluorescent protein (eYFP). For this, mice expressing the Cre recombinase under the 
promoter of the RORγt encoding gene Rorc (Rorc-Cre) (199) were used. Rorc-Cre animals 
were further bred to Rosa26-stopfl/fl-eYFP reporter mice, which express eYFP under the 
ubiquitously active Rosa26 promoter upon Cre-mediated excision of a loxP flanked stop 
cassette. In Rorc-Cre x Rosa26-stopfl/fl-eYFP fate map mice (here referred to as Rorcfm+), 
RORγt expression results in continuous expression of eYFP (RORγtfm+ cells), which is how 
RORγt-dependent lineages can be traced.  
The co-transfer of purified lineage negative RORγtfm+ ILCs together with B16F10-IL-12 cells 
into an IL-12Rβ2-deficient host (Il12rb2-/-) elicited a potent suppression of tumour growth. As 
B16F10 cells were shown not to bear the IL-12R on their surface, in this system, the 
transferred populations were the only IL-12 responsive cells. Thus, the transfer of RORγtfm+ 
ILC demonstrated that these cells were sufficient to induce a potent anti-tumour response 
upon IL-12 activation. In contrast, growth of B16F10-IL-12Fc tumours was not impaired upon 
transfer of NK cells (198) or T cells (K. Nussbaum and S. Burkhard, observation). The failure 
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of splenocytes harvested from RORc-deficient mice at inducing tumour rejection, suggested 
that RORγt-dependent ILC were not only sufficient, but also necessary for the IL-12-induced 
anti-tumour immunity (198). Although RORγtfm+ ILC secreted high amounts of IFNγ upon 
IL-12 activation, the tumour suppression was found to be IFNγ independent. B16F10-IL-12Fc 
tumours showed increased levels of the adhesion molecules ICAM-1 and VCAM-1 on the 
tumour vasculature and the accumulation of immune cells was observed. This suggested that 
the promotion of leukocyte migration into the tumour tissue could be involved in the 
mechanism behind IL-12-induced tumour rejection (198).  
 
 
 
 
 
 
 
 
 
 
 
 
Illustration 5: The effects of IL-12 stimulation in the tumour tissue. IL-12 primarily acts on the lymphoid 
compartment, involving NK cells, T cells and ILCs and enhances their IFNγ secretion. The majority of the tumour-
suppressing pathways, occurring upon IL-12 treatment, are mediated by IFNγ. In turn, IL-12 and IFNγ stimulate 
cytotoxic effector functions by NK cells and CD8+ T cells, which involve the production of perforin and granzyme. 
IFNγ further directly impacts the tumour vasculature by upregulating ICAM-1 and VCAM-1 and suppressing 
angiogenesis. The enhanced adhesion molecule expression is thought to promote leukocyte recruitment to the 
tumour site. IFNγ activates myeloid cells, inducing CXCL9 and CXCL10 secretion and suppressing VEGF and 
MMP-9 production, processes which promote the anti-angiogenic effect. IL-12 treatment leads to enhanced 
antigen presentation and cross-presentation by APCs, further promoting the cytotoxic activity of CD8+ T cells and 
cytokine release by CD4+ T cells. T helper cell-derived GM-CSF has been observed to be involved in tumour 
suppression upon IL-12 stimulation. T: T cell. Illustration adapted from Tugues et al., 2014 (206). 
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»4.1.2 Cancer immunotherapy with IL-12 
The success of IL-12 as a cancer therapeutic in preclinical models was promising in matters 
of future immunotherapy of human cancer patients. In a phase II study conducted by Leonard 
and colleagues, systemic i.v. IL-12 treatment, however, triggered unexpectedly severe 
adverse effects (200,201). These side effects included dyspnea, stomatitis, leukopenia, 
thrombocytopenia, and elevated blood levels of transaminases and bilirubin, and required 
hospitalisation of some probands. Two patients developed gastrointestinal bleeding with 
consecutive hypotension or a sepsis-like syndrome with multiorgan failure, in both cases 
leading to death of the proband (201). Both the toxic effects and the impact on cancer 
disease were correlated with high and sustained levels of IFNγ (201,202). In general, clinical 
response rates to i.v. IL-12 therapy appeared moderate, with few probands suffering from 
renal cancer (201-203), melanoma (203), ovarian cancer (204) and breast cancer (205) 
benefitting from partial or transient responses. The awareness of these clinical limitations 
increased the focus on combining IL-12 with other anti-cancer treatments and localised 
strategies of administration in preclinical and clinical studies. To more specifically target the 
tumour, recombinant IL-12 has been injected intratumourally and coupled to tumour antigen 
specific antibodies (immunocytokines). In addition, the delivery of IL-12 encoding DNA by 
electroporation, hydrodynamic injection, viral vectors, polymeric microspheres or 
nanoparticles, or transfer of engineered cells, have been utilised to achieve local secretion of 
IL-12 (reviewed in Tugues et al., 2014 (206)). The advances made in this field indeed led to 
the success of some clinical studies. Out of 10 patients with cutaneous T cell lymphomas, 
receiving IL-12 injections s.c. and intratumourally (i.t.), 9 responded and 2 showed complete 
remission (207). In combination with rituximab, an antibody directed against CD20 
expressing B cells, s.c. IL-12 administration yielded a 69% response rate and 26% complete 
remissions (208).   
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»5 Innate lymphoid cells 
The recently identified family of ILCs is currently attracting much attention. By now, ILCs are 
recognised to be a heterogeneous group of cells involved in retaining homeostasis and tissue 
repair. When inadequately activated they can, however, contribute to inflammatory 
processes. ILCs are  localised in lymphoid and non-lymphoid tissues, but predominantly 
reside at mucosal barriers of the gut, lung and skin. While sharing their morphology with 
other cells of the lymphoid lineage, they lack rearranged antigen specific receptors and are 
thought to respond to pathogens promptly. ILCs develop from common lymphoid progenitors 
and can secrete a variety of TH cell-related cytokines. Moreover, they mirror TH cell-
associated transcriptional features and surface marker expression, and have therefore been 
suggested to be evolutionary precursors of adaptive immune cells (reviewed in 
(50,209,210)). 
The discovery of ILC subsets started with the identification of CD4+CD3- cells, accumulating 
in the anlage of murine lymph nodes (211,212). Subsequently, two groups demonstrated that 
the transfer of such CD4+CD3- cells to alymphoplastic mice resulted in the formation of 
peyers patches (secondary lymphoid structures in the small intestines) (213) and nasal-
associated lymphoid tissue (214). Due to their non-redundant role for the formation of 
secondary lymphoid tissues, they were later termed lymphoid tissue inducer cells (LTis) 
(215). Subsequently, LTis were identified in human fetal mesenteric lymph nodes but, in 
contrast to mouse LTis, these cells did not express CD4 (216). Discovery of the essential role 
for the transcription factor RORγt for LTi generation (217) allowed fate map studies, which 
revealed that LTis persisted in the gut of adult mice (199). LTis were later also detected in 
adult spleens, where they were suggested to establish B and T cell segregation (218) and 
restore the splenic architecture upon viral disruption (219). In addition, adult LTis retained the 
ability to induce the de novo generation of lymphoid tissues (220). In 2009, adult splenic LTis 
were identified to be an innate source of the cytokines IL-17 and IL-22 (221). At the same 
time, innate cells expressing RORγt and natural cytotoxicity receptors (NCRs; in this case 
NKp46 in mouse and NKp44 in human) were detected in the murine gut and human tonsils, 
and were demonstrated to secrete IL-22 (222-225). These cells were clearly distinct from NK 
cells, as they showed no or low expression of the NK cell marker NK1.1, and failed to secrete 
IFNγ and exert cytotoxic effector functions (222,224). Despite some similarities with LTis, 
these cells did not express IL-17 (222-224). Nevertheless, these discoveries initiated a 
discussion about a possible lineage relationship between the novel NCR+ IL-22 producing 
cells, NK cells and LTis (226,227).  
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The described populations were ultimately unified in the family of ILCs, due to their innate 
nature, lymphoid morphology and common requirement for the transcriptional regulator Id2 
(inhibitor of DNA binding 2) (209). Id2 prevents the binding of enhancer (E) proteins to E-box 
sites and thereby hampers the differentiation of precursor cells towards the T and B cell 
lineage (228). Id2-deficient animals have been demonstrated to lack various subtypes of 
ILCs, including mature NK cells (229-232). This suggests that a common Id2+ ILC precursor 
exists, such cells, however, yet have to be identified (233). Two independent groups recently 
isolated Id2 expressing precursor cells from the murine bone marrow, which could develop 
into various ILC subsets, but failed to generate conventional NK cells (234,235) or CD4+ LTis 
(235). Moreover, ILCs require cytokine signalling through the IL-2 receptor subunit gamma. 
Whereas IL-15 is important for both NK cell development and maintenance (236), the 
generation of other ILC subsets has been shown to rely on IL-7 signalling (231). Regarding 
their transcriptional profile and their pattern of cytokine expression, ILCs have been classified 
into three different groups in both mice and humans, reminiscent of the diverse TH cell 
subsets (50). The following paragraphs will summarise characteristics of these groups, 
focusing on murine ILCs. 
 
»5.1 Group 1 ILCs  
These cells are defined by their capacity to produce IFNγ and comprise NK cells and the 
recently identified ILC1s. Both populations express the transcription factor T-bet during 
development. ILC1s also share certain surface molecules with NK cells, such as NKp46 and 
in some mouse strains NK.1.1 (234). In contrast to NK cells, ILC1s in the gut were shown to 
lack expression of the integrin CD49b (234). While Klose and colleagues found that ILC1s 
were reduced in IL-15-deficient mice (234), this was not the case in the study by Fuchs et al. 
(237). ILC1s characterised in these two studies also diverged regarding expression of 
eomesodermin (Eomes) (234,237), a transcription factor which in NK cells cooperates with 
T-bet (238).  
Classical group 1 ILCs develop independently of RORγt transcription (234). Phenotype and 
function of ILC1s can, however, be adopted by RORγt-dependent group 3 ILCs (239-241). 
This transition involves down-regulation of RORγt, which is why these cells are commonly 
referred to as “ex-RORγt” ILC3s (239,240). Conversely, they upregulate T-bet, authorising 
the cells to express IFNγ and NKp46 (240). In the gut, this transition depends on the host 
microbiota, as germ free mice had lower numbers of NKp46+ ILC3s (240). Interestingly, 
differentiation towards the ILC1 phenotype is supported by IL-12 and IL-18 signalling, which 
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further stimulate IFNγ secretion (240,241). Moreover, IL-15 was shown to be critical for the 
maintenance of NKp46+ILC3 (234). Cells with ILC1 function have been ascribed a protective 
role in Salmonella enterica and Toxoplasma gondii infections of the gut (234,240). 
It is still disputed whether NK cells should be incorporated in the group 1 of ILCs. A study by 
Boos et al. reported that normal numbers of NK cell progenitors were present in the bone 
marrow of Id2-deficient mice. The lack of nearly all the mature NK cells indicated that rather 
than defining NK cell lineage, Id2 was required for maturation (230). Furthermore, NK cells 
are enabled to exert cytotoxic effector functions, whereas both ILC1s and ILC3s lack this 
capacity (222,224,234).  
 
»5.2 Group 2 ILCs 
The second group of ILCs are characterised by the secretion of the TH2-associated cytokines 
IL-5, IL-13 in response to IL-25 and IL-33. Similar to TH2 cells, ILC2s depend on the 
transcription factor GATA3 for their development and maintenance (242,243). A recent study 
by Yagi and collaborators, however, demonstrated that also the development of other ILC 
subsets required GATA3 expression. Using conditional knock out mice for GATA3, they 
revealed that both ILC2 and group 3 ILC precursors were decreased in the bone marrow. 
Whereas the ILC2 population also required GATA3 for its maintenance, group 3 ILCs did not 
(244). Moreover, transcription factor RORα expression was shown to control ILC2 
development (245,246). Functionally, ILC2s are related to immunity against helminth 
infection, as IL-13 for instance supports worm expulsion, by promoting hyperplasia of mucus 
producing goblet cells, (232,247). ILC2s can, however, also mediate pathology as shown in 
models of airway hyper reactivity (248,249).  
 
»5.3 Group 3 ILCs 
Group 3 ILCs are related by their capacity to secrete the cytokines IL-22 and IL-17, and their 
responsiveness to IL-23. They rely on RORγt expression for their development and function. 
This group is composed of LTis and ILC3s, the latter is further subdivided into NCR+ and 
NCR- ILC3s.  
LTis organise the development of secondary lymphoid tissues, a process which is achieved 
by a complex interplay between LTis and stromal organiser cells (250). This crosstalk 
critically relies on LTis expressing lymphotoxin α1β2, which binds to the lymphotoxin β 
receptor on the stromal cells. Signalling induces the expression of chemokines (CCL19, 
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CCL21 and CXCL13) and adhesion molecules, such as ICAM-1, VCAM-1 and mucosal 
vascular addressin cell adhesion molecule 1 (MADCAM-1). Thereby lymphocytes are not 
only attracted to the site of lymphoid tissue development, but are also retained there (250). 
While lymph nodes and peyers patches are formed before birth, other mucosal-associated 
lymphoid tissues (MALT) develop postnatally, some of which arise in the absence of LTis 
(250). The interaction of the immune system with the microbiota has been suggested to 
influence the development of certain postnatal lymphoid structures (251).  
The term ILC3s incorporates group 3 ILCs that are functionally distinct from LTi cells. Some 
of these cells have been described to express the NCR NKp46 and are the main source of 
IL-22 in the gut after birth (252). Moreover, a subtype of CD4+ ILCs were demonstrated to 
contribute to intestinal IL-22 (253). IL-22 in turn has been shown to maintain epithelial barrier 
integrity upon exposure to pathogens (254,255). Thus, the lack of NCR+ILC3s results in a 
lower expression of anti-microbial molecules (224) and increased susceptibility to intestinal 
infection (222). ILC3s thereby seem to control the microbiota, but there is also evidence that 
the commensal bacteria influence IL-22 producing ILC3s. How exactly pathogens achieve 
this and how they may affect development, maintenance and function of ILC3s is not yet 
completely understood (256). Just like the transition of ILC3s towards ILC1 function the 
generation of NCR+ILC3s was demonstrated to rely on T-bet expression. In mice deficient for 
T-bet the population of NCR+ILC3s is decreased, leading to compromised IL-22 production 
(257). ILC3s have also been found to promote inflammation in a colitis model (258). This 
population was characterised by the secretion of IL-17 and IFNγ and did not express NKp46 
(NCR-ILC3s) (258). In comparison to NCR+ILC3s these cells did not depend on T-bet and 
potently induced innate colitis in mice deficient for both T-bet and RAG2 (259). Furthermore, 
the accumulation of human NCR- ILC3s and increased IL-17 secretion was detected in the 
inflamed intestine of patients suffering from Crohns disease (260). 
 
A great challenge for the research on recently identified ILC populations remains the fact that 
no exclusive ILC markers have been identified so far. Thus, ILCs have mainly been defined 
by their lack of lineage markers (261). Furthermore, they have been characterised by the 
expression of surface molecules related to hematopoietic progenitors (SCA-1 and cKit), T 
cells (CD4, Thy-1) and NK cells (NKp46, NK1.1) (50). In table 1 the distribution of 
phenotypical markers over distinct ILC populations is summarised. 
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Illustration 6:  ILC development into three groups and their expression patterns. Illustration summarising 
the development of different ILC subsets from a common Id2+ precursor cell their requirement for distinct 
transcription factors and their individual cytokine profiles. The dashed arrow indicates the transition of NCR+ILC3s 
towards ILC1 phenotype and function. The table below depicts the expression profile of the various ILC subsets 
as characterised up to now. ND: not determined, +: expressed, -: not expressed; +/-: may or may not be 
expressed. Illustration is adapted from Spits et al., 2013 (50). 
 
»5.4 Innate lymphoid cells and cancer 
Few studies have dealt with the role of ILCs in cancer. A report by Shields et al. described 
that tumour-derived CCL21 promoted the accumulation of LTis and the development of 
lymphoid structures in the tumour margins. These structures were absent in RORγt-deficient 
mice, supporting the necessity for LTis. The formation of such lymphoid tissue was 
correlated with accelerated tumour growth and development of a tolerogenic environment. 
For instance, Tregs were abundant in the tumour and TGF-β levels increased, while 
suppressed levels of IFNγ and fewer tumour-antigen specific CD8+Tcells were detected 
(262). Another study by Kirchberger and collaborators supported the hypothesis that group 3 
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ILCs acted as tumour promoters. In a model of bacteria and carcinogen-induced colorectal 
carcinoma, IL-22 secretion by NCR-ILC3s was shown to maintain tumour growth. After the 
appearance of epithelial dysplasia, neutralisation of IL-22 and anti-Thy-1 antibody-mediated 
depletion of ILC3s reduced tumour burden in experimental mice. Moreover, IL-22 signalling 
was shown to increase the proliferation of dysplastic epithelial cells (263). In addition, in a 
mammary carcinoma model the accumulation of IL-13 secreting ILC2s has been linked to the 
enhanced tumour growth upon IL-33 administration (264). Thus, the study by our group 
deviates from other reports by ascribing an anti-tumour activity to RORγt-dependent ILCs 
(198). Although the upregulation of ICAM-1 and VCAM-1 in the tumour tissue was 
reminiscent of LTi function, tumour suppression was independent of lymphotoxin β receptor 
signalling (198). 
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V Specific aims of the thesis  
Immune modulation by IL-12 treatment remains an interesting approach to combat cancer. 
Many questions regarding the precise mechanism, by which IL-12 achieves the elimination of 
tumours have, however, been left unanswered. Particularly, the implication of various 
immune cell types responding to IL-12 in this context is conflicting. Our group previously 
identified the tumour suppressive potential of RORγt-dependent ILCs. The role of such ILCs 
was, however, only tested in an artificial model of IL-12 secreting tumour cells, providing the 
B16F10 tumours with IL-12 during tumour tissue establishment. Thus, it is of interest, 
whether the action of RORγt-dependent ILCs is still required for the rejection upon 
therapeutical IL-12 intervention after tumour formation. Moreover, the recent awareness of 
various subtypes within the ILC3 compartment asks for the further characterisation of 
phenotype and function of the tumour suppressive ILCs. This description may facilitate the 
understanding of what molecular and cellular players are involved in the ILC-mediated anti-
tumour response elicited by IL-12. 
In this thesis I investigated the time dependency of IL-12 treatment by comparing the 
mechanisms of tumour rejection upon early preventive with late therapeutic treatment of s.c 
B16F10 tumours. The involvement of different cell types in tumour rejection upon late 
therapeutic administration of IL-12 was examined, using transgenic mice. 
RORγt-dependent ILC populations within spleen and small intestines were characterised 
regarding phenotype and tumour suppressive function. In the appendix we elaborate on how 
to improve the gating strategy on ILCs. 
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VI Results 
»6 IFNγ is required for the rejection of late, but not early IL-
12-treated tumours. 
The mechanism by which IL-12 rejects tumours has been suggested to depend on the timing 
of IL-12 treatment (177). For the continuous administration, as in B16F10-IL-12Fc tumours, 
growth suppression was shown to rely on the activation of RORγt-dependent ILCs through 
IL-12Fc (198). In such tumours, IL-12Fc was present from early tumour formation onwards. 
We aimed to assess whether RORγt-dependent ILCs were also required upon late 
therapeutic delivery of IL-12. Therefore, we treated B16F10 tumours from early or late time 
points during tumour growth. 2 x 105 B16F10 cells were inoculated subcutaneously, leading 
to the establishment of a solid tumour, which reached withdrawal criteria towards day 21. In 
one group of mice, administration of IL-12Fc was started simultaneously with B16F10 
inoculation (day 0), mimicking the “treatment” modality of IL-12Fc secreting B16F10 
tumours. The second group received IL-12Fc after day 7, when a small tumour had formed, 
in order to replicate a therapeutic intervention (Illustrated in Figure 1 A). In both groups, 
IL-12Fc or PBS was administered three times a week via s.c. injections before, and i.t. after 
establishment of a palpable lesion. As the IL-12-mediated anti-tumour effect was shown to 
be mainly induced by stimulating IFNγ secretion in previous studies (183), we compared 
tumour suppression in wild type (WT) animals and mice deficient for the IFNγ receptor 
(Ifngr1-/-).  
In WT animals, early and late IL-12Fc treatment led to a substantial reduction of tumour 
growth (Figure 1 B). On day 7 upon B16F10 inoculation, early IL-12Fc treated tumours were 
significantly smaller than tumours from controls, in WT and Ifngr1-/- mice. Until day 21, these 
tumours had merely reached 10 to 15% of the size of PBS administered tumours. In late 
treated WT mice the tumour size was reduced compared to controls. This treatment modality 
failed in Ifngr1-/- mice, where similar tumour sizes were measured upon late IL-12Fc or PBS 
administration. To adjust for the overall accelerated tumour growth in Ifngr1-/- in contrast to 
WT mice, day 21 tumour sizes of the treated groups were compared to the corresponding 
PBS treated tumours to evaluate the effect of treatment. While late IL-12Fc administration 
yielded a 70 % reduction of tumour size in WT mice, tumours in Ifngr1-/- mice were only 6% 
smaller than control tumours. (Figure 1 B).  
Thus, IFNγ signalling is critical for the anti-tumour immunity upon late IL-12Fc injection while 
early treated tumours were rejected in its absence. We concluded that the time point of 
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treatment initiation influences the quality of the subsequent anti-tumour response. Thus, we 
hypothesised that distinct cellular and molecular responses may be involved in the rejection 
of early compared to late treated tumours. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The anti-tumour response upon late IL-12Fc treatment requires IFNγ  signalling. (A) Illustration of 
early and late treatment with IL-12Fc or administration of PBS to controls. (B) Top row: Tumour growth curve 
upon early and late IL-12Fc treatment in WT and Ifngr1-/- mice. Bottom row: Left: Quantification of tumour size in 
WT and Ifngr1-/- animals on day 7 and day 21 after inoculation of tumours corresponding to top row. Right: Effect 
of IL-12Fc treatment measured by the ratio of IL-12Fc treated versus control tumour size for WT and Ifngr1-/- mice 
corresponding to top row. (Data is pooled from 3 independent experiments n=15 (n refers to the number of 
individual mice used in the experiment), mean ± S.E.M) 
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Figure 2. NK cells and CD8+ T cells are the main source of IFNγ  in late IL-12Fc treated tumours. (A) 
Representative FACS plots showing gating on CD45+, singlets, leukocytes and exclusion of dead events in 
tumours on day 10 of growth. Similar gating strategies were used for all analyses of leukocytes in the tumour 
tissue. (B) Representative histogram and quantification of IFNγ+ cell frequency within CD45+ live events isolated 
from late IL-12Fc treated compared to PBS administered tumours. (C) Representative graphs showing gating on 
CD3+ versus CD49b+ - and within the CD3+ events CD4 versus CD8 - in IFNγ+CD45+ events of PBS administered 
or late IL-12Fc treated tumours. (D) Quantification of the frequencies of cells within the IFNγ+CD45+ population 
shown in C. (n=5, mean ± S.E.M, experiment performed once) 
 
Results 
 
48 
»7 The mechanism upon late IL-12Fc treatment 
»7.1 NK cells and CD8+ T cells are the main cellular source of IFNγ  
Due to the necessity of IFNγ for tumour control upon late IL-12Fc treatment, we aimed to 
identify the cellular source of IL-12Fc stimulated IFNγ. We examined leukocytes within 
tumours on day 10 upon B16F10 inoculation, when IL-12Fc would generally have started to 
affect the tumour growth. This allowed us to explore the first phase of B16F10 rejection. 
Leukocytes were isolated from IL-12Fc treated and control tumours and analysed for their 
IFNγ secretion by flow cytometry. The gating on intratumoural leukocytes involved exclusion 
of doublets, cellular debris and dead cells from the CD45 expressing leukocytes (Figure 2 A). 
Within this population IL-12Fc treatment doubled the frequency of IFNγ-secreting cells, 
compared to control tumours (Figure 2 B). Upon IL-12Fc stimulation, IFNγ was solely 
produced by intratumoural lymphocytes as no myeloid cells – characterised by their high 
expression of CD11b – were detected within the IFNγ+CD45+ leukocytes (Data not shown). 
The IFNγ+ population was then further divided by gating on CD4+ and CD8+ CD3+CD49b- T 
cells, CD3+CD49b+ NKT cells and CD3-CD49b+ NK cells (Figure 2 C). CD8+ T cells and NK 
cells were identified as the main source of IFNγ in the tumour tissue as they together 
accounted for 80% of the IFNγ+ fraction (Figure 2 D). While IL-12Fc treatment boosted the 
IFNγ production, the contribution of distinct cell subsets to the IFNγ secretion was not altered 
in comparison to control tumours (Data not shown).  
  
Figure 3. IL-12Fc-induced tumour suppression upon late treatment does not require T cells or NK cells 
but depends on the common gamma chain signalling. (A) Growth of PBS administered or late IL-12Fc treated 
B16 F10 tumours in Rag1-/- mice and Rag2-/-Il2rg-/- mice compared to WT. Tumour sizes were assessed on day 
21 and the effect of treatment (ratio of IL-12Fc treated versus PBS administered tumour) was elaborated (n=5-6, 
experiment performed twice) (B) Tumour growth curve and corresponding tumour sizes on day 21 of late IL-12Fc 
treated or PBS administered Il15ra-/- mice compared to control (n=5, experiment performed twice). (C) 
Quantification of NKp46+Eomes+ NK cell frequencies within tumours of anti-NK1.1 IL-12Fc treated or PBS 
administered mice upon late IL-12Fc administration. (D) Tumour growth upon anti-NK1.1 treatment of Rag1-/- mice 
and corresponding tumour area measured on day 19 (n=4, experiment performed once). (mean ± S.E.M)  
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»7.2 NK and T cells are dispensable for suppression of late treated tumours. 
Since T cells and NK cells were the main contributors to IFNγ secretion, we next assessed, 
whether these cells was required for successful repression of tumour growth by IL-12Fc upon 
late treatment. To study the role of T cells, tumour growth was monitored in RAG1-deficient 
mice (Rag1-/-), lacking T and B cells, and compared to tumour growth in WT and Rag2-/-Il2r-/- 
mice. In Rag2-/-Il2r-/- mice, the tumour suppressing effect of IL-12Fc was abolished (Figure 3 
A). The accelerated tumour growth in both PBS treated Rag1-/- and Rag2-/-Il2r-/- mice 
compared to WT, suggested that tumour growth was controlled by T cells. In the presence of 
IL-12Fc, however, Rag1-/- mice were still able to mount an anti-tumour immunity comparable 
to WT mice (Figure 3 A). We therefore conclude that tumour rejection relies on lymphoid 
cells, but that T cells are dispensable in this context. 
In order to investigate the role of NK cells in tumour control, mice that lack IL-15 receptor 
expression (Il15ra-/-), deficient in mature NK cells, were challenged with B16F10 tumours. 
Those mice efficiently suppressed tumour growth upon injection of IL-12Fc to the same 
extent as WT mice (Figure 3 B).  Thus, we hypothesised that T and NK cells may 
compensate for the absence of the other to secrete sufficient amounts of IFNγ for successful 
suppression of tumour growth. In a preliminary experiment, we attempted to eliminate NK 
cells in Rag1-/- mice, by anti-NK1.1 antibody mediated depletion. The weekly monitoring of 
depletion efficiency in the blood of experimental animals showed a drastic reduction of NK 
cells (Data not shown). The lack of peripheral NK cells was further supported by a low 
frequency of NKp46+Eomes+ cells in the tumours of anti-NK1.1 treated mice (Figure 3 C). 
Even in the absence of both NK and T cells, tumour growth was potently suppressed upon 
late IL-12Fc treatment (Figure 3 D).  
 
»7.3 Tumour growth upon late IL-12Fc treatment is not controlled by RORγt-
dependent ILCs 
The intact anti-tumour response in mice lacking NK and T cells, suggested a role for residual 
innate lymphoid cells upon late IL-12Fc treatment. The potent anti-tumour activity of RORγt-
dependent ILCs may, thus, also impact tumour growth in the therapeutical setting. The 
observation that such ILCs secreted IFNγ upon IL-12 stimulation in vitro (198), further 
supported this hypothesis. To study RORγt-dependent ILCs, we utilised a RORc-eGFP 
reporter mouse (Rorcrep+), in which all RORc transcribing cells simultaneously express 
enhanced green fluorescent protein (eGFP). Mice homozygous for this allele (referred to as 
Rorc-/-) fail to express functional RORγt, as the coding sequence for eGFP is inserted into 
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exon 1 of the RORc locus, (215). Thus, in Rorc-/- mice the IL-12Fc-mediated anti-tumour 
response could be studied in absence of RORγt-dependent lineages. Rorc-/- and Rag1-/- 
animals were crossed to obtain Rorc-/-Rag1-/- mice, which differed from Rag1-/- mice only by 
the absence of RORγt-dependent ILCs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. IL-12Fc suppresses tumour growth independent of RORγt expressing ILCs. (A) Gating strategy 
on Thy-1+IL-7Ra+ ILCs in the gut of naïve Rorc-/-Rag1-/- and Rorcfm+Rag1-/- mice pre-gated on CD45+ live events. 
(General gating strategy for gut lymphocytes is shown in figure 12.) RORγtfm expression on Thy-1low Sca-1+ and 
Thy-1high cells within the Thy-1+IL-7Ra+ population in Rorcfm+Rag1-/- mice. Frequencies of these subpopulations in 
Rorc-/-Rag1-/- and Rorcfm+Rag1-/- mice (n=3, experiment performed twice). (B) Growth curve and tumour sizes on 
day 21 post inoculation of late IL-12Fc treated or PBS administered tumours in Rorc-/-Rag1-/- mice and Rag1-/- 
controls. (n=5, experiment performed twice) (mean ± S.E.M)  
 
First we confirmed the lack of RORγt-dependent ILCs in Rorc-/-Rag1-/- mice and thereby also 
assessed their requirement for the transcription factor RORγt. For this reason, ILCs from 
Rorc-/-Rag1-/- mice were compared to cells from Rorcfm+ fate map animals bred to Rag1-/- 
mice (Rorcfm+Rag1-/-), in which only RORγt-dependent ILCs were RORγtfm+. For the flow 
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cytometric analysis, the lamina propria of the small intestine was selected, due to the 
abundance of RORγt-dependent ILCs in this location. Total ILCs were defined as 
Thy-1+IL-7Rα+ cells within the CD45+ live compartment (Figure 4 A). ILCs were then further 
subdivided into a Thy-1lowSca-1+ and a Thy-1high population. In Rorcfm+Rag1-/- mice the 
Thy-1lowSca-1+ population contained very few RORγtfm+ cells, whereas, the majority of 
Thy-1high cells expressed YFP (Figure 4 A). We therefore concluded that the Thy-1high cells 
referred to the RORγt-dependent subgroup among ILCs. As expected, this RORγt-dependent 
Thy-1high ILC population was absent from the small intestine of Rorc-/-Rag1-/- mice, which is 
illustrated by a drastic decrease in frequency compared to control (Figure 4 A).  
Rorc-/-Rag1-/- mice were challenged with B16F10 tumours, which were IL-12Fc treated from 
day 7 onwards. The lack of RORγt-dependent ILCs did not affect the anti-tumour response 
upon IL-12Fc treatment as illustrated by comparable tumour sizes in Rag1-/- and Rorc-/-Rag1-
/- mice on day 21 of tumour growth (Figure 4 B).  
Thus we concluded that RORγt-dependent ILCs were dispensable for the tumour rejection 
upon late IL-12Fc treatment. Thereby, the cellular responses underlying the tumour 
suppression upon early or late IL-12Fc treatment seemed to diverge.  
 
»8 Cellular targets of IL-12-induced IFNγ  in late treated tumours 
»8.1 The effects of IFNγ  on tumour myeloid cells 
Thus far, our data suggested that IL-12Fc-stimulated lymphocytes secrete IFNγ, which was 
required for the subsequent anti-tumour immunity. Interestingly, the elimination of various 
lymphocyte populations did not impair tumour suppression. Apart from suggesting that the 
depleted cells were dispensable for a solid IFNγ induction, these experiments show that 
neither NK cells nor cells of adaptive immunity were required to respond to IFNγ for the 
IL-12Fc-induced anti-tumour response to occur. Since IFNγ promotes myeloid cell functions, 
such as antigen presentation and secretion of ROS and NO (174), we hypothesised that this 
compartment may also be involved in the rejection of IL-12Fc treated tumours. 
»8.1.1 IL-12-induced IFNγ  activates of monocyte-derived cells in tumours 
In order to characterise the intratumoural myeloid compartment we first aimed to determine 
at which time points leukocytes responded to IL-12Fc-induced IFNγ. Thus, tumours from WT 
and Ifngr1-/- mice were analysed for infiltrating leukocytes early (day 10) and late (day 19) 
during tumour rejection upon late IL-12Fc treatment. Whereas in WT animals, IL-12Fc 
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administration provoked a 4-fold increase of intratumoural CD45+ leukocyte numbers, this 
was not observed Ifngr1-/- mice on day 10 of tumour growth (Figure 5 A). In comparison, day 
19 tumours showed less infiltrates and the number of CD45+ cells was comparable in IL-12Fc 
or PBS administered WT and Ifngr1-/- mice (Figure 5 A). Thus, the further flow cytometric 
analysis of myeloid cells was performed on day 10 of tumour growth, when IL-12Fc initiated 
the IFNγ-dependent accumulation of leukocytes.  
Granulocytes were identified by their high expression of Ly6G within the CD45+ compartment 
(Figure 5 C). The majority of CD11b+ Ly6G- cells were observed to express high levels of 
Ly6C, a characteristic marker for monocytic cells. A large proportion of the Ly6ChighLy6G- 
fraction stained positive for MHC class II (MHCII+), indicating that intratumoural monocytes 
differentiated to monocyte-derived macrophages or DCs. Of the MHCII+ population some 
cells expressed iNOS, suggesting elevated NO secretion. Moreover, we identified APCs by 
their expression of CD11c and MHC class II within CD45+ cells in the tumour. The majority of 
these APCs also expressed Ly6C and CD11b, indicating that they were the progeny of 
monocytes. In contrast, a small proportion of CD11b- DCs was detected (Figure 5 C). 
Further, we quantified the frequencies and total numbers of tumour myeloid populations in 
IL-12Fc treated or PBS administered WT and Ifngr1-/- mice. The frequency of Ly6ChighLy6G- 
cells was significantly elevated in IL-12Fc treated WT mice, whereas these changes were not 
observed in the absence of IFNγ signalling (Figure 5 D). In contrast the frequency of CD11b- 
DCs was decreased in IL-12Fc treated WT mice, compared to Ifngr1-/- mice. Although the 
proportion of Ly6G+ granulocytes seemed to decline upon IL-12Fc administration to WT 
animals, this observation was not significant. The total number of monocytes, and monocyte-
derived macrophages and DCs within IL-12Fc administered tumours was substantially 
elevated in an IFNγ-dependent manner. The accumulation of MHCII+ and iNOS+ cells upon 
treatment in WT but not in Ifngr1-/- mice suggested a general activation of myeloid cell 
function by IFNγ. In contrast, the numbers of non-monocytic cells, such as granulocytes and 
CD11b- DCs were not influenced by IL-12Fc treatment (Figure 5 D). The increase of 
monocytes and monocyte-derived cells and decrease of other myeloid populations was 
further confirmed in tumours on day 19 of growth (Data not shown). Due to the reduced 
leukocyte numbers in such tumours these changes were, however, generally less 
pronounced compared to day 10 tumours. 
In conclusion, the accumulation of monocytes and their progeny in the tumour tissue 
correlated with the IL-12-induced anti-tumour effect. 
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Figure 5. IL-12Fc treatment leads to IFNγ-dependent recruitment of monocytic cells to the tumour. (A) Bar 
graph displays total numbers of intratumoural CD45+ leukocytes on day 10 and 19 of tumour growth in WT and 
Ifngr1-/- mice (n=4-5, mean ± S.E.M, experiment performed twice (day 10) and three times (day 19)). (B) 
Illustration suggesting the activating role of IFNγ on the myeloid cell compartment. (C) Gating strategy on different 
myeloid cell populations in PBS administered or late IL-12Fc treated WT tumours on day 10 of growth. (D) 
Quantification of frequencies (top row) and total numbers (bottom row) of myeloid cells in IL-12Fc treated or PBS 
administered WT and to Ifngr1-/- tumours on day 10 of growth. (n=4-5, mean ± S.E.M, experiment performed 
once) 
 
»8.1.2 CCR2 driven migration of myeloid cells is not required for the anti-tumour 
effects of late IL-12Fc treatment  
To determine whether monocytes and monocyte-derived cells were essential for the anti-
tumour response upon late IL-12Fc treatment, we made use of mice deficient for the 
chemokine receptor CCR2 (Ccr2-/-) (266). This receptor binds the monocyte chemoattractant 
protein-1 (MCP-1/CCL2) and mediates the chemotaxis of monocytes and lymphocytes (267). 
CCR2 is implied in monocyte trafficking during homeostasis (267,268) and is particularly 
essential for the recruitment of monocyte-derived cells to inflammatory tissues (35) and 
tumours (101).  
In Ccr2-/- mice, the IL-12Fc-initiated anti-tumour effect was comparable to suppression of 
B16F10 tumours in WT controls (Figure 6 A). To investigate the impact of CCR2-deficiency 
on the infiltrating myeloid cells we isolated leukocytes from the tumours on day 22 of growth. 
Ccr2-/- tumours showed a drastic decrease in frequency and total number of Ly6ChighLy6G- 
monocytic cells (Figure 6 B and C). The reduction of monocytes was, however, accompanied 
by an increase in the frequency of Ly6G+ granulocytic cells, which was more pronounced 
upon IL-12Fc treatment (Figure 6 B and C). This counterbalance may explain the comparable 
total numbers of CD45+ infiltrating leukocytes in WT and Ccr2-/- mice (Figure 6 D). The lack of 
Ly6ChighLy6G- monocytes influenced the presence of monocyte-derived cells illustrated by 
the reduction in frequency and absolute numbers of CD11c+ cells in the tumour (Figure 6 C 
and D). In contrast, immunofluorescent analysis revealed that F4/80+ cells were frequently 
detected in tumours form Ccr2-/- mice on day 13 of growth. (Figure 6 E). Thus, we assume 
that CCR2-independent F4/80+ tumour macrophages are present within B16F10 tumours.  
We concluded that the IL-12Fc-induced anti-tumour response is independent of CCR2, but 
may still involve Ly6G+ granulocytes or residual myeloid cells observed in Ccr2-/- tumours. 
Tissue resident macrophages within the subcutis may, for instance, populate the tumour 
independently of CCL2 signalling or accumulate by local proliferation. 
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Figure 6. CCR2-dependent migration of monocytes is dispensable for the anti-tumour effect upon late IL-
12Fc treatment. (A) Growth of IL-12Fc treated or PBS administered tumours in Ccr2-/- and WT mice and 
quantification of tumour area on day 22 (pooled from 3 independent experiments, n=13-15, mean ± S.E.M) (B) 
Gating on Ly6C+Ly6G- and Ly6G- cells within CD45+ live cells in PBS administered Ccr2-/- and WT tumours. (C) 
Top row: Frequencies of Ly6C+Ly6G-, Ly6G- and CD11c+ cells within the CD45+ population of IL-12Fc treated or 
PBS administered tumours from Ccr2-/- and WT mice. Bottom row: Total numbers of the populations depicted in 
top row. (n=3-7, mean ± S.E.M, experiment performed twice) (D) Immunofluorescent staining for F4/80 combined 
with nuclear stain 4',6-diamidino-2-phenylindole dilactate (DAPI, blue) of late IL12Fc treated or PBS administered 
tumours from Ccr2-/- and WT mice on day 13 of growth (scale bar refers to 50 µm, n=5, experiment performed 
twice). 
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»8.1.3 The direct response of LysM expressing cells to IFNγ  is not required for the 
late IL-12Fc-dependent anti-tumour immunity  
We further aimed to examine the role of mature macrophages and granulocytes during the 
IL-12Fc-mediated anti-tumour response. These cells are characterised by high expression of 
Lysozyme 2 (LysM), an enzyme with bacteriolytic activity (269,270). Moreover, LysM 
expression was demonstrated to gradually increase during differentiation and upon activation 
of myeloid cells (271). LysM expressing cells were targeted by utilising mice that express the 
Cre recombinase under the LysM promoter (LysM-Cre+) (272). LysM-Cre animals were bred 
to mice expressing conditional alleles of the IFNγ receptor (Ifngrfl/fl) to obtain LysM-Cre+Ifngrfl/fl 
mice. In these mice the Cre recombinase deletes the loxP site flanked exons 4-6 of the 
IFNγR gene (273), whereby LysM expressing myeloid cells become unresponsive to IFNγ. 
 
 
 
 
 
 
 
 
 
Figure 7. The lack of IFNγ  signalling on LysM expressing cells does not impact the anti-tumour response 
upon late IL-12Fc treatment. (A) Left: Growth of IL-12Fc treated or PBS administered tumours in LysM-
Cre+Ifngrfl/fl mice and Cre-Ifngrfl/fl littermates. Right: quantification of tumour area on day 21-post inoculation. (Data 
pooled from two experiments n=10-11, mean ± S.E.M) (B) Histogram showing pSTAT1 staining on Ly6G+CD45+ 
cells in the blood of naïve Cre-Ifngrfl/fl, LysM-Cre+Ifngrfl/fl, and Ifngr1-/- mice (n=2; experiment performed once). 
 
We then compared the tumour growth upon late IL-12Fc treatment in LysM-Cre+Ifngrfl/fl mice 
to their Cre-Ifngrfl/fl littermates. LysM-Cre+Ifngrfl/fl mice did not show an impairment of the 
IL-12Fc-induced anti-tumour immunity and tumour sizes were comparable to Cre-Ifngrfl/fl 
controls (Figure 7 A). A preliminary experiment indicated that Ly6G+ granulocytes in the 
blood were less responsive to IFNγ, as STAT1 phosphorylation (pSTAT1) was decreased in 
LysM-Cre+Ifngrfl/fl compared to Cre-Ifngrfl/fl mice (Figure 7 B). pSTAT1 staining intensities in 
granulocytes from LysM-Cre+Ifngrfl/fl and Ifngr1-/- mice nearly overlapped, suggesting 
successful recombination upon Cre expression in those cells (Figure 7 B). Due to the lack of 
Results 
 
58 
mature macrophages in the blood, the pSTAT1 staining could not be assessed in those cells. 
Detection of pSTAT1 in tumour infiltrating myeloid cells failed due to low cell numbers.  
We concluded that granulocytes are likely to be dispensable for IL-12-mediated tumour 
rejection, whereas the involvement of macrophages cannot be excluded. 
 
»8.2 The effects of IFNγ  on the tumour vasculature 
Our data suggested that lymphocytes and monocyte-derived cells were not required to 
respond to IFNγ to induce IL-12Fc-mediated tumour suppression upon late treatment. As this 
excluded the majority of immune cell types that accumulated in the tumour tissue upon IL-12 
treatment, we focused our further studies on tumour stromal cells. IL-12-induced IFNγ has 
previously been shown to elicit potent anti-angiogenic effects, inhibiting tumour growth (274). 
Anti-angiogenic mediators were mostly described to derive from IFNγ responsive leukocytes 
and tumour cells (189,191), but direct effects of IFNγ on the endothelial cells have also been 
suggested (188). Moreover, IL-12 administration was previously shown to elicit an up-
regulation of ICAM-1 and VCAM-1 on tumour vessels (189,198). This alteration of the 
adhesion molecule expression on the vasculature may facilitate leukocyte infiltration. Thus 
the accumulation of immune cells within IL-12Fc treated tumours, observed in this study, 
further supports a role of the tumour endothelium.  
»8.2.1 IL-12-induced IFNγ  increases ICAM-1 and VCAM-1 expression and inhibits 
growth of endothelial cells  
The effect of IFNγ on the tumour vasculature was examined in IL-12Fc or PBS administered 
tumours from WT and Ifngr1-/- mice on day 19 of growth (Figure 8 A). Upon isolation of 
CD31+CD45- endothelial cells from the tumours, expression of the adhesion molecules 
ICAM-1 and VCAM-1, and endothelial cell numbers were determined by flow cytometry 
(Figure 8 B).  
Figure 8. IL-12Fc treatment leads to IFNγ-dependent alterations of the tumour vasculature. (A) Gating 
strategy on live population, singlets, and CD45- and CD45+ cells within WT tumours. Similar gating approaches 
were used to analyse endothelial cells isolated from the tumour. (B) Representative FACS plots showing gating 
on CD31+ CD45- events and expression of ICAM-1 and VCAM-1 on these CD31+ tumour endothelial cells in late 
IL-12Fc treated or PBS administered WT tumours. (C) Quantification of median fluorescent intensities for ICAM-1 
and VCAM-1 on CD31+CD45- cells for treated or PBS administered tumours grown in Ifngr1-/- and WT mice. (D) 
Frequency of CD31+ endothelial cells in CD45- events and of CD45+ leukocytes within live, cells in IL-12Fc treated 
or PBS administered tumours from Ifngr1-/- and WT mice. (n=3-4, mean ± S.E.M, experiment performed twice). (E) 
Total number of CD31+ and CD45+ cells in treated or PBS administered tumours of Ifngr1-/- and WT mice (n=3-4, 
mean ± S.E.M, experiment performed twice). (F) Illustration of working hypothesis showing the stimulatory effect 
of IFNγ on adhesion molecule expression on the tumour vasculature, facilitating leukocyte transmigration to the 
tissue.  
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This analysis confirmed that IL-12Fc treatment induced a substantial up-regulation of ICAM-1 
and VCAM-1 on the tumour vasculature compared to PBS administered controls (Figure 8 B 
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and C). The increase of ICAM-1 and VCAM-1 expression was highly dependent on IFNγ 
signalling, as it was abrogated in Ifngr1-/- mice (Figure 8 B, C). In late IL-12Fc treated animals 
the frequency and total numbers of CD31+CD45- cells was markedly reduced in an IFNγ-
dependent manner (Figure 8 B, D, E). Similar changes were also detected on day 13 of 
tumour growth and were, thus, independent of the tumour size (Data not shown). These 
results suggested, that IFNγ inhibits angiogenesis by its direct or indirect effects on 
endothelial cells, which may cause the growth regression of IL-12Fc treated tumours. The 
frequency of infiltrating leukocytes increased upon IL-12Fc treatment in WT and Ifngr1-/- 
mice. (Figure 8 D). As previously demonstrated, the absolute number of CD45+ infiltrating 
leukocytes was comparable in presence and absence of IFNγ signalling at this late time point 
in tumour growth (Figure 8 E). Thus, on day 19 of tumour progression the leukocyte 
migration into the tumour was disconnected from the enhanced ICAM-1 and VCAM-1 
expression induced by IL-12Fc and IFNγ.  
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Figure 9. IFNγ-dependent upregulation of ICAM-1 expression on the tumour vasculature upon IL-12Fc 
treatment assessed by immunofluorescence analysis. Representative graphs showing detection of ICAM-1 
(red) and CD31 (green) by immunofluorescent staining in late IL-12Fc treated or PBS administered B16F10 
tumours on day 13 of growth in Ifngr1-/- and WT mice. (scale bar refers to 500 µm, n=5, experiment performed 
twice 
 
To confirm these results, immunofluorescent analysis of tumour sections from IL-12Fc or 
PBS administered WT and Ifngr1-/- mice was performed. Only IL-12Fc treated WT mice 
showed a strong ICAM-1 signal on CD31+ tumour vessels, supporting the essential role of 
IFNγ for the induction of this adhesion molecule (Figure 9). A decreased number of small 
vessels were observed in IL-12Fc treated tumours of WT mice although this was not 
quantified (Figure 9). This would further support the evidence of anti-angiogenic mechanisms 
provoked by IL-12Fc  
Thus, IFNγ seems to regulate tumour vessel formation and adhesion molecule expression in 
IL-12Fc treated tumours. 
»8.2.2 IFNγ  signalling on endothelial cells regulates ICAM-1 and VCAM-1 expression 
in vitro. 
In order to distinguish direct from indirect effects of IFNγ on endothelial cells an in vitro assay 
was utilised. Cells from the MS-1 (MILE SVEN 1) pancreas-derived endothelial cell line were 
cultured in the presence or absence of cytokines and/or purified lymphocytes. After culture 
for 48 hours the MS-1 cells were harvested and analysed by flow cytometry. Treatment with 
IL-12Fc alone showed no effect on ICAM-1 and VCAM-1 expression on MS-1 cells, while 
IFNγ induced a significant up-regulation of both adhesion molecules (Figure 10 A). Purified 
RORγtfm+ ILCs or NK1.1+ NK cells stimulated with IL-12Fc provoked elevated adhesion 
molecule levels on MS-1 cells. Blocking IFNγ by an anti-IFNγ antibody led to a complete 
ablation of the adhesion molecule up-regulation induced by the IL-12-treated lymphocytes 
(Figure 10 A). Labelling of MS-1 cells with a fluorescent dye allowed the quantification of cell 
proliferation. Interestingly, IFNγ increased MS-1 proliferation rates, while all other conditions 
had no impact (Figure 10 B).  
These results suggest that direct IFNγ signalling may regulate adhesion molecule expression 
on endothelial cells. 
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Figure 10. IFNγ  secreted by lymphocyte populations directly effects the adhesion molecule expression 
on the MS-1 endothelial cell line. (A) Median fluorescent intensity of ICAM-1 (left) and VCAM-1 (right) on MS-1 
cells co-cultured with RORγtfm+ ILCs and fm-NK1.1+ NK cells FACS purified from Rorcfm+Rag1-/- mice upon in vitro 
addition of IL-12Fc alone or in combination with a blocking anti-IFNγ antibody compared to controls. IFNγ 
supplementation was used as control. (B) MS-1 proliferation determined by using the dye cell trace violet under 
the conditions described in A. (n=3, mean ± S.E.M, experiment performed twice) 
 
»8.2.3 Direct IFNγ  signalling causes endothelial cell alterations but is dispensable 
for IL-12Fc-induced tumour suppression in vivo. 
In vivo, endothelial cells were targeted by utilising mice that express the Cre recombinase 
under the endothelium specific VE-Cadherin promoter (VEC-Cre) (275). VE-Cadherin is a 
transmembrane protein involved in homotypic cell adhesion, which is continuously expressed 
by differentiated quiescent endothelial cells (275-277). Notably, VE-Cadherin is also 
transcribed in hematopoetic stem cells with endothelial origin, which are targeted in VEC-Cre 
mice (275,278). Using a similar approach as for the LysM-specific ablation of IFNγ signalling, 
we bred VEC-Cre+Ifngrfl/fl mice to disrupt IFNγ receptor expression on endothelial cells.  
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Figure 11. Alteration of tumour vasculature upon late IL-12Fc treatment mainly relies on the direct impact 
of IFNγ  on the endothelium. (A) Growth curve and size on day 21 of tumours collected from VEC-Cre+Ifngr1fl/fl 
mice and Cre-Ifngr1fl/fl littermates upon late IL-12Fc treatment compared to PBS administered controls (pooled 
data from two independent experiments, n=7-11, mean ± S.E.M) (B) Median fluorescent intensity of ICAM-1 and 
VCAM-1 on CD31+CD45- cells from tumours of VEC-Cre+Ifngr1fl/fl and Cre-Ifngr1fl/fl mice treated with IL-12Fc or 
PBS administered. (C) Frequency and absolute numbers of the CD31+ population in CD45- cells within treated 
and control tumours in VEC-Cre+Ifngr1fl/fl and Cre-Ifngr1fl/fl mice. (D) Frequency of live CD45+ cells and total 
numbers within treated or PBS administered tumours in VEC-Cre+Ifngr1fl/fl and Cre-Ifngr1fl/fl mice. (n=3-6, mean ± 
S.E.M) (E) Representative immunofluorescent images showing ICAM-1 (red) and CD31 (green) and DAPI (blue) 
in treated and control tumours on day 21 of growth from VEC-Cre+Ifngr1fl/fl and Cre-Ifngr1fl/fl mice (scale bar refers 
to 50 µm). (n=5, experiments performed twice)  
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VEC-Cre+Ifngrfl/fl mice and Cre-Ifngrfl/fl littermates were challenged with B16F10 tumours and 
the IL-12Fc-induced tumour suppression was compared. Tumour growth upon IL-12Fc 
treatment was similar in VEC-Cre+Ifngrfl/fl and Cre-Ifngrfl/fl animals (Figure 11 A). In tumours 
from Cre-Ifngrfl/fl mice ICAM-1 and VCAM-1 were upregulated upon IL-12Fc treatment, 
whereas this effect was largely abolished VEC-Cre+Ifngrfl/fl mice (Figure 11 B). Frequency 
and absolute numbers of CD31+CD45- endothelial cells were reduced in Cre-Ifngrfl/fl but not in 
VEC-Cre+Ifngrfl/fl mice, although statistical testing did not reach significance (Figure 11 C). 
The accumulation of immune cells in the tumour tissue was not influenced by the mouse 
genotype (Figure 11 D). Thereby, the endothelium in VEC-Cre+Ifngrfl/fl mice underwent similar 
changes as observed in Ifngr1-/- mice. This implied that recombination upon Cre expression 
in endothelial cells was successful in VEC-Cre+Ifngrfl/fl mice. In contrast, immunofluorescent 
detection of ICAM-1 and CD31 in tumour sections showed an increase of ICAM-1 signal on 
IL-12Fc treated tumours from both Cre-Ifngrfl/fl and VEC-Cre+Ifngrfl/fl mice. In tumours from 
VEC-Cre+Ifngrfl/fl compared to Cre-Ifngrfl/fl mice the ICAM-1 staining was observed to be 
surrounding tumour vessels rather than locating on the cell surface of CD31+ cells. ICAM-1 
expression on IFNγ responsive tumour cells and leukocytes in the tumour may have 
influenced this result.  
Taken together, we conclude that the direct effect of IFNγ on the tumour vasculature does not 
influence tumour growth upon late treatment with IL-12Fc.  
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»9 Cellular responses to early IL-12Fc treatment of s.c. B16F10 
tumours  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. IL-12Fc responsive splenic but not gut RORγt-dependent ILCs are sufficient to induce tumour 
suppression upon early IL-12Fc treatment. (A) Gating strategy for singlets, lymphocytes, live events and 
CD45+ RORγtfm+ cells from spleen and the lamina propria of the small intestines (from here on referred to as LP 
gut) in Rorcfm+Rag1-/- mice. (B) Illustration of the experimental setup for the purification of RORγtfm+ ILCs form 
Rorcfm+Rag1-/- donors and their co-transfer together with B16F10-IL-12Fc cells into Il12rb2-/- recipients. (C) 
Growth of B16F10-IL-12Fc tumours in Il12rb2-/- mice upon transfer of 6ʼ000-10ʼ000 RORγtfm+ ILCs derived from 
spleen or LP gut, or PBS and correspondent tumour sizes on day 22 post inoculation. (n=4-5, mean ± S.E.M, 
experiment performed 3 times. Cell purification was performed by K. Nussbaum and S. Burkhard; K. Nussbaum 
measured the tumours) 
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»9.1 Splenic, but not gut-derived RORγt-dependent ILCs induce the anti-tumour 
response upon early IL-12Fc treatment 
RORγt-dependent ILCs derived from the spleen have previously been described to induce 
the suppression of tumour growth upon stimulation with IL-12Fc (198). Moreover, the 
immune system of the gut harbours a large population of RORγt-dependent ILCs (50). Thus, 
we aimed to investigate whether these cells shared the tumour suppressive potential with 
their splenic counterpart. RORγtfm+ ILCs in the lamina propria of the small intestines (referred 
to as gut ILCs) and from the spleen of Rorcfm+Rag1-/- mice were identified by their expression 
of eYFP and CD45, and FACS purified (Figure 12 A). Similar to previous experiments (198), 
we co-injected  RORγtfm+ ILCs together with B16F10-IL-12Fc into Il12rb2-/- mice (Figure 12 
B). Upon transfer, splenic RORγtfm+ ILCs efficiently controlled tumour growth, whereas gut-
derived ILCs failed to mount this response (Figure 12 C).  
This data shows that there are functional differences between RORγtfm+ ILCs in the gut and 
spleen. We hypothesised that their diverging function could be explained by the presence of 
different ILC subsets or developmental stages in these two organs.   
 
»9.2 RORγtfm+ ILCs from the tumour, spleen and gut differ regarding their 
expression of surface markers 
In order to investigate the differences between gut- and spleen-derived ILCs we first 
analysed their phenotype. The population of RORγtfm+ ILCs in gut and spleen were 
characterised by surface markers that have previously been used to scrutinise ILC subsets. 
The expression pattern observed on RORγtfm+ ILCs was compared to fm-CD49b+NK1.1+ NK 
cells from the spleen (Figure 13 B). NK cell markers such as NKp46, CD49b and NK1.1 were 
expressed at similar levels on both splenic ILCs and NK cells, whereas gut ILCs expressed 
lower levels (Figure 13 A). In the case of ILC characteristic surface markers, such as Thy-1, 
IL-7Rα and cKit, expression levels were lower on splenic ILCs and NK cells compared to gut 
RORγtfm+ ILCs. Sca-1 expression was similar in all populations (Figure 13 A). In conclusion, 
splenic ILCs mirrored the expression pattern of NK cells whereas gut RORγtfm+ ILCs clearly 
diverged phenotypically. This was supported by gene array data, further illustrating 
transcriptional differences between RORγtfm+ ILCs from gut and spleen (Data not shown).  
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Figure 13. RORγtfm+ ILCs 
from spleen and gut 
differ in their surface 
marker expression. (A) 
Representative 
histograms showing 
surface expression levels 
of NK cell markers 
(NKp46, CD49b and 
NK1.1) and classical ILC 
markers (Thy-1, IL-7ra, 
Sca-1 and c-Kit) on 
splenic and LP gut 
RORγtfm+ cells and fm-
CD49b+NK1.1+ cells 
isolated from 
Rorcfm+Rag1-/- mice. (B) 
Gating on CD49+NK1.1+ 
cells within the fm-CD45+ 
compartment. (n=3, mean 
± S.E.M, experiment was 
performed 6 times, 
depicted data by S. 
Burkhard) 
 
 
Thus, we sought to investigate the expression of surface markers on RORγtfm+ ILCs within the 
tumour tissue. For this purpose Rorcfm+Rag1-/- mice were challenged with B16F10 tumours, 
which were administered with IL-12Fc form day 0 onwards. We investigated early IL-12Fc 
treated tumours on different days after B16F10 inoculation and found that RORγtfm+ ILC 
density was highest on day 2 and 4 of growth (Data not shown). Thus, tumours and spleens 
from IL-12Fc or PBS administered mice were further compared for the presence of these 
cells on day 4-post inoculation, (Figure 14 A). Similar to their splenic counterpart, the majority 
of intratumoural RORγtfm+ ILCs expressed CD49b and NKp46 (Figure 14 A, B). In contrast, 
RORγtfm+ cells from the tumour displayed a uniform high expression for Thy-1, whereas 
splenic cells expressed variable levels (Figure 14 B). Early IL-12Fc treatment increased the 
frequency of RORγtfm+ ILCs within the tumour infiltrating CD45+ leukocytes, while 
phenotypical characteristics did not change (Data not shown).  
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Total numbers of intratumoural ILCs were not elevated (Figure 14 C), which may be 
explained by the reduced tumour size in IL-12Fc treated mice. Due to small tumour masses 
on day 4, diameters of the lesions and tissue weight could not be determined accurately. In 
the spleen IL-12Fc treatment led to both elevated frequency and total numbers of RORγtfm+ 
ILCs (Figure 14 C). However, the enlargement of the spleen upon IL-12Fc treatment should 
be taken into account.  
In summary, these data suggest that tumour infiltrating RORγtfm+ ILCs share similarities with 
both spleen- and gut-derived ILCs. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. RORγtfm+ ILCs infiltrate the IL-12Fc-treated tumour at early time points and share similarities 
with both their splenic and gut counterpart. (A) Gating on RORγtfm+ CD45+ live cells isolated from spleens and 
tumours Rorcfm+Rag1-/- mice, upon early IL-12Fc or PBS administration. (B) Representative histograms showing 
expression of CD49b, NKp46 and Thy-1 on RORγtfm+ ILCs and fm- NK cells in tumour and spleen. (C) Frequency 
and total numbers of RORγtfm+ cells within the CD45+ compartment in IL-12Fc treated or PBS administered 
tumours. (D) Frequency and total numbers of RORγtfm+ events within the CD45+ compartment in the spleen of 
treated or PBS administered mice. (n=5, mean ± S.E.M, experiment was performed twice by S. Burkhard) 
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»9.3 Splenic and gut RORγtfm+ ILCs differ in transcriptional levels of IL-12Rβ2 and 
IL-23R. 
Next, we investigated whether the discrepancy in the anti-tumour function of splenic and gut 
ILCs could be explained by different responsiveness to IL-12Fc. RORγtfm+ ILCs from the gut 
and spleen were purified and cultured in presence or absence of IL-12Fc for 12 hours. 
Thereafter, transcriptional levels of IL-12Rβ2 and IL-23R receptor subunits were quantified 
by qPCR. Notably, IL-12Rβ2 expression was approximately 5 fold higher in splenic compared 
to gut RORγtfm+ ILCs (Figure 15 A). In contrast, the transcription level for IL-23R was elevated 
on gut compared to splenic ILCs, although this was not observed to be statistically significant 
(Figure 15 B). Due to low RORγtfm+ ILCs numbers obtained from the spleen, the relative 
expression values varied substantially, but always showed the same trends. Stimulation of 
purified RORγtfm+ ILCs with IL-12Fc in vitro increased mRNA levels for IL-12Rβ2 on both ILC 
populations (Figure 15 C). Moreover, IFNγ levels in the supernatants were elevated upon 
IL-12Fc exposure of splenic compared to gut RORγtfm+ ILCs (Data not shown).  
The observed differences in IL-12Rβ2 expression imply that RORγtfm+ ILCs form the spleen 
are more responsive to IL-12 compared to gut ILCs. This may explain why only splenic cells 
could reject IL-12Fc secreting tumours in the transfer experiment. 
 
 
 
 
 
 
 
 
 
Figure 15. Splenic RORγtfm+ ILCs express higher levels of IL-12rβ2 compared to gut ILCs. (A) IL-12rb2 (left) 
and IL-23r (right) expression levels in FACS purified splenic and LP gut RORγtfm+ ILCs , assessed by quantitative 
PCR. (C) IL-12rb2 expression levels upon in vitro stimulation with IL-12Fc for 12 hours of RORγtfm+ ILCs derived 
from spleen and LP gut. (mean ± S.E.M, pooled data from 3 individual experiments with 3 technical replicates 
each, statistical significance was assessed by a paired T test. Purification of cells was performed by K. Nussbaum 
and S. Burkhard. Isolation of mRNA and quantification of expression levels was performed by S. Burkhard) 
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»9.4 RORγtfm+ ILCs in the spleen down-regulate RORγt and adopt ILC1 
characteristics 
RORγt-dependent ILC3s are reported to adopt phenotypical and functional features of ILC1s, 
such as expression of NK cell markers and the production of IFNγ, which coincide with the 
loss of RORγt expression (239,240). More recently, this differentiation was shown to be 
induced upon IL-12 and IL-18 stimulation (240,241). As splenic RORγtfm+ ILCs clearly 
displayed characteristics of ILC1s, we investigated the RORγt expression by splenic and gut-
derived cells. These populations were analysed in Rorcrep+Rag1-/- mice, in which RORγt 
expressing ILCs were labelled with eGFP (RORγtrep+), and compared to RORγtfm+ cells. While 
in the gut a population of RORγtrep+ was detected, in the spleen nearly all cells from the 
Rorcrep+Rag1-/- reporter mice were eGFP negative (Figure 16 A). This suggested that some 
RORγtfm+ ILCs from the gut actively expressed RORγt, while most splenic RORγtfm+ ILCs had 
down-regulated RORγt. The expression of the transcription factors RORγt and T-bet in 
RORγtfm+ ILCs was further assessed by intracellular staining and compared to CD49b+ NK 
cells and CD4+ TH cells. Whereas the vast majority of gut RORγtfm+ ILCs expressed RORγt, 
the majority of the splenic compartment was RORγt-. Instead, RORγtfm+ ILCs from the spleen 
and NK cells expressed T-bet, while in the gut both T-bet+ and T-bet- cells were detected 
(Figure 16 B). Approximately 20% of splenic RORγtfm+ ILCs were shown to secrete IFNγ, 
while only 2.5% of gut-derived cells expressed this cytokine. The IL-17A secretion was 
observed to be low in both RORγtfm+ ILC populations in naïve mice (Figure 16 C). 
This data demonstrates that RORγtfm+ ILCs in the spleen have down-regulated RORγt and 
express T-bet. Thus, we assume that these cells have undergone the transition from ILC3 to 
ILC1 function, which allows them to secrete IFNγ and possibly supplies them with their anti-
tumour properties.  
 
 
 
 
 
 
 
 
Results 
 
71 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Splenic RORγtfm+ are have down-regulated their RORγt expression and thereby adopt ILC1 
characteristics. (A) Left: Splenic and LP gut RORγtfm+ and RORγtrep+ ILCs isolated from Rorcfm+Rag1-/- and 
Rorcrep+Rag1-/- mice, respectively. Right: Frequency of RORγtfm+ and RORγtrep+ events in spleen and LP gut. (n=3-
4, mean ± S.E.M performed 3 times, depicted data by S. Burkhard) (B) Top row left: Representative histograms of 
RORγt and T-bet expression, assessed by intracellular staining of purified RORγtfm+ ILCs , CD49+ NK cells and 
CD4+ T cells form spleen and LP gut. Top row right: frequencies of RORγt and T-bet expressing splenic and LP 
gut-derived RORγtfm+ ILCs. Bottom row: FACS plots showing IFNγ secretion and frequencies of IFNγ and IL-17A 
expressing RORγtfm+ ILCs in spleen and LP gut (mean ± S.E.M, experiment performed twice by K. Nussbaum). 
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»9.5 The anti-tumour response upon early IL-12Fc administration does not depend 
on IL-15 signalling 
NCR+ ILCs were recently demonstrated to depend on IL-15 for their development or 
maintenance, as their population was found to be decreased in the gut of IL-15-deficient 
mice. More specifically, the numbers of ILC1s and ILC3s, expressing the natural cytotoxicity 
receptors NKp46 and NK1.1, were shown to be reduced (234). Thus, we aimed to assess the 
role of IL-15 signalling on the maintenance of the splenic pool of ILCs and the anti-tumour 
response upon early IL-12Fc treatment by utilising IL-15 receptor-deficient mice (Il15ra-/-).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. The effect of early IL-12Fc treatment on the tumour growth is independent of IL-15 signalling. 
(A) Left: Gating on Eomes positive and negative NKp46+CD3-CD5- cells in the spleen of naïve WT and Il15ra-/- 
mice. Right: Quantification of the frequencies Eomes+ and Eomes- cells defined in the FACS plots (left). (n=3, 
mean ± S.E.M, experiment performed once). (B) Left: Tumour growth in Il15ra-/- and WT mice upon early IL-12Fc 
treatment or PBS administration. Right: Tumour sizes were quantified on day 7- and day 21-post inoculation (n=5, 
mean ± S.E.M, experiment performed twice).  
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NKp46+CD3-CD5-CD45+ lymphocytes were isolated from the spleen and further distinguished 
by their expression of Eomes (Figure 17 A). Comparison of the Eomes+NKp46+ population in 
the spleen of Il15ra-/- and WT mice revealed a dramatic decrease in frequency of the Eomes 
expressing population. In contrast, the pool of Eomes-NKp46+ cells in was only marginally 
reduced in Il15ra-/- compared to WT mice, although statistical values did not reach 
significance (Figure 17 A). B16F10 cells were inoculated to Il15ra-/- mice and tumour growth 
was compared to WT controls. Il15ra-/- mice showed no impairment in tumour control in 
comparison to WT mice upon early treatment with IL-12Fc (Figure 17 B). A preliminary 
experiment further indicated that the majority of RORγtfm+ ILCs in the spleen expressed the 
transcription factor Eomes (Observation by K. Nussbaum not shown). 
Thus, tumours were still rejected in absence of IL-15 signalling and thereby Eomes+ NK cells 
and ILCs. We therefore hypothesised that such ILCs may not be necessary for the IL-12Fc-
induced tumour suppression. 
 
»9.6 RORγtfm+ ILCs are not necessary for the rejection of early IL-12Fc treated 
tumours 
Similar the previous study by our group (198), we have demonstrated that the response of 
splenic RORγtfm+ ILCs to IL-12Fc is sufficient to induce the subsequent anti-tumour immunity. 
Further, we aimed to establish whether RORγt-dependent ILCs are also necessary for the 
rejection of tumours. To address this, we compared tumour growth of early IL-12Fc treated or 
PBS administered tumours in Rorc-/-Rag1-/- animals to those in Rag1-/- mice. Interestingly, the 
anti-tumour response in Rorc-/-Rag1-/- mice was unaffected by the absence of RORγt-
dependent ILCs (Figure 18 A). To further support this data Rorc-/-Rag1-/- splenocytes were 
co-transferred with B16F10-IL-12Fc to Il12rb2-/- mice and compared with splenic cells derived 
from Rag1-/- mice in a preliminary experiment. Both Rorc-/-Rag1-/- and Rag1-/- splenocytes 
were equally efficient at suppressing the tumour growth (Figure 18 B).       
This suggests that RORγtfm+ ILCs are not necessary for the IL-12Fc-induced anti-tumour 
response. This implies that other cell populations harbour similar tumour suppressive effects. 
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Figure 18. RORγt-dependent ILCs are not necessary for early IL-12Fc-induced anti-tumour responses. (A) 
Left: Growth of early IL-12Fc treated or PBS administered B16F10 tumours in Rorc-/-Rag1-/- and Rag1-/- mice. 
Right: Quantification of the tumour size on day 7 and day 21 of tumours corresponding to the left graph. (n = 4-5, 
mean ± S.E.M, experiment performed twice) (B) Left: Tumour growth in Il12rb2-/- mice upon transfer of 2 x 105 
splenocytes (SPLC) isolated from Rorc-/-Rag1-/- and Rag1-/- mice together with B16F10-IL-12Fc tumour cells. 
Right: Quantification of tumour area on day 21 of tumours depicted in left graph. (n=4-5, mean ± S.E.M, 
experiment performed once) 
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VII Discussion   
»10 Distinct involvement of IFNγ  and immune cells upon early and 
late IL-12Fc treatment 
The potent anti-tumour effects elicited by IL-12 treatment have been demonstrated in various 
experimental models, and raised expectations for the immunotherapy of human cancers. The 
occurrence of severe side effects upon systemic IL-12 treatment of cancer patients, however, 
frustrated these hopes. In contrast, several clinical studies reported encouraging effects of 
IL-12 on human malignancies (206-208,279). Thus, the uncertainty remains, whether modern 
medicine can benefit from the treatment potential of IL-12 and avoid adverse effects. Many 
research groups have focused on a more localised and thereby safer delivery of IL-12 to the 
tumour tissue (206). Understanding the mechanistic principles of IL-12-induced tumour 
suppression and side effects may further support the development of successful cancer 
therapies. Molecules, such as cytokines, involved in the IL-12-mediated tumour suppression 
may themselves be implemented as anti-cancer agents. Furthermore, the function of tumour 
suppressing cell types in this context could be supported by other immune modulating 
components. Unfortunately, many studies dedicated to the characterisation of this 
mechanism presented conflicting results. These discrepancies may be explained by the 
timing and dosage of IL-12 administration (177), as well as the anatomical location of the 
tumour (196). 
In order to investigate the time dependency of IL-12 treatment we compared two different 
treatment regimens with IL-12Fc. While both treatment modalities elicited strong anti-tumour 
effects, different mechanisms of tumour rejection regarding the involvement of IFNγ were 
observed. What causes this discrepancy that is solely influenced by the timing of IL-12Fc 
treatment can only be speculated. IL-12Fc transferred simultaneously with B16F10 cells 
may, for instance, alter or delay the formation of the tumour mass. In this respect, one could 
investigate whether IL-12Fc can also inhibit the establishment of tumours in 3 dimensional 
tissue culture assays. Moreover, if early IL-12Fc treatment only depends on this initial 
obstruction of tumour formation, a single bolus of IL-12Fc would be expected to cause the 
same suppression of tumour growth as early treatment. In contrast, the low number of 
tumour cells at the time of inoculation may be more controllable by the few tumour 
suppressive immune cells. 
Previous studies suggested the importance of direct effects of IFNγ on the tumour cells, 
resulting in suppression of their proliferation (280) and induction of anti-angiogenic effects 
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(191,280). The B16F10 cells employed in our experiments, however, always entailed the 
same responsiveness to IFNγ. Thus, the failure of the late IL-12-mediated anti-tumour 
response in Ifngr1-/- mice suggests that direct IFNγ signalling on B16F10 cells is dispensable 
in our model. To exclude that autocrine positive feedback loops are necessary for the 
maintenance of sufficient IFNγ levels, one could further determine the concentration of IFNγ 
tumours from Ifngr1-/- and WT mice.  
For the study of early anti-tumour response, it is essential to bear in mind that the late IFNγ-
dependent anti-tumour effect occurs in addition to the IFNγ-independent early response. 
Thereby, the late tumour suppression may mask the failure of early treatment in the 
genetically modified mouse models used in this study. Thus, the study of early and late 
tumour suppression in different knock out strains was predominantly performed 
simultaneously. The quantification of tumour sizes on day 7 of tumour growth, where early 
treatment already shows its tumour suppressive effect, however, could be biased due to 
small lesions and resulting inaccuracy of the measurements. To avoid confusion between the 
effects of early and late treatment, one could block the late IL-12Fc-induced anti tumour 
response by administration of an anti-IFNγ antibody to tumour-bearing mice. 
In summary, our results support the fact that the mechanism of tumour rejection upon IL-12 
administration is highly dependent on the timing of the treatment regimen. 
 
»11 Sources of IFNγ  upon late treatment 
In late IL-12Fc-treated tumours, IFNγ was solely secreted by lymphoid cells. This contrasts 
previous reports showing that also myeloid cells can produce IFNγ upon IL-12 stimulation, 
although these findings are controversial (281). For instance, a subset of CD8α+ lymphoid 
DCs was observed to contribute strongly to the IFNγ secretion in response to IL-12 and 
listeria monocygotes stimulation in NK cell depleted Rag2-/- mice (282). In fact, serum levels 
of IFNγ were observed to be comparable to those of WT mice, whereas sera of Rag2-/-Il2gc-/- 
mice lacked IFNγ (282). Whether such compensation also takes place in the tumours of anti-
NK1.1 treated Rag1-/- mice in our study remains to be established. This sustained IFNγ 
secretion may explain the unaffected anti-tumour response in those mice. Particularly, the 
contribution of ILCs to intratumoural IFNγ production in the absence of NK and adaptive 
immune cells needs to be further characterised. Given the abundance of NK cell markers 
expressed on the surface of ILCs with group 1 function, these cells may also be targeted by 
anti-NK1.1 treatment. Indeed, preliminary data suggests a loss of splenic RORγtfm+ ILCs upon 
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both anti-NK1.1 and anti-asialo GM1 treatment (Data not shown). These experiments need to 
be repeated with focus on ILC populations in the tumour tissue. Moreover, IL-15 was 
suggested to be essential for the generation and/or maintenance of RORγtfm+ cells with ILC1 
function. Thus, such cells would also lack in Il15ra-/- mice, in which the anti-tumour response 
is maintained.  
By employing Rorc-/-Rag1-/- mice, RORγt-dependent ILCs could be excluded as mediators of 
the late IL-12Fc-induced anti-tumour response. In these animals, classical ILC1s are, 
however, still present (50). Furthermore, the absence of RORγt-dependent ILCs was only 
confirmed in the small intestine of Rorc-/-Rag1-/- mice. Thus, we cannot exclude that the 
splenic RORγtfm+ ILCs detected in Rorcfm+Rag1-/- fate map animals truly depend on RORγt 
expression and are absent from Rorc-/-Rag1-/- mice.  
Similar to the study of Park and colleagues (196) the late IL-12Fc-mediated anti-tumour 
response of s.c. B16F10 melanomas was observed to fail in Rag2-/-Il2r-/- mice, but was 
independent T, B or NK cells. The findings suggest that these lymphocyte populations are 
dispensable for IFNγ production. Furthermore, these data also indicate that the depleted 
lymphocytes are not required to respond to IFNγ in order for the IL-12Fc-mediated anti-
tumour immunity to occur. The sustained tumour suppression in NK cell depleted Rag1-/- 
mice implies that also IFNγ stimulated cytotoxic effector functions are dispensable in this 
system. Although phenotypic and functional similarities between ILCs, NK and T cells have 
been described, previous reports have failed to demonstrate cytotoxic activity of ILCs (222-
224,234). In order to further exclude the autocrine stimulation of lymphocytes by IFNγ to 
activate cytotoxicity, we aim to investigate the anti-tumour response upon late IL-12Fc 
treatment in perforin-deficient animals.  
 
»12 IFNγ  controls the infiltration of leukocytes to the tumour 
The treatment with IL-12Fc led to the accumulation of immune cells at the tumour site, as 
previously observed (198). This effect was highly dependent of IFNγ on day 10 of tumour 
growth upon late IL-12Fc treatment, as it was not observed in Ifngr1-/- mice. Thus, the 
presence of intratumoural leukocytes correlated with the suppression of tumour growth. This 
suggested that immune responses towards the tumour tissue were important and that the 
IFNγ responsive population may be of hematopoietic origin. The abundance of leukocytes in 
treated tumours could reflect on a facilitated migration of effector cells to the tumour tissue 
due to a local inflammatory response caused by IL-12Fc-induced IFNγ. Similar to previous 
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results (198), the elevated number of intratumoural leukocytes was shown to result from an 
increase of both lymphocytes and myeloid cells (Data not shown). IL-12Fc-mediated 
alterations of the tumour vasculature are therefore likely to support the migration of 
inflammatory cells to the tumour. Interestingly, the numbers of CD45+ cells was more 
comparable in IL-12Fc treated and control tumours at later stages of tumour progression. 
The usage of a density gradient to enrich leukocytes from large tumours on day 19 may have 
influenced these results. This finding could also reflect the abundance of tumour cells in the 
exponentially growing lesions at late stages. 
  
»13 Monocytes and their progeny are dispensable for late IL-12-
mediated tumour rejection 
The fraction of myeloid cells, among tumour infiltrating leukocytes, was observed to be 
particularly large in IL-12Fc treated tumours on day 10 of growth. The many stimulatory 
effects of IFNγ on this immune cell compartment described in the literature (174) supported 
the hypothesis that the IFNγ responsive tumour suppressing cell type may be of myeloid 
origin. Similar to previous studies, we found the majority of the intratumoural myeloid 
population was composed of monocytes and monocyte-derived cells that are dependent on 
CCR2 signalling (96-98). IL-12Fc treatment induced an increase of MHCII+Ly6ChighLy6G- 
cells within tumours. This indicated monocyte differentiation to macrophages or monocyte-
derived inflammatory DCs (35). In addition, the co-expression of CD11c by the majority of 
MHCII+ cells was indicative of this differentiation. Although the accumulation of MHC class II 
expressing cells suggests increased antigen presentation within IL-12Fc treated tumours, the 
anti-tumour response was shown to be independent of T cell responses. Thus, we interpret 
the elevated numbers of MHCII+ cells as a general activation and differentiation of the 
monocytic compartment to exert pro-inflammatory functions. A small fraction of the 
Ly6ChighLy6G-MHCII+CD11c+ monocyte-derived cells expressed iNOS upon IL-12 stimulation. 
These cells are reminiscent of monocyte-derived TNF and iNOS producing (Tip)-DCs, 
described in infectious models (35) Therefore, it may be of interest to screen for TNF 
secretion within the tumour tissue. Although previous reports have related iNOS activity with 
tumour promoting functions of myeloid cells (94), in our study, iNOS expression correlated 
with the suppression of tumour growth. iNOS production was completely dependent on IFNγ 
signalling, which is supported by the literature (174). Since iNOS expression was confined to 
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the monocytic compartment, Ccr2-/- mice should be examined for the potential lack of iNOS+ 
cells. 
Our experiments in Ccr2-/- mice excluded a role of monocyte-derived cells in IL-12Fc-
mediated tumour suppression. Notably, an increased influx of Ly6Ghigh granulocytes seemed 
to compensate for the loss of monocytes. The LysM specific depletion of IFNγ signalling did 
not lead to impaired tumour suppression by IL-12Fc. The pSTAT1 analysis of blood 
leukocytes suggests that the IFNγR had been depleted on granulocytes. However, we still 
need to determine, which specific myeloid cell subsets lost IFNγ signalling in tumours of 
LysM-Cre+Ifngrfl/fl mice. Thus, an involvement of myeloid cells in the IL-12Fc-induced anti-
tumour response cannot be excluded. This notion is further supported by the presence of 
residual F4/80 expressing cells within tumours of Ccr2-/- mice. CCR2-independent tumour-
associated macrophages may potentially be directly targeted by the injection of an anti-
CSFR1 depleting antibody into tumour bearing mice, as demonstrated previously (283).  
The function of DC subsets has previously been implied to be essential for the rejection of 
tumours upon IL-12Fc administration (196). DCs were, however, never excluded to be part of 
the tumour suppressive mechanism upon late IL-12Fc treatment in our study. These cells 
should be targeted by using CD11c-Cre Ifngrfl/fl mice, in which DCs would be unresponsive to 
IFNγ. Most of the DCs within tumours were, however, shown to be monocyte-derived and 
were therefore absent from Ccr2-/- mice. A small proportion of CD11b- DCs were identified 
within the tumour tissue, but absolute numbers were generally low and did not increase upon 
IL-12Fc administration. Thus, it seems unlikely that DCs play a major role in the rejection of 
IL-12Fc treated tumours. 
In conclusion it is not entirely clear, whether the IFNγ-responsive cell type, mediating the 
IL-12Fc-induced tumour rejection, can be found within the hematopoietic cell pool. For this 
reason, we plan to compare the effect of IL-12Fc on tumour growth in bone marrow 
chimeras, transferring Ifngr1-/- bone marrow to WT animals and vice versa. Thereby, we may 
be able to distinguish effects of IFNγ on hematopoietic cells and stromal populations of the 
B16F10 tumours.  
 
Discussion 
 
80 
»14 The tumour endothelium is not required to respond to IFNγ  for 
late tumour rejection 
We hypothesised that stromal cells may be involved, as various leukocyte populations were 
excluded to be essential for the IL-12Fc-mediated tumour suppression. The IFNγ-induced 
anti-angiogenic effect has been considered to be an important pillar of the tumour 
suppression elicited by IL-12 (183,274). Both direct and indirect effects of IFNγ have been 
suggested to impact the tumour endothelium (188). Our data confirms that IFNγ induces 
alterations of the vasculature in IL-12Fc treated tumours. This was illustrated by an up-
regulation of adhesion molecules and decreased endothelial cell numbers. The data obtained 
by flow cytometry was further supported by immunohistochemical analysis of tumour 
sections. Similar to a previous report (284) our histological analysis indicated that particularly 
the microvasculature was reduced in IL-12Fc treated tumours. Examination of tumours from 
VEC-Cre+Ifngrfl/fl mice suggested that the up-regulation of adhesion molecule expression and 
the reduction in endothelial cell number depended on direct IFNγ signalling on the tumour 
vessels. Due to expression of VE-Cadherin in hematopoietic stem cells (275,278) we also 
expect a proportion of mature leukocytes to be targeted in the VEC-Cre+Ifngrfl/fl mice. Thus, 
modelling the anti-tumour response upon IL-12Fc administration in VEC-Cre+Ifngrfl/fl mice 
may have limitations in distinguishing direct from indirect effects on the endothelium.  
The data obtained in the VEC-Cre+Ifngrfl/fl mice disconnects the observed effects of IL-12Fc 
treatment on the endothelium from effects on tumour growth. Thus, the anti-angiogenic effect 
in our model did not cause the tumour suppression, which is opposing a multitude of previous 
reports (183,186,274). In comparison to Ifngr1-/- mice we could still detect significant changes 
of ICAM-1 and VCAM-1 expression in VEC-Cre+Ifngrfl/fl mice. The up-regulation was, 
however, not as pronounced as seen in Cre-Ifngrfl/fl littermates and may be explained by an 
incomplete targeting of the endothelial cells in this system. We intend to investigate STAT1 
phosphorylation in endothelial cells, in order to estimate the frequency of endothelial cells 
that have lost IFNγ responsiveness in VEC-Cre+Ifngrfl/fl mice.  
Interestingly, adhesion molecule expression did not correlate with the accumulation of 
immune cells in the tumour tissue at late stages of growth. The extensive necrosis observed 
in large B16F10 tumours and structural damage to the tumour vessels may support the influx 
of immune cells independent of trans endothelial migration. In contrast, IFNγ was shown to 
regulate the infiltration of leukocytes to the tumour at early stages (day 10) of tumour 
suppression. A characterisation of immune cells in day 10 tumours of VEC-Cre+Ifngrfl/fl 
animals may clarify if endothelial alterations cause the infiltration of leukocytes. 
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Beyond the inhibition of endothelial cell growth and increase of adhesion molecules on 
tumour vessels, IL-12Fc treatment may also influence the vessel permeability or perfusion. A 
decrease in vessel perfusion upon IL-12 treatment was for instance demonstrated by Doppler 
ultrasound examination of murine tumours (285).  These parameters of the tumour blood 
supply were not assessed in our studies. Moreover, indirect effects of IFNγ on the 
endothelium cannot be excluded to be important for the IL-12Fc-induced anti-tumour 
response. Thus, the impact of IL-12Fc-induced IFNγ on tumour vessels may still play a role in 
the rejection of late IL-12Fc treated tumours.  
 
»15 Concluding remarks 1 
The mechanism, by which IL-12Fc rejects solid B16F10 tumours upon late treatment, 
remains elusive. Similar to previous reports, IFNγ was attributed a central role in the process 
of tumour suppression (183,184). In regard to the clinical application, this finding is 
disappointing, as tumour regression and the occurrence of side effects have been linked to 
IFNγ signalling. While we have excluded several pathways, by which IFNγ was thought to 
affect tumour growth, we failed to show which cell type respond to IFNγ stimulation and 
causes the anti-tumour effect upon late IL-12Fc treatment. The tumour microenvironment, 
however, contains additional cell subsets, which could be the target of IFNγ. For instance, 
tumour cells induce the proliferation of fibroblasts and myofibroblasts, which contribute to the 
tumour structure by producing components of the ECM (4). The involvement of such cells is 
unlikely, as B16F10 tumours are known for their paucity in tumour-associated fibroblasts 
(personal communication with Kristian Pietras, Lund University). Several distinct pathways 
may contribute to the anti-tumour effect of IL-12Fc stimulated IFNγ. In this case, the blockade 
of one mechanism would not affect tumour growth. Thus, the experimental abrogation of 
multiple IFNγ-induced pathways would be required and it is difficult to speculate which 
combination would succeed.  
 
»16 Splenic RORγtfm+ ILCs are sufficient to induce early anti-tumour 
responses 
The group of ILC3s have been discovered to harbour distinct subtypes, which exert 
remarkably diverse functions (50). Our group described the essential role of RORγt-
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dependent ILCs in the IL-12Fc-mediated anti-tumour response (198). At this time, the 
knowledge about different ILC3 subtypes was still limited. Thus, further characterisation of 
the tumour suppressive cell type was required to understand, which subsets of ILCs were 
capable of eliciting this response. We found distinct subpopulations colonising spleen and 
small intestines of the gut, differing in terms of phenotype and function. Most prominently, 
RORγtfm+ ILCs derived from those two organs differed regarding their tumour suppressive 
potential upon IL-12Fc treatment. While splenic RORγtfm+ ILCs induced the rejection of s.c. 
tumours, ILCs from the gut did not influence tumour growth. Whether this observation solely 
relies in the difference in responsiveness to IL-12Fc remains to be established. In order to 
study the sensitivity of ILC to IL-12Fc activation, we determined transcriptional levels of the 
β2 subunit of the IL-12R, which was found to be elevated in splenic compared to gut ILCs. 
How this difference affects the biological stimulation with IL-12Fc is not entirely clear. A 
larger proportion of splenic RORγtfm+ ILCs secreted IFNγ compared to gut ILCs, further 
indicating elevated responsiveness to IL-12Fc. IFNγ was, however, shown not to be involved 
in the rejection of early treated tumours and thus does not explain the differences in anti-
tumour activity. 
Splenic RORγtfm+ ILCs appear similar to conventional NK cells, as they also express surface 
markers and transcription factors related to NK cells. Moreover, these ILCs show a paucity of 
ILC characteristic markers. In fact, distinction of splenic RORγtfm+ ILCs and NK cells was only 
achieved by the ILCs fate map positivity for RORγt. It is questionable whether this feature is 
sufficient to classify the RORγtfm+ population as an ILC3 subset and to segregate them from 
conventional NK cells. This separation is particularly problematic as splenic RORγtfm+ cells 
down-regulated the expression of RORγt. Thus, it is uncertain, whether RORγt is critical for 
the development and function of the splenic subset or if RORγtfm+ expression rather 
represents a stochastic event in such cells. The RORγtfm+ signal may be caused by leakiness 
of Cre expression in Rorc-Cre mice. In contrast, the difference in anti-tumour activity between 
RORγtfm+ ILCs and NK cells clearly shows that these cells are functionally distinct. While 
RORγtfm+ ILCs suppressed tumour growth of B16F10-IL-12Fc tumours, fm- splenic NK failed 
to do so. Interestingly, all RORγtfm+ ILCs in the tumours were found to express Thy-1 to the 
same extent as gut ILC3s and thereby segregate from their splenic counterpart. There is still 
no understanding of the origin of the tumour suppressive ILCs under more physiological 
conditions of IL-12Fc administration. These ILCs may migrate to the tumour from a distant 
organ or may be resident within the subcutis. Thus, Thy-1 expression could be induced on 
tumour infiltrating RORγtfm+ ILCs or characterise a specific population of resident cells. 
Therefore, it would be intriguing to evaluate, whether co-injected ILCs form the spleen 
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upregulate Thy-1 expression in the tumour tissue. Moreover, the uniform expression of Thy-1 
creates the opportunity of experimentally depleting intratumoural RORγtfm+ ILCs by injection 
of an anti-Thy-1 antibody. This has previously been proven to be a successful approach for 
the elimination of ILCs in the gut (258).   
Transition of ILC3s towards ILC1 function occurs upon the stimulation with IL-12 and involves 
the down-regulation of RORγt and induction of T-bet expression (240). As splenic RORγtfm+ 
ILCs were shown to lack RORγt and instead expressed T-bet, we assume that this 
population has adopted ILC1 characteristics. Whether these cells are more likely to 
accumulate in the spleen or if the organ microenvironment fosters ILC3 to ILC1 transition is 
not known. It is unclear why gut ILC3s cannot undergo this transition in the tumour, where 
they are exposed to IL-12Fc. As we assume that the tumour suppressive effects of ILCs 
occur during tumour establishment, gut ILC3s may not acquire ILC1 characteristics in time to 
exert this function. Thus, it would be interesting to induce gut ILC3s to attain ILC1 function by 
IL-12Fc stimulation in vitro to thereafter test their tumour suppressive capacity. The RORγtfm+ 
population in the spleen may also represent a distinct cellular subset compared to ILCs 
colonising the small intestines.  
ILC1s have been shown to lack (286) or express (237) the transcription factor Eomes. A 
preliminary experiment suggested that the majority of RORγtfm+ ILCs from the spleen 
expressed Eomes, whereas this transcription factor was absent from most gut ILC3s. In that 
regard, splenic ILCs seem to be similar to the intraepithelial ILC1s described by Fuchs and 
colleagues (237). The Eomes+ fraction among the NKp46+ cells in the spleen highly 
depended on IL-15 signalling. The anti-tumour response upon early IL-12Fc treatment was, 
however, not compromised in Il15ra-/- mice. These results suggest that the anti-tumour 
response persists in absence of RORγtfm+Eomes+ splenic ILCs. The potential existence of 
other cell populations with similar anti-tumour properties within these mice may explain this 
observation. The finding of Eomes-NKp46+ cells suggests that the spleen contains an Eomes- 
ILC1 subset. In contrast to the Eomes expressing fraction, this population was not markedly 
reduced in the absence of IL-15 signalling and could potentially exert the tumour suppressive 
function upon IL-12Fc activation. The hypothesis that RORγtfm+ ILCs may not be the only cell 
type exerting anti-tumour function was further supported by the persistent tumour 
suppression in Rorc-/-Rag1-/- mice upon IL-12Fc treatment. Together, these data suggest that 
RORγtfm+ ILCs are sufficient, but not necessary for the anti-tumour response upon early 
IL-12Fc treatment. Conversely, this could indicate that splenic RORγtfm+ ILCs are not 
dependent on the expression of RORγt, and are thus still present in mice, which lack this 
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transcription factor. As the distinction of RORγtfm+ ILCs and NK cells is only possible in 
Rorcfm+ mice, we could not confirm the absence of splenic ILCs in Rorc-/-Rag1-/- mice. 
The transfer of Rorc-/-Rag1-/- splenocytes additionally supports that RORγtfm+ ILCs are not 
required during the early IL-12Fc-induced anti-tumour response. Moreover, this experiment 
contrasts the failure of the anti-tumour response upon transfer of Rorc-/- splenocytes 
performed previously (198). To what extend the absence of T cells in Rorc-/-Rag1-/- compared 
to Rorc-/- mice would explain these differences is unclear. A report by Hepworth et al. 
suggested that RORγt expressing ILCs can regulate T cell function. The absence of ILCs was 
shown to leave the T cells in a hyper responsive state, causing spontaneous intestinal 
inflammation (287). In Rorc-/- animals such pathogenic T cells may potentially influence 
tumour growth. We aim to explore this by a side-by-side comparison of tumours supplied with 
Rorc-/-Rag1-/- or Rorc-/- splenocytes. 
 
»17 Concluding remarks 2 
Although IL-12Fc responsive RORγtfm+ ILCs were confirmed to be sufficient in suppressing 
tumour growth, they do not seem to be necessary, as demonstrated by the intact anti-tumour 
response in their absence. This function is therefore unlikely to be exclusive for RORγtfm+ 
ILCs, but is rather supported by multiple cells types. The nature of such populations has not 
yet been determined. It is possible that RORγt-independent ILC subsets could bear anti-
tumour capacity. The question of how such ILCs suppress tumour growth remains to be 
answered. Interference with tumour tissue formation would be one potential mechanism. Due 
to the low number of RORγtfm+ ILCs observed in tumours, further stimulation of other cell 
types is likely required during tumour rejection.  
The action of RORγtfm+ ILCs seems to be restricted to the very early phases of tumour 
suppression. This certainly puts the clinical relevance of the early treatment and the role of 
ILCs into perspective, as cancer patients usually present themselves at late stages of tumour 
growth. The strong tumour suppressive capacity may, however, present a novel function of 
ILC subsets and thus further contributes to the characterisation of those cells. Moreover, 
unravelling the anti-tumour function of ILCs could lead to better understanding of the various 
mechanisms, by which the immune system controls cancer development and growth. 
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VIII Appendix: T Cell Contamination in Flow Cytometry 
Gating Approaches for Analysis of Innate Lymphoid 
Cells 
»18 Results and Discussion 
»18.1 CD5+ fraction remains in the ILC3 gate after exclusion of T cells using CD3 
and TCRβ  
Besides its importance for ILC3s, RORγt is also involved in the development of T cells, 
mainly TH17 and γδ T cells (217,288). However, most ILC3 and T cell subsets will 
subsequently down-regulate the expression of RORγt (239). By utilising Rorcfm+ mice, the fate 
of RORγtfm+ positive RORγt-dependent cells was mapped (199). 
Using leukocytes isolated both from lymphoid (spleen) and non- lymphoid organs (colon and 
lung), we compared different gating approaches for the efficiency in separating ILC3s and T 
cells. The gating strategy involved exclusion of doublets, dead cells and B220 expressing 
events from CD45+ leukocytes. In order to exclude T cells, CD3 and TCRβ positive events 
were negatively selected followed by gating on RORγtfm+ cells (Figure 1a). Similar gating 
approaches are used to characterize both murine and human ILCs but are often not depicted 
in any figure or involve gating out multiple lineage markers in one fluorescent channel 
(241,242,289,290). However, upon further scrutiny of the assumed ILC3s, we discovered a 
significant percentage of these cells to stain positive for CD5, a molecule described to inhibit 
the T and B cell receptor signalling and was historically used as a pan T cell marker. 
Whereas in the colon this frequency was relatively low with 43.9% CD5+ cells within the ILC3 
gate, in spleen and lung it reached 78.2% and 68.9%, respectively (Figure 1b). Strikingly, in 
Rorcfm+Rag1-/- mice no expression of CD5 was detected, suggesting that the CD5+ cells 
obtained from Rorcfm+ mice belong to the T cell lineage (Figure 1c). Notably, as CD5 is 
upregulated upon TCR engagement, it is highly expressed in activated TCRlow and CD3low T 
cells, which will appear close to the ILC gate (291).  
 
Figure 1. Flow cytometric analysis of ILC3s using RORcfm+ fate map mice. (A) Gating strategy for ILC3s in 
Rorcfm+ mice: after exclusion of doublets, live CD45+B220-CD3-TCRβ- RORγtfm+ cells were selected. (B) The 
population gated in panel A contains a significant fraction of CD5+ cells both in spleen, lung and colon. (C) In 
Rorcfm+Rag1-/- mice all RORγtfm+ CD45+ live cells stain negative for CD3, TCRβ and also CD5. Representative 
plots for n = 3 (mean ± S.E.M). 
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»18.2 CD5+ cells remaining within the CD32 TCRb2 ILC3 gate consist of αβ  T cells 
To determine the nature of the CD5 expressing CD3-TCRβ- cells, this population was purified 
by flow cytometric cell sorting from the spleen (Figure 1a and b). The mRNA levels for the 
constant region of the T cell receptor α and δ chain (TRAC and TRDC) were compared to 
that of CD5- ILC3s, αβ and γδ T cells as well as monocytes. As a genetic control we used 
ILC3s derived from Rorcfm+Rag1-/- mice. Whereas CD3-TCRβ-CD5- ILC3s showed minor 
expression of both TRAC and TRDC (probably reflecting inevitable contamination from the 
sort purification), purified αβ and γδ T cell populations as expected transcribed high levels of 
TRAC or TRDC, respectively (Figure 2). Strikingly, when analyzing TRAC and TRDC 
expression levels in CD3-TCRβ-CD5+ cells we detected high levels of TRAC, suggesting that 
this population indeed consisted mainly of αβ T cells. 
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Figure 2. CD5+ cells within the ILC3 gate 
express high levels of TRAC. Normalized fold 
expression for TRAC (A) and TRDC (B) comparing 
CD5+ and CD5- cells within the ILC3 gate 
(ʻʻCD5+ILC3sʼʼ, pregated on CD45+B220-CD3-TCRβ- 
RORγtfm+ cells), αβ and γδ T cells, monocytes 
(Mono) purified from Rorcfm+ mice and ILC3s derived 
from Rorcfm+Rag1-/- mice (ILC3s Rag-/- ). Results are 
presented relative to those obtained from ILC3s of 
Rorcfm+Rag1-/- mice (mean ± S.E.M). 
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»19 Concluding remarks 
We conclude that gating on lineage negative cells only using CD3 is not sufficient to firmly 
exclude αβ T cells from further analysis. This problem becomes particularly evident, when a 
CD3 containing ʻʻdump channelʼʼ is employed, where cells expressing lineage markers at 
different intensities are gated out in a single fluorescence channel. Furthermore, the scarcity 
of ILCs together with the high number of T cells, which depending on their activation status 
might express different levels of CD3, seems to cause limits for a separation based on one T 
cell marker. Thus, results obtained from contaminated ILC populations will be biased and T 
cells will contribute to the detected cytokine levels. This may not only produce artefacts but 
also mislead the characterization of ILC subsets according to the nomenclature based on 
cytokine and transcription factor expression. 
Given that within the past years a strong association between ILC and T cell effector function 
has been proposed, we suggest that a thorough separation between these two populations is 
essential. Hence, lineage negative gating should not only be performed using CD3 only, but 
also CD5, preferably in a separate fluorescent channel. 
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Materials and Methods  
»19.1 Mice 
C57BL/6 mice were purchased from Janvier. Rag1−/−, Rag2−/−Il2rg−/−, Ifngr1r−/−, RorcGFP, 
Il12rb2-/- and LysM-Cre mice were acquired from Jackson Laboratories. S. Bulfone-Paus 
(University of Manchester) provided us with Il15ra−/− mice. VE-Cadherin-Cre mice were kindly 
contributed by C. Halin Winter (ETH, Zurich). W. Müller supplied the Ifngrfl/fl mice. Rorc-Cre x 
ROSA26-stopfl/fl-eYFP mice were kindly provided by A. Diefenbach (Freiburg University, 
Germany). All mice were kept under specific pathogen free conditions and treated according 
to animal guidelines by the Swiss Cantonal Veterinary Office (License 147/2012, Zurich, 
Switzerland). 
 
»19.2 Inoculation of tumour cells, growth monitoring and animal handling 
Cells were detached using trypsin and washed with PBS. After centrifugation at 400g for 5 
min (conditions used for wash steps if not mentioned otherwise) cells were filtered through a 
70mm mesh and diluted in PBS to the concentration of 2 x 106 cells/ml. The cell 
concentration was determined by using a Neubauer counting chamber. 2 x 105 B16F10 cells 
were injected s.c. into the left flank of each animal under isoflurane anaesthesia. For the 
transfer experiments B16F10-IL-12Fc cells were prepared as described above and 2x105 
cells were mixed and co-injected with either 10ʼ000 FACS purified leukocyte populations or 
2x105 splenocytes per mouse. Tumour growth was monitored by perpendicular measurement 
of the diameter and calculation of the tumour area in mm2 from day 7 of tumour growth. 10ml 
of IL-12Fc (200ng per injection) or PBS were injected s.c. before the development of a 
palpable lesion or i.t. after tumour formation and treatment was commenced on day 0 (early 
treatment) or day 7 (late treatment) in the experiment.  Both determination of tumour size and 
injection of IL-12Fc or PBS took place three times a week. A tumour diameter of ≥ 20mm, 
ulceration of the lesion or body weight loss of ≥ 15% were the main withdrawal criteria for 
individual mice. Depending on the tumour growth in different mouse strains the experiments 
were terminated between day18 and 22.  
For the depletion of NK cells in Rag1-/- mice we used the 200mg anti-NK1.1 (PK136, 
BioXCell) per mouse and injection. Treatment was initiated 5 days prior to tumour cell 
inoculation and continued every second day over the course of the experiment. NK cell 
depletion was confirmed in the blood of the mice using flow cytometry before B16F10 
injection and thereafter weekly. 
Materials and Methods 
 
90 
   
»19.3 DNA isolation and genotyping 
DNA was isolated from either ear or toe tip biopsies, which were digested using 400 ml of tail 
lysis buffer containing 8ml proteinase K for 2 h at 55°C. After centrifugation for 10 min at 
13.000 rpm the supernatant was mixed with 400ml of isopropanol to precipitate the DNA and 
centrifuged for 10 min at 13.000 rpm and 4°C. Supernatants were removed, the pellet was 
washed with 100 μl of ice cold 70% ethanol, centrifuged for 5 minutes at 13.000 rpm and 
supernatants were discarded. Pellets were air-dried for 10-15 min, resuspended in 100 μl of 
TE buffer and kept at 4°C.  
The genotyping was performed using the following PCR protocols and the amplicons were 
analysed using a 1-2% agarose gel in TEA buffer. 
 
RORc-Cre 
Primer sequences: 
TTA CCG GTC GAT GCA ACG AGT 
TTC CAT GAG TGA ACG AAC CTG G 
 
PCR reaction mixture per sample: 
10X PCR buffer with MgCl2 (New England Biolabs):  2.5 μl 
Primer each (10 μM)        0.5 μl 
dNTPs (10 μM)        1.25 μl 
Taq DNA Polymerase (New England Biolabs)   0.1 μl 
Template (DNA)        2 μl 
dH2O          18.15 μl  
 
Amplification: 
1. 94°C  5 min 
2. 94°C  30 sec 
58°C  1 min 
72°C  1 min  repeat 35x 
3. 72°C  10 min 
4. keep at 12°C 
 
Band analysed: 400bp 
 
ROSA26-stopfl/fl-eYFP 
Primer sequences: 
 
AAG ACC GCG AAG AGT TTG TC 
   Materials and Methods 
 
91 
AAA GTC GCT CTG AGT TGT TAT 
GGA GCG GGA GAA ATG GAT ATG 
 
PCR reaction mixture per sample: 
10X PCR buffer with MgCl2 (New England Biolabs):  1.2 μl 
Primer each (10 μM)        1.2 μl 
dNTPs (10 μM)        0.24 μl 
Taq DNA Polymerase (New England Biolabs)   0.06 μl 
Template (DNA)        2 μl 
dH2O          4.9 μl  
 
Amplification: 
1. 94°C  3 min 
2. 94°C  30 sec 
58°C  1 min 
72°C  1 min  repeat 35x 
3. 72°C  2 min 
4. keep at 12°C 
 
Bands analysed:  
Transgene:  320 bp 
WT:   600 bp 
 
Rag1-/- 
Primer sequences: 
TGG ATG TGG AAT GTG TGC GAG 
CCA GAC AAG TTT TTC ATC GT 
GAG GTT CCG CTA CGA CTC TG 
 
PCR reaction mixture per sample: 
10X PCR buffer with MgCl2 (New England Biolabs):  3 μl 
Primer 1 & 3 (10 μM)       0.3 μl 
Primer 2 (10 μM)        0.15 μl 
dNTPs (10 μM)        0.3 μl 
Taq DNA Polymerase (New England Biolabs)   0.1 μl 
Template (DNA)        2 μl 
dH2O          5.85 μl  
 
Amplification: 
1. 94°C  3 min 
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2. 94°C  30 sec 
58°C  45 sec 
72°C  30 sec  repeat 35x 
3. 72°C  2 min 
4. keep at 12°C 
 
Bands analysed:  
Rag1-/-:  530 bp 
WT:  474 bp 
 
RorcGFP 
Primer sequences: 
 
CCC CCT GCC CAG AAA CAC T 
GGA TGC CCC CAT TCA CTT ACT TCT 
CGG ACA CGC TGA ACT TGT GG 
 
PCR reaction mixture per sample: 
10X PCR buffer with MgCl2 (New England Biolabs):  2 μl 
Primer 1 & 3 (10 μM)       1 μl 
dNTPs (10 μM)        1 μl 
Taq DNA Polymerase (New England Biolabs)   0.5 μl 
Template (DNA)        1 μl 
dH2O          12.5 μl  
 
Amplification: 
1. 94°C  3 min 
2. 94°C  30 sec 
60°C  30 sec 
72°C  30 sec  repeat 35x 
3. 72°C  5 min 
4. keep at 12°C 
 
Bands analysed:  
RorcGFP:  241 bp 
WT:  174 bp 
 
VEC-Cre (general Cre) 
Primer sequences: 
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Transgene   GCG GTC TGG CAG TAA AAA CTA TC 
  GTG AAA CAG CAT TGC TGT CAC TT 
Internal control  CTA GGC CAC AGA ATT GAA AGA TCT 
  GTA GGT GGA AAT TCT AGC ATC ATC C 
 
PCR reaction mixture per sample: 
10X PCR buffer with MgCl2 (New England Biolabs):  1.2 μl 
Primer each (10μM)        1.2 μl 
dNTPs (10μM)        1.25 μl 
Taq DNA Polymerase (New England Biolabs)   0.1μl 
Template (DNA)        1 μl 
dH2O          4.65 μl 
Amplification: 
1. 94°C  3 min 
2. 94°C  30 sec 
51°C  1 min 
72°C  1 min  repeat 35x 
3. 72°C  3 min 
4. keep at 12°C 
 
Bands analysed: 
Transgene:  100bp  
Control:  324 bp 
 
LysM-Cre 
Primer sequences: 
CTT GGG CTG CCA GAA TTT CTC 
TTA CAG TCG GCC AGG CTG AC 
CCC AGA AAT GCC AGA TTA CG 
 
PCR reaction mixture per sample: 
10X PCR buffer with MgCl2 (New England Biolabs):  2.5 μl 
Primer each (10μM)        0.5 μl 
dNTPs (10μM)        1.25 μl 
Taq DNA Polymerase (New England Biolabs)   0.1μl 
Template (DNA)        1 μl 
dH2O          18.9 μl 
Amplification: 
1. 94°C  3 min 
2. 94°C  30 sec 
62°C  30 sec 
72°C  1 min  repeat 35x 
3. 72°C  3 min 
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4. keep at 12°C 
 
Bands analysed: 
LysM-Cre:  700 bp  
WT:   350 bp 
 
»19.4 Production and purification of IL-12Fc 
For the production of IL-12Fc the 293T cell line (human embryonic kidney cells) were 
transfected using co-precipitates of calcium phosphate and vector DNA (pCEP4-mIL-
12IgG3). The transfection was performed according to standard protocols using 25μg of DNA 
per 15cm tissue culture plate.  Cells were thereafter cultured in high glucose DMEM medium 
(PAN-Biotech), containing 10% fetal calve serum (FCS), 1% penicillin streptomycin, 1% L-
glutamine and 1% sodium pyruvate (media containing these supplements will be referred to 
as complete media), which was substituted with 1% nutridoma SP (Roche). The supernatant 
was collected 2-3 days and 4-6 days after transfection depending on cell density in the 
culture dish. After centrifugation at 3520 g for 10 min the supernatant was sterile filtered 
through a 0.22mm mesh. IL-12Fc was then purified using a protein G column (1ml, HiTrap, 
GE Healthcare) and the ÄktaPrime purifier. The protein elution was performed using 0.1 M 
citric acid (pH 3.0) and the flow through was collected in 1M Tris pH 8.8. This step was 
followed by an over night dialysis of the eluate in PBS pH 7.4, and purified IL-12Fc was 
stored at -20°C. IL-12Fc concentration was measured by a BCA assay (PierceTM BCA 
Protein assay kit, Thermo Scientific) and by p40 ELISA (OptEIA Il-12/23p40, BD 
Pharmingen). Protein purity was determined by SDS-PAGE followed by a silver staining and 
immunoblotting. IL-12Fc was detected with a rat anti-mouse IL-12p40 antibody (C17.8, 
BioExpress) and a goat anti-rat HRP coupled antibody (Jackson).  
 
»19.5 Cell lines and culture conditions 
B16F10 cells were obtained from ATCC and propagated in complete DMEM medium. 
B16F10-IL-12Fc were generated by Johannes vom Berg and Maya Eisenring in our group as 
described in Eisenring et al. (198). These cells were cultured in complete DMEM medium 
containing 0.25 mg/ml hygromycin and 0.2 mg/ml zeocine. The MS1 cell line was kindly 
provided by M. Detmar (ETH, Zurich) and kept in complete DMEM medium. All cells were 
passaged every second day.  
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»19.6 In vitro assay using MS1 cells 
MS1 cells were labelled using 1µM cell trace violet (Molecular Probes) working solution and a 
cell density of 1x106 cells/ml. Thereafter 2000 MS1 cells were plated per well in a 98 well cell 
culture dish. 6ʼ000-10ʼ000 FACS purified lymphocyte populations were added with or without 
5 ng/ml IL-12Fc. The anti-IFNγ antibody (R4-6A2; BioExpress) was utilised at a 
concentration of 10 ng/ml and 10 ng/ml IFNγ was added as a positive control. The MS1 cells 
were then cultured for 48 hours in RPMI (PAN-Biotech) complete. After removing the non-
adherent lymphocytes the MS1 cells were incubated with 1/5 diluted trypsin for 3 min 
followed by mechanical disturbance to detach the cells. After a wash with PBS, the cells were 
stained for flow cytometric analysis.  
 
»19.7 Isolation of leukocytes from tumour tissue 
Mice were euthanized using rising concentrations of CO2 on day 5 or 10 of tumour growth or 
at the endpoint of the tumour experiment. Tumours were resected and separated from skin 
and adjacent subcutaneous tissue and weight of the lesion was determined. The tissue 
material was in general kept on ice or at 4°C if not mentioned otherwise. Tumours were cut 
into small pieces and processed in digestion medium (10ml/gram of tumour tissue) under 
continuous agitation at 37°C for 45 min. Digestion medium consisted complete RPMI 
containing collagenase IV (Sigma) 0.4mg/ml and DNAse (Roche) 100 µg/ml. The lysate was 
further disrupted using a syringe and a 19 gauge needle and was thereafter filtered through a 
70 mm cell strainer and washed with PBS. At this stage tumours obtained on day 5 or 10 of 
tumour growth were then stained for flow cytometric analysis immediately or taken in culture 
for restimulation. The leucocytes in lesions resected at later time points were further enriched 
by a density gradient using 70% and 40% isotonic Percoll (1.124 g/ml, Biochrom) and spun 
at 1350g for 30 min at 18°C without brakes. The interphase was collected and filtered 
through a 70 mm mesh and washed with PBS before continuing with further procedures.  
 
»19.8 Isolation of leukocytes from tumour tissue 
The isolation of endothelial cells was adapted from the procedure described in van Beijnum 
et al. (292). Tumours were resected from the flank of euthanized mice as described above 
and weight of the lesion was determined. The tissue was always kept on ice and in EC 
isolation medium if not described otherwise.  All the media used in this procedure are listed 
below and were used at 4°C. Tumours were disrupted by cutting and processed in a 
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digestion medium - 10ml/gram of tumour tissue - and kept agitating at 37°C for 60 min. After 
30 min of digestion DNAse (Roche, final concentration: 100 µg/ml) was added to the mixture. 
To increase the yield of endothelial cells the digested tumours were then mixed with EC 
isolation medium (5ml per 10ml digestion medium) containing heparin-Na (B. Braun) to avoid 
clustering of endothelial cells in thrombi and filtered through a 100µm mesh. The filter was 
then rinsed with additional 5 ml of EC isolation medium and pelleted by centrifugation. After 
discarding the supernatant a density gradient was performed to enrich tumour endothelial 
cells. The pellet was resuspendend in 4ml (tumours below 0.5 g) or 10ml (tumours above 0.5 
g) of an anti-coagulating Ficoll medium and was layered on top of 3 ml or 7.5ml of Ficoll-
Paque PLUS (1.0771+/-0.001g/ml), respectively. After centrifugation at 400g for 20min at 
18°C without brakes the interphase was collected and washed with EC isolation medium. A 
second wash with PBS was performed and the samples were stained for flow cytometric 
analysis. 
EC medium     complete RPMI with 20% FCS 
 
EC medium+    EC medium containing: 
     0.001% Heparin-Na 25000 I.E/5ml (B. Braun) 
     1% NEAA (Gibco) 
1% Hepes (Gibco) 
1% MEM Vitamins (Gibco) 
 
Conditioned EC medium  Medium from cultured MS-1 cells; filtered  
through a 0.2 µm mesh and stored at -20°C 
 
EC isolation medium   80% EC medium+ and 20% conditioned medium 
 
Digestion medium   RPMI only containing: 
     Collagenase VI (Sigma) 0.4mg/ml 
     Dispase (Gibco) 2.4mg/ml 
 
Ficoll medium    EC medium containing 1% sodium citrate  
(stock 2M) 
  
»19.9 Isolation of leukocytes from spleen 
After excision spleens were mechanically disrupted using a syringe plunger or by cutting 
them into small pieces. For the purification of ILCs from spleens the samples were at this 
point additionally incubated with collagenase IV (0.4mg/ml, Sigma) diluted in RPMI complete 
for 20 min at 37°C to increase the yield of cells. The lysate was then filtered through a 70mm 
mesh and washed with PBS.  After centrifugation the pellet was resuspended in 1ml red 
blood cell (RBC) lysis buffer and kept on ice for 10 min. Splenocytes were then washed and 
stained for flow cytometric analysis, FACS sort or directly transferred to the animals.  
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»19.10 Isolation of leukocytes from the lamina propria of the small intestines and 
colon 
The gut was removed and divided into small intestines (below the stomach to the entrance 
into the ceacum) and colon (ceacum to rectum). Mesenteric fat tissue and remaining faeces 
were removed; the intestinal tube was cut open and dissected into smaller pieces. The 
samples were then washed three times in 10 ml hankʼs balanced salt solution (HBSS) 
without Ca2+ and Mg2+ containing 2% FCS (CM), vortexing the samples for 20 min with each 
wash step. Gut pieces were then incubated in CM containing 1 mM Dithiothreitol (DTT) and 
1.35 mM EDTA for 15 min at 37°C to remove remaining mucus and the epithelial layer. After 
an additional incubation in CM complemented with EDTA for 30 min at 37°C the samples 
were cut into small pieces. The digestion steps described so far were performed under 
continuous agitation. The gut tissue was then digested using 0.4 mg/ml collagenase IV 
(Sigma) diluted in HBSS with Ca2+ and Mg2+ containing 10% FCS for 45 min at 37°C. The 
samples were then homogenised using a syringe with an 18 gauge needle, filtered through a 
70 mm cell strainer and used for subsequent procedures. 
 
»19.11 Isolation of leukocytes from the lung 
Lungs were mechanically disrupted using scissors and were thereafter digested in IMDM 
containing 1 mg/ml Collagenase D (Roche), 0.5 mg/ml DNAse (Sigma Aldrich), 25 mM 
HEPES and 2% FCS for 60 min at 37°C. The remaining tissue pieces were additionally 
homogenised using syringes and 18 gauge needles, filtered through a 70 mm cell strainer 
and washed with PBS. Red blood cells were removed using RBC lysis buffer for 10 min, 
samples were washed and stained for flow analysis. 
 
»19.12 Flow cytometry 
Before IFNγ staining, isolated cells were in vitro re-stimulated for 4 h at 37°C using complete 
RPMI supplemented with PMA (50 ng/ml), Ionomycin (500 ng/ml) and GolgiPlug (diluted 
1:1000). pSTAT1 was stained after cell stimulation with IFNγ (50 ng/ml) for 30 min and was 
performed according to the protocol by BD using the perm buffer II (BD). For all other 
intracellular staining cells were fixed for one hour in either Cytofix/Cytoperm buffer (BD) for 
IFNγ and iNOS staining or in Foxp3 Fixation/Permeabilization buffer for Eomes and RORγt, 
according to the manufacturers protocols. Wash steps were then performed in a Perm/Wash 
buffer from BD or a homemade solution containing Saponin. Flourochrome-conjugated or 
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biotinylated antibodies were purchased from BD, BioLegend or eBioscience and incubated 
with the samples for 20 min on ice. EOMES and RORγt were stained at 4°C over night. A list 
of the most frequently used antibody clones can be found below. Aqua Live/Dead fixable 
staining reagent (Invitrogen) was used to exclude dead cells, and single events were gated 
on using FSC-A vs. FSC-H. Compensation was performed using single stained anti-
rat/hamster compensation beads, stained with the fluorophores used in the experiment. The 
samples were acquired using a LSR II Fortessa (special order research product, BD) with 
four laser lines (405 nm, 488 nm, 561 nm and 640 nm). The data was analysed using the 
FlowJo V9.x software (Treestar). Absolute cell numbers were calculated using Accu check 
counting beads (BD). For cell sorting a FACS Aria III (BD) was used. 
Antibody Dilution Clone 
   
anti CD3 - AF700 / PE Cy7 1:100 / 1:400 17A2 
anti CD4 - PE-CF594 1:400 GK1.5 
anti CD5 - APC 1:800 53-7.3 
anti CD8 - FITC 1:400 53-6.7 
anti CD11b - APC Cy7 / BV 605 1:400 M1/70 
anti CD11c - PE-Cy7  1:400 N418 
anti CD31 - FITC / PerCP Cy5.5 1:200 / 1:400 390 
anti CD45 - APC-Cy7 / PB 1:400 / 1:800 30-F11 
anti CD49b - PE / BIO 1:100 DX5 
anti CD54 (ICAM-1) - APC  1:400 3E2 
anti CD90.2 (Thy-1.2) - PB / AF700 1:200 30-H12 
anti CD106 (VCAM-1) - FITC  1:100 429 
anti CD117 (c-Kit) - APC 1:100 2B8 
anti CD127 (IL-7Rα) - PE / PE-Cy7 1:100 SB/199 
anti Ly-6A/E (Sca-1) - PE Cy7  1:200 D7 
anti Ly-6C - FITC 1:400 AL-21 
anti Ly6G - AF647 1:400 1A8 
anti NK1.1 - V450 / AF700 1:100 PK136 
anti NKp46 - perCP-eFluor 710  1:100 29A1.4 
anti F4/80 - Biotin 1:200 CI:A3-1 
anti TCR β - perCP Cy5.5 1:400 H57-597 
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anti TCR γδ - PE-Cy7 1:400 GL3 
anti I-A / I-E (MHCII) -PB / AF700 1:800 M5/114.15.2 
anti IFNγ - PE Cy7 1:400 XMG1.2 
anti IL17A-eFlour660 (APC) 1:200 17B7 
anti T-bet - BV605 1:200 4B10 
anti RORγt - BV421 1:800 Q31-378 
anti Eomes - PE 1:100 Dan11mag 
anti pSTAT1-PE (pY701) 1:10 4a 
anti-NOS2 (iNOS) - PE 1:100 CXNFT 
 
»19.13 Immunofluorescence 
The tumour was excised with the surrounding skin and connective tissue and was fixed in 
HOPE I (BioSciences) solution for 48-72 h at 4°C. Samples were then dehydrated in 100% 
Acetone containing 1:1000 HOPE II (BioSciences) for two hours followed by three 
incubations in 100% Acetone only, each for 2 h. The tumours were then put in paraffin at 
55°C over night and thereafter embedded, cut into 10 µm sections and freed from paraffin 
using isopropanol and acetone. Slices were then incubated with blocking buffer (PBS with 
3% bovine serum albumin (BSA), 5% FCS, 0.1% Triton) for 40 min and stained with the 
primary antibodies at 4°C over night. The samples were then incubated with secondary 
antibodies at room temperature for 2 h. After washing the samples with PBS slides were 
mounted using mounting medium DAPI (Dianova). Imaging was performed using an inverse 
fluorescence microscope IX81 (Olympus) and analysed using the ImageJ64 software. 
Primary Antibody Dilution Clone 
   
anti CD31  1:500 MEC 13.3 (rat) 
anti CD54 (ICAM-1) - PE / APC 1:200 3E2 (hamster) 
anti F4/80 - Biotin 1:100 CI:A3-1 (rat) 
   
Secondary Antibody Dilution  
   
goat anti-rat IgG AF488 1:500  
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»19.14 RNA isolation and quantitative PCR 
Purified cells were resuspended in 1 ml trizol (Invitrogen) and stored at -80°C if the isolation 
was not performed immediately. 200 ml of chlorophorm was added, mixed in gel lock tubes 
and centrifuged at 13ʼ200 g for 20 min at 4°C. The upper aqueous phase was collected and 
mixed with an equal volume of ice cold 70% ethanol. Thereafter RNA was extracted using 
the PureLink RNA Micro kit (Invitrogen) according to the manufacturers protocol. An 
additional wash step was performed with 80% ethanol at the end of the procedure and RNA 
was eluted in 12 ml of pre-warmed RNAse free water. RNA concentration was estimated 
using a spectrophotometer (NanoDrop). Subsequent first-strand cDNA synthesis was 
performed using Superscript II reverse transcriptase (Invitrogen) and oligo (dt) primers 
(PeproTech) according to the Invitrogen protocol. Quantitative analysis was conducted using 
a SYBR Green master mix (Roche) using the following master mix: 
6.25 μl SYBR-Mix (2x) 
3.25 μl H2O 
0.25 μl of each primer 
2.5 μl cDNA  
 
The reaction was measured by a C1000 Touch thermal cycler (BioRad). mRNA levels were 
determined by the cycle threshold values and normalised to the expression of the Pol2 gene. 
Primers were designed using the Roche Universal probe library:  
IL-12Rb2: TGT GGG GTG GAG ATC TCA GT forward 
  TCT CCT TCC TGG ACA CAT GA reverse 
IL-23R: CCA AGT ATA TTG TGC ATG TGA AGA forward 
  AGC TTG AGG CAA GAT ATT GTT GT reverse 
TRAC:  ACAAGCTTCACCTGCCAA forward  
GCTTTTCTCAGTCAACGTGG reverse  
TRDC:  CTACGACTGCTGTTTGCCA forward  
TAGTCTCCTCATGTCAGCCC reverse  
 
»19.15 Buffers 
Biopsy lysis buffer   50 ml 1M Tris/HCl pH 7.5 
5 ml 0.5M EDTA (AppliChem) 
5 ml 20% SDS 
20 ml 5M NaCl 
500 ml H2O bidest 
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Red blood cell lysis buffer  4.15 g NH4Cl 
0.55 g KHCO3 
0.185 g EDTA 
500 ml H2O bidest  
sterile filtered 
 
Homemade Perm/Wash Buffer PBS 
2% BSA 
0.5% Saponin 
 
TAE buffer (50x)   484 g Tris base 
14.2 ml acetic acid 
200 ml 0.5M EDTA (pH 8.0) 
adjust pH to 7.5 
2000 ml H2O dest 
 
TE buffer    10mM Tris/HCl pH 7.5 
1mM EDTA (2 ml per 1000 ml of buffer) 
 
»19.16 Statistical analysis 
Statistical analysis was performed using Prism version 5.0a (GraphPad Software Inc.). 
Statistical significance was determined by unpaired two-tailed T-test for the comparison of 
two groups or by one-way ANOVA with Bonferroni post-test unless mentioned otherwise. In 
case of significant differences in variances between the groups T-tests were adjusted using 
Welshʼs correction. A p value below 0.5 was considered statistically significant. 
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